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ABSTRACT
The increase in obesity has been accompanied by a rise in the prevalence of
painful peripheral neuropathy. Recently, studies have suggested a role for gut
microbiome in the development of some peripheral pain, including chemotherapyinduced pain and fibromyalgia. In the present dissertation, we showed that modulation
of gut microbiome in obese mice alleviated neuropathic indices, concurrent with
changes in immune cell profile within the peripheral nerve system. We demonstrated
that fecal transplantation from lean to obese mice decreased obesity-induced pain and
restored nerve density in the skin. These improvements were accompanied by changes
in peripheral nerve system gene expression, calcium signaling and inflammatory cells.
Our results suggested that circulating butyrate, a metabolite secreted by gut microbiome
upon fiber digestion, may be involved in pain improvement by acting directly on
peripheral nerve system cells. We also observed that increasing circulating butyrate
correlated with mechanical pain improvement and decreased inflammatory markers in
the PNS of obese mice.
Because obesity is a state of chronic low-grade inflammation, we hypothesized
that butyrate could modulate inflammation levels to improve neuropathy in obese mice.
Using a caspase-1 biosensor murine model to monitor inflammation, we observed
caspase-1 activation in metabolic and neural tissues, including heart, brown adipose
tissue and brain of lean, obese controls and obese mice subjected to butyrate
ix

treatment. Our data highlighted that butyrate acts on a tissue-specific manner and
rescue some caspase 1-dependent inflammatory responses dysregulated in obesity
settings.

x

CHAPTER I
STATEMENT OF THE PROBLEM
Obesity affects millions of people worldwide and it is currently a major health
problem in the United States. The prevalence of obesity increased from 15% in the late
1970’s, to 42% in 2018 (Hales CM, 2020.). This increase in obesity prevalence has
been followed by a surge in obesity-associated complications, including chronic daily
pain (Nahin, 2015). Approximately, 25 million adults in the United States reported
experiencing chronic pain daily in 2015 (Nahin, 2015). The Institute of Medicine
identified obesity among the main contributors to chronic pain development (Institute of
Medicine (US) Committee on Advancing Pain Research, 2011). In addition, a study from
Stokes et al. linked body-mass index (BMI) with opioid use: higher BMIs were
associated with higher percent of individuals reporting chronic opioid (Stokes et al.,
2019). Remarkably, the association between BMI and opioid use was more pronounced
for morphine and stronger opioids (Stokes et al., 2019). Thus, this cross-sectional study
identified that obese patients are more likely to receive strong opioid treatment, partially
due to a high prevalence of chronic pain conditions among them (Stokes et al., 2019).
Painful peripheral neuropathy is highly correlated with some metabolic
syndrome (MetS) components, especially obesity and type 2 diabetes mellitus
(T2DM) (Callaghan, Gao, et al., 2018; Callaghan, Reynolds, et al., 2020;
Callaghan et al., 2016). Nearly 50% of obese Americans experience neuropathy
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symptoms (Feldman, Nave, Jensen, & Bennett, 2017), irrespective of their glycemic
levels (Callaghan, Gallagher, Fridman, & Feldman, 2020). Moreover, normoglycemic
obese patients show indices of peripheral neuropathy (Petropoulos et al., 2018),
suggesting that mechanisms other than hyperglycemia could be involved in the
pathophysiology of obesity-induced neuropathy. The current therapies available to treat
obesity-induced neuropathy mainly focus on lifestyle changes, such as (i) dietary
modifications and exercise – aiming at weight loss – and (ii) pain management
(Feldman et al., 2019). This lack for disease-modifying treatments is mainly due to a
poor understanding of the neurobiology underlying painful peripheral neuropathy in
obese individuals.
Recently, studies showed that obese individuals have a distinct gut microbiome
composition, usually presenting less overall bacterial diversity and abundance (de
Clercq, Groen, Romijn, & Nieuwdorp, 2016; Dugas, Bernabe, et al., 2018; Dugas, Lie, et
al., 2018). A large body of evidence has linked gut microbiome diversity to metabolic
health, while alterations of gut microbiome composition have been linked to disease,
including obesity (K. E. Bouter, van Raalte, Groen, & Nieuwdorp, 2017; de Clercq,
Frissen, Groen, & Nieuwdorp, 2017; de Clercq et al., 2016; Nieuwdorp, Gilijamse, Pai, &
Kaplan, 2014). The gut microbiome has been shown to exert fundamental roles in
metabolism, inflammation, and brain function, conferring protective role against weight
gain and obesity-associated metabolic insults and cognitive impairment (Dalile, Van
Oudenhove, Vervliet, & Verbeke, 2019; Gupta, Osadchiy, & Mayer, 2020; Patterson et
al., 2016).
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Recently, the gut microbiome was demonstrated to play a role in
peripheral pain states (Aguilera, Cerdà-Cuéllar, & Martínez, 2015; Minerbi et al.,
2019; Shen et al., 2017; SM, Dinan, & Cryan, 2017). A seminal work
demonstrated that gut microbiome eradication protected mice from developing
chemotherapy-induced pain (Shen et al., 2017). Another study showed that a
specific gut microbiome metabolite – butyrate – alleviated neuropathic pain in a
chronic constriction injury model (Kukkar, Singh, & Jaggi, 2014). However, to
date, there are no clear links between neuropathic pain and the gut microbiome
in the context of obesity. Thus, this dissertation aimed at deciphering the role of
gut microbiome and one of its derived metabolites – butyrate – in obesity-induced
neuropathy and neuropathic pain.

CHAPTER II
INTRODUCTION
Literature Review
Obesity, Metabolic Syndrome and Complications.
Obesity (defined as body-mass index (BMI) greater than or equal to 30 Kg/m2) is
one of the main epidemiological health issues worldwide (Hales, Carroll, Fryar, &
Ogden, 2017). The prevalence of obesity has risen from 15% in 1980 to 42% in 2018 in
the United States (Hales CM, 2020.) and it continues to grow yearly, mainly as a result
of modern lifestyle choices (O'Brien, Hinder, Callaghan, & Feldman, 2017). Obesity has
been implicated in the pathogenesis of many disorders, including cardiovascular
disease and metabolic syndrome (MetS) (Grundy et al., 2004). Overweight and obese
patients can be categorized according to BMI as: (i) overweight (25 ≥ BMI < 30), (ii)
obese I (30 ≥ BMI < 35), (iii) obese II (35 ≥ BMI < 40), and (iv) obese III (40 ≤ BMI ≤ 80)
(Hales et al., 2017). The increase in adiposity is concurrent with increases in risk for
cardiovascular disease development, increases in circulating factors associated with
MetS worsening, such as pro-inflammatory cytokines and nonesterified fatty acids, as
well as increases in death risk (Grundy et al., 2004).
MetS affects more than 3 million people in the U.S. (Grundy et al., 2004) and in
2017, 22% of adults in the United States met MetS criteria (Stino & Smith, 2017).
According to the National Cholesterol Education Program Adult Treatment Panel III
(ATP III) from the National Heart, Lung, and Blood Institute, MetS comprises: (i)
4
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abdominal obesity; (ii) dyslipidemia; (iii) hypertension; (iv) insulin resistance (with
or without glucose intolerance); (v) proinflammatory state; and (vi) prothrombotic
state (Grundy et al., 2004) (Figure 1).

Figure 1. Metabolic Syndrome. In order to be diagnosed with metabolic syndrome
(MetS), a patient must present with three or more of the following or currently be under
treatment for them: (1) insulin resistance (fasting glucose ≥ 100 mg/dL), (2)
hypertension (blood pressure ≥ 130/85 mmHg), (3) hypertriglyceridemia (≥ 150 mg/dL),
(4) low HDL (< 40 mg/dL in men; < 50 mg/dL in women) and (5) abdominal obesity
(waist circumference ≥ 102 cm in men; > 88 cm in women). Obesity is defined as a body
mass index (BMI) > 30 kg/m2 in both men and women and it has been mostly
associated with neuropathy. Individuals with metabolic syndrome tend to persist in a
prothrombotic and proinflammatory state that leaves them at high risk of a wide range of
complications including but not limited to cardiovascular disease, type 2 diabetes, nonalcoholic steatohepatitis and portal vein thrombosis. From Bonomo et al., Antioxidants
and Redox Signaling, under review.
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Briefly, abdominal obesity is presented as increased waist circumference (> 88
cm in women and > 102 cm in men) (Grundy et al., 2004). Dyslipidemia refers to
elevated blood levels of triglycerides (higher than 150 mg/dL) and altered levels of
circulating lipoproteins, such as decreased high-density lipoprotein (HDL) cholesterol (<
50 mg/dL for women and < 40 mg/dL for men) (Grundy et al., 2004). Hypertension is
defined as elevated systolic and/or diastolic blood pressure (≥ 130/ ≥ 85 mm Hg).
Insulin resistance commonly refers to the body’s inability to respond to insulin mainly
due to impaired signaling in insulin-dependent tissues, such as skeletal muscle. Insulin
resistance often leads to hyperinsulinemia, and generally precedes glucose intolerance,
prediabetes (fasting glucose ≥ 110 mg/dL) and diabetes (fasting glucose ≥ 126 mg/dL)
(Grundy et al., 2004). Proinflammatory state is defined clinically as elevated levels of Creactive protein, an acute phase reactant produced by the liver in response to
inflammation (≥ 2 mg/L; Mayo Clinic) (Yousuf et al., 2013) (Grundy et al., 2004). Lastly,
prothrombotic state refers to elevated levels of plasminogen activator inhibitor (PAI)-1
and fibrinogen; acute phase reactants produced in response to elevated cytokine
release (Grundy et al., 2004). Remarkably, all of the MetS components are strongly
associated with obesity, thus, although being one of the MetS constituents, MetS can be
viewed as a cluster of obesity complications (Grundy et al., 2004) (Table 1).
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Table 1. ATP III Clinical Identification of the Metabolic Syndrome. (Grundy et al., 2004).

Obesity is highly associated with complications beyond the MetS scope,
including arthritis and chronic pain (Stokes et al., 2019). Obesity is also a risk
factor for the development of neurological disorders of the central and peripheral
nervous systems (CNS and PNS, respectively) and it correlates with mild
cognitive impairment and peripheral neuropathy (O'Brien et al., 2017). Recent
evidence suggests obesity as one of the main drivers of painful peripheral
neuropathy . The present literature review will discuss some of the current
knowledge regarding the pathophysiology of neuropathy and neuropathic pain in
obese patients, and it will later introduce a novel potential therapeutic approach
involving modulation of the gut microbiome.
Neuropathy in Diabetes and Obesity.
Recent investigations reveal that obesity (with impaired glucose tolerance
but without overt and persistent hyperglycemia) is significantly associated with
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peripheral neuropathy (Callaghan, Gao, et al., 2018; Callaghan, Reynolds, et al., 2020;
Callaghan, Xia, et al., 2018; Cortez, Singleton, & Smith, 2014). It is estimated that
neuropathy affects approximately 25% of obese, pre-diabetic Americans (Cortez et al.,
2014). In peripheral neuropathy, autonomic, motor and sensory peripheral nerves are
damaged (Barrell & Smith, 2019). Many peripheral neuropathies have been identified to
date and are classified according to the number of nerves affected: (i) mononeuropathy
– only one nerve is damaged, (ii) mononeuropathy multiplex – two or more nerves, and
(iii) polyneuropathy – when many nerves are injured (Hanewinckel, Ikram, & Van Doorn,
2016). The symptoms vary according to the type of nerve affected: neuropathy of
autonomic nerves typically leads to innervated organ dysfunction, for instance, urinary
incontinence or cardiac arrythmias. Motor neuropathies result in muscle weakness and
atrophy. Sensory neuropathies are known to cause neuropathic pain and/or numbness
(Barrell & Smith, 2019; Hanewinckel, Ikram, et al., 2016). Additionally, neuropathies can
either be acute or chronic depending on the disease time course (Hanewinckel, Ikram,
et al., 2016). Among chronic polyneuropathies, diabetic polyneuropathy is the most
prevalent as it accounts for up to 50% of all polyneuropathies (Hanewinckel, van Oijen,
Ikram, & van Doorn, 2016). Diabetic neuropathy is a direct consequence of chronic
diabetes in 50% of cases and commonly presents as distal symmetric polyneuropathy
(DSP) (Feldman et al., 2019). Twenty to sixty percent of affected individuals report
neuropathic pain as one of the main symptoms (Callaghan, Cheng, Stables, Smith, &
Feldman, 2012; Hanewinckel, van Oijen, et al., 2016).
Interestingly, 20-50% of peripheral neuropathies are idiopathic (Thomas et al.,
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2019) and associated with prediabetes, obesity and MetS (Barrell & Smith,
2019). A large body of evidence indicates that components of MetS are non
glucose-dependent and are linked to peripheral neuropathy onset and
progression (Calcutt, 2020; Callaghan, Little, Feldman, & Hughes, 2012; Cortez
et al., 2014; Feldman et al., 2019; O'Brien et al., 2017; Smith & Singleton, 2008,
2013; Stino & Smith, 2017). Studies have demonstrated that intensive glucose
control is ineffective at improving neuropathic pain in some patients with type 2
diabetes mellitus (T2DM) (Duckworth et al., 2009; Gerstein et al., 2007; IsmailBeigi et al., 2010). In addition, prediabetic obese patients and individuals with
MetS show indices of peripheral neuropathy, despite the absence of diabetes
(Petropoulos et al., 2018). A recent study from Callaghan et al. showed that
obese patients had higher prevalence of neuropathy when compared to lean
control individuals, including among normoglycemic participants (Callaghan et
al., 2016). Moreover, the obese participants from this study had severe indicators
of neuropathy, as observed by alterations in nerve conduction studies (NCS) and
intraepidermal nerve fiber (IENF) density analysis, hallmarks of neuropathy
(Callaghan et al., 2016). Together, these data implicate mechanisms other than
hyperglycemia as possible underlying causes of peripheral neuropathy in obese
patients.
Neuropathic Pain and the Pain Pathway.
As mentioned, up to 60% of neuropathy patients experience neuropathic
pain as one of the main symptoms (Callaghan, Cheng, et al., 2012; Hanewinckel,
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van Oijen, et al., 2016). Pain, recently redefined as “an unpleasant sensory and
emotional experience associated with, or resembling that associated with, actual
or potential tissue damage” by the International Association for the Study of Pain (IASP)
(Raja et al., 2020), is a critical conserved protection mechanism that aims at evading
tissue damage, inflammation and disease. This acute adaptive function is crucial for our
wellbeing. However, acute pain can become maladaptive due to central or peripheral
sensitization and lead to chronic pain states (Raja et al., 2020; Scholz & Woolf, 2002).
Because of the several nuances, complexity, and subjectivity involving pain, it is
necessary to distinguish nociceptive from neuropathic pain. Nociceptive pain is defined
by IASP as “pain that arises from actual or threatened damage to non-neural tissue and
is due to the activation of nociceptors”. On the other hand, neuropathic pain is "pain
caused by a lesion or disease of the somatosensory nervous system”. These definitions
are contrasted by the fact that nociceptive pain indicates a normally functioning
somatosensory system, while neuropathic pain denotes abnormal activity in the
nociceptive pathway that is unrelated to nociceptor stimulation (Raja et al., 2020).
Nociceptive pathway. The nociceptive pathway comprises the neuronal fibers
that detect peripheral stimuli and convey that information to higher orders of the brain
(Scholz & Woolf, 2002) (Figure 2). These fibers, named nociceptors, are the primary
sensory afferents that initiate pain transduction and are able to sense a range of
noxious stimuli, including thermal, mechanical, and chemical insults (Julius & Basbaum,
2001). This diverse repertoire signifies that, often, a given afferent fiber is capable of
detecting more than one stimulus – polymodality (Basbaum, Bautista, Scherrer, &

11
Julius, 2009). The stimulus that initiates pain response can be distinguished based on
nociceptors’ electrophysiological properties (Julius & Basbaum, 2001) for instance,
currents (ionic flow) produced by heat differ from currents produced by mechanical
stimulation. Moreover, nociceptors present specific activation thresholds that are
dependent on receptor potentials generated by the transduction molecules expressed
on the neuronal surface (Julius & Basbaum, 2001; Scholz & Woolf, 2002; Woolf &
Salter, 2000). Receptor potentials are graded potentials produced in response to
nociceptor activation. They are responsible for the initial neuronal depolarization and,
when threshold is reached, they give rise to action potentials and consequent
transduction of the pain signal from the PNS to the CNS (Julius & Basbaum, 2001;
Scholz & Woolf, 2002; Woolf & Salter, 2000).
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Figure 2. Nociceptive Pathway. Primary nociceptors (in blue) transduce pain
information from the nerve endings to neuronal cell bodies located in the dorsal root
ganglia (DRG). From there, nociceptors synapse to secondary order neurons located
within the dorsal horn of the spinal cord, while mechanosensory fibers synapse to
secondary neurons in the cuneate and gracile nuclei at the level of the medulla. Noxious
and mechanosensory information is then relayed to the somatosensory cortex via the
thalamus. Neuroscience 5th Edition.
The nociceptors have yet another unique characteristic: they are pseudo-unipolar
neurons and thus have one long axonal projection innervating both ends (i) at the
terminal organ and (ii) at the spinal cord (Basbaum et al., 2009). They are classified in
Ad and C fibers with respect to morphology and the type of stimulation able to elicit a
response (Figure 3), and have their cell bodies located within the dorsal root ganglia
(DRG), when innervating the body, and within the trigeminal ganglion, when innervating
the face (Basbaum et al., 2009). Ad nociceptors are of medium diameter, thinly
myelinated fibers that can respond to mechanical, thermal and chemical stimulation. Ad
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Type I afferents have a high thermal threshold, while Ad Type II fibers are mostly
mechanically insensitive (Julius & Basbaum, 2001). Differently, C-fibers are small and
unmyelinated, but much like the Ad nociceptors, C afferents are polymodal and respond
to diverse types of stimuli (Julius & Basbaum, 2001; Scholz & Woolf, 2002; Woolf &
Salter, 2000). Lastly, C-fibers can be peptidergic or non-peptidergic, which refers to the
ability of a subpopulation of C nociceptors to secrete neuropeptides, such as calcitoningene related peptide (CGRP) and substance P, that act as modulators of synaptic
transmission (Basbaum et al., 2009)

Figure 3. Types of Afferents. Afferent fibers and nociceptors can be classified as:
myelinated with medium and large diameters (Aa, Ab) afferents; thinly myelinated with
small diameter (Ad); and unmyelinated with small diameter fibers (C). (Julius &
Basbaum, 2001)
Acute pain. As mentioned above, nociceptive pain is a normal state in which the
organism is able to differentiate noxious from non-noxious stimulation. The threshold for
nociceptor activation, and consequently for differentiation of noxious insults, is set by
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receptors and channels located on afferent terminals (Julius & Basbaum, 2001; Scholz
& Woolf, 2002; Woolf & Salter, 2000). Several transducer proteins have been described
to date, including some from the Transient Receptor Potential (TRP) family, such as
Transient Receptor Potential Cation Channel Subfamily V Member 1 (TRPV1) and
Transient Receptor Potential Melastatin-8 (TRPM8), among others. Briefly, TRPV1 are
heat-sensitive, non-selective cation channels with a thermal threshold of around 43oC
(Basbaum et al., 2009). TRPV1 channels are also sensitive to low pH and capsaicin.
TRPM8, differently, are menthol- and cold-sensitive channels with a threshold around
25oC (Basbaum et al., 2009). Transducers, when activated at or above threshold,
generally allow for cation influx, depolarization and activation of voltage-gated ion
channels responsible for generation of action potential and subsequent conduction of
the pain signal (Basbaum et al., 2009). The ability of the nervous system to modulate
nociceptor activation threshold is called neuronal plasticity and it distinguishes adaptive
from maladaptive pain responses that lead to chronic pain states, including neuropathic
pain (Scholz & Woolf, 2002).
Current Therapies for Obesity-induced Neuropathy and Neuropathic Pain.
The increase in obesity prevalence has been accompanied by a rise in chronic
opioid use, mostly due to a high prevalence of chronic pain, neuropathies, and
neuropathic pain among obese individuals (Stokes et al., 2019). Besides opioids,
current chronic pain therapies mainly focus on alleviating the symptoms and are not
disease-modifying. Anticonvulsants (pregabalin and gabapentin), serotonin and
noradrenaline reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) are the
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first line drugs recommended for neuropathic pain management in obese patients
(Feldman et al., 2019) (Figure 4).
Anticonvulsants promote presynaptic inhibition of calcium currents through
voltage-gated calcium channels containing the a2δ subunits, and ultimately
diminish pain by reducing neurotransmitter release and postsynaptic excitability
(Tzellos, Papazisis, Toulis, Sardeli, & Kouvelas, 2010). Among SNRIs, dulexetine
and venlafaxine are effective against neuropathic pain by increasing serotonin
and noradrenalin concentrations in the synaptic cleft, with minimal-to-no effect on
the postsynaptic neuron (Sindrup, Otto, Finnerup, & Jensen, 2005).
Amitriptyline is the main TCA recommended to treat neuropathic pain associated
with obesity (Feldman et al., 2019) and act by inhibiting presynaptic reuptake of
monoamines and also by blocking postsynaptic α- adrenergic, H1-histaminergic
and muscarine receptors (Sindrup et al., 2005).
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Figure 4. Treatments for Neuropathic Pain. Anticonvulsants, Serotonin and
Noradrenaline Reuptake Inhibitors (SNRIs) and Tricyclic antidepressants (TCA) are
first-line treatments for neuropathic pain. Modified from Feldman, Callaghan, et al.
Weak opioids, such as tramadol, in addition to lidocaine and capsaicin, are
generally used as second-line drugs due to low-to-moderate quality of evidence
(Finnerup et al., 2018). Strong opioids and botulinum toxin type A are considered thirdline drugs due to adverse effects and low quality of evidence, respectively (Finnerup et
al., 2018). Lastly, cannabinoids, N-Methyl-D-Aspartate (NMDA) antagonists, and nonsteroidal anti-inflammatory drugs (NSAIDs), among other drugs, have limited evidence
as treatment for obesity-induced neuropathic pain and their recommendation is
inconclusive. (Finnerup et al., 2018) (Table 2).
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Table 2. Therapeutic Recommendations for Neuropathic Pain. First-, second- and
third-line drugs recommended to treat neuropathic pain. *FDA and EMEA approval for
the treatment of postherpetic neuralgia. **Common side effects: antidepressants:
somnolence, constipation, dry mouth (particularly TCAs), nausea (particularly
duloxetine); pregabalin/gabapentin: somnolence, dizziness, weight gain; opioids
(including tramadol): constipation, nausea, vomiting, tiredness, somnolence, dizziness,
dry mouth, itch; lidocaine patches: local irritation; capsaicin patches: local pain, edema,
erythema; botulinum toxin A: local pain. Abbreviations: SNRIs=serotonin noradrenaline
reuptake inhibitors. TCAs=tricyclic antidepressants ; BTX-A : botulinum toxin type A ;
ER= extended release. From Finnerup et al.

Hyperglycemia-independent Mechanisms Involved in Obesity-induced
Neuropathy and Neuropathic Pain.
The lack of disease-modifying therapies for obesity-induced neuropathy
and neuropathic pain prompted a switch in research from a glucose standpoint
towards alternative underlying mechanisms. Two of the most well-studied nonglucotoxic insults linked to peripheral neuropathy in obesity are: (i) impaired
insulin signaling and (ii) dyslipidemia (Calcutt, 2020). A study led by
Romanovsky, showed that insulin resistant Zucker rat model of type 2 diabetes
mellitus (T2DM) developed pressure pain during pre-diabetes that persisted
throughout disease progression (Calcutt, 2020). The authors compared glucose
metabolism and pressure pain thresholds among Zucker lean (ZL), Zucker fatty
(ZF) and Zucker diabetic fatty (ZDF) rats from 6 to 10 weeks of age. Remarkably,
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pressure pain was significantly different among experimental groups throughout the
experimental paradigm, including at timepoints preceding diabetes development by ZDF
(Romanovsky, Walker, & Dobretsov, 2008). ZL consistently presented the lowest
pressure pain thresholds, while ZF showed intermediate, and ZDF had the highest
ones. Surprisingly, ZDF’s hypersensitivity thresholds were maintained throughout the
study and did not aggravate with diabetes – that progressed from a glucose intolerant
stage to chronic hyperglycemia and severe diabetes (Romanovsky et al., 2008). Lastly,
at 8.5 and 9 weeks of age, hyperinsulinemic ZF animals had significant lower pressure
thresholds than ZL rats, although no statistical differences were detected in glycemic
levels (Romanovsky et al., 2008). These data suggest that pressure pain and nerve
impairment preceded hyperglycemia in this model, are linked to impaired insulin
signaling, and are likely independent of animals’ glycemic status.
PNS insulin resistance has also been demonstrated in a T2DM mouse model
(using the leptin-deficient mouse, ob/ob) (Grote et al., 2013). Reduced activation of
insulin downstream targets can be used as a hallmark of insulin-resistance. Grote et al.
showed that intrathecal injections of insulin or insulin-like growth factor 1 (IGF-1) did not
activate well-known insulin targets in the DRG or sciatic nerve (SN) of diabetic mice
when compared to nondiabetic controls (Grote et al., 2013). Moreover, DRG of ob/ob
mice had decreased expression of the insulin receptor, a mechanism involved in insulin
resistance (Grote et al., 2013). Together, this study is the first to demonstrate PNS
insulin resistance in vivo in obese diabetic mice. The data also suggest that
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hyperinsulinemia, seen in ob/ob mice, is likely to mediate insulin resistance observed in
the PNS of diabetic mice through downregulation of insulin receptors in PNS cells.
Dyslipidemia i.e., hypertriglyceridemia and altered levels of lipoproteins, is yet
another main driver of painful peripheral neuropathy in obesity (Calcutt, 2020; Grisold,
Callaghan, & Feldman, 2017; Wiggin et al., 2009). A study by O’Brien et al. identified
elevated triglycerides derived from saturated fatty acids in nerves of diet-induced obese
(DIO) mice (O'Brien et al., 2020). The authors revealed that animals fed a diet high in
saturated fatty acids for 16 weeks developed neuropathy indices, as previously showed
(Hinder et al., 2017; O'Brien et al., 2020). However, when switched to standard chow for
8 more weeks, both neuropathy and increased triglycerides were reversed (O'Brien et
al., 2020). This study suggests that saturated fatty acids may be a pro-neuropathic
factor that likely underlies neuropathy and neuropathic pain in obesity.
In another particular study, Rumora et al. demonstrated that mice fed a lardbased diet (consistent of saturated fatty acids) had reversed indices of neuropathy, such
as intraepidermal fiber loss and neuropathic pain, when switched to a monounsaturated
fatty acid-rich diet (Rumora et al., 2019). Monosaturated fatty acids, for instance olive
oil, are known to improve metabolic parameters, lower insulin resistance, and normalize
dyslipidemia by restoring triglycerides levels. (Rumora et al., 2019) The authors
determined that the different fatty acid composition of the two diets had effects on
neuronal mitochondria motility and function, as well as on apoptosis and lipid drop
formation (Rumora et al., 2019). These data indicate that adjusting dietary fatty acid

20
composition from saturated to unsaturated fat can restore nerve function and improve
neuropathy in obese rodents.
Remarkably, the change in focus from glucotoxic to alternative mechanisms is
still recent and research in these areas is ongoing. Despite some evidence regarding
hyperglycemic-independent pathways, such as insulin resistance and dyslipidemia, in
the pathophysiology of obesity-induced neuropathy and neuropathic pain, the disease
pathogenesis remains largely unclear, prompting investigations in novel areas (Figure
5).
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Figure 5. Hyperglycemia-independent Pathways Involved in Obesity-induced
Neuropathy. Recently, non-glucotoxic mechanisms have been described to play a role
in neuropathy in the context of obesity. For instance, altered insulin signaling and
dyslipidemia have been linked to neuropathy and neuropathic pain. Both mechanisms
have been shown to lead to defective pain transmission by affecting specific peripheral
primary afferents that comprise the peripheral nerves and that have cell bodies located
within the dorsal root ganglia (DRGs) in the PNS. However, the CNS, including the
spinal cord and the somatosensory cortex, remain largely understudied in obesityinduced neuropathy and could be important sites to decipher disease pathophysiology.
Modified from Bonomo et al., Antioxidants and Redox Signaling, under review.
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Rodent Models to Study Obesity-induced Neuropathy and Neuropathic Pain.
Animal models can offer insights about disease onset and progression;
Biessels et al. published an in-depth review of the animal models suitable for
studying diabetic and obesity-induced neuropathy (Biessels et al., 2014). The
streptozotocin (STZ) diabetic rat has been the most used model. These animals
illustrate neuropathy observed in patients with insulin deficient Type 1 Diabetes
Mellitus (T1DM) and they present behavioral and structural changes
characteristic of the disease, such as allodynia and impaired nerve conduction
velocities (Biessels et al., 2014). Shorter STZ treatments are used to investigate
early neuropathy symptoms, including behavioral changes and defective nerve
conductance, while longer STZ duration are usually required to observe
structural changes, such as nerve damage and fiber loss (Biessels et al., 2014).
Despite known hyperglycemic mechanisms, there has been a lot of interest in
non-glucotoxic events that may underlie the pathophysiology of diabetic and
especially of obesity-induced neuropathy. Among these studies, a few have
shown particularly strong associations between insulin deficiency and early
neuropathy signs. A study by Romanovsky et. al. demonstrated that
normoglycemic rats, injected with streptozotocin (STZ) at doses that reduce
circulating insulin, presented with lower thresholds to elicit pressure pain
(Romanovsky, Cruz, Dienel, & Dobretsov, 2006). Moreover, when
normoglycemic-STZ rats were subjected to insulin therapy, pressure nociception
was alleviated (Romanovsky et al., 2006). Importantly, during insulin therapy, the
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plasma insulin was maintained at levels within the range of hypo and hyperglycemia.
This study, therefore, indicated that insulinopenia in a normoglycemic state is
associated with early signs of neuropathy (Romanovsky et al., 2006). However, the
main limitation of the STZ model is that STZ-treated mice often lose weight and may
become cachectic and therefore it does not represent the best model to study obesityinduced neuropathy and neuropathic pain.
Two of the most common genetic models of obesity include the leptin receptor
deficient mouse (db/db) and the leptin deficient mouse (ob/ob) (Table 3). These animals
develop insulin resistance and glucose intolerance, alongside impaired nerve
conduction velocity, decreased cutaneous nerve fiber densities, and altered pain
behavior: thermal hypoalgesia starting at 12 weeks of age and tactile allodynia at 21
weeks of age (Biessels et al., 2014; O'Brien, Sakowski, & Feldman, 2014). Although
relevant, two main drawbacks of genetic mouse models of obesity are: (i) the leptin
receptor is broadly expressed, including in the PNS, and (ii) leptin pathways are altered
in the nervous systems of these animals, thus confounding interpretation. Grote et al.
demonstrated PNS insulin resistance in the leptin-deficient mouse, ob/ob, since
intrathecal injections of insulin did not activate insulin pathways in the DRG and SN of
diabetic mice (Grote et al., 2013). Furthermore, human obesity is rarely linked to genetic
mutations in leptin pathways. Thus, animal models of obesity using special diets are
more physiologically appropriate to study obesity-induced neuropathy.

23
Table 3. Genetic Models to Study Obesity-induced Neuropathy and Neuropathic
Pain. Genetic rodents present distinct neuropathy phenotyping with regards to different
strains and age. DRG, dorsal root ganglia; IENFD, intraepidermal nerve fiber density;
MNCV, motor nerve conduction velocity; NCV, nerve conduction velocity; Ns Δ, no
significant change; SNCV, sensory nerve conduction velocity. a Phenotyping was
performed at final age unless indicated otherwise (O'Brien et al., 2014).

Diet-induced obesity (DIO) animal models include high-fat diets (HFD) and
more recently, Western diet (WD) (Figure 5). Rodents fed respective diets
become obese, insulin resistant and develop early indices of neuropathy, such as
mechanical allodynia and IENF loss (Biessels et al., 2014; O'Brien et al., 2014).
Importantly, different from genetic models, mice on these diets develop ‘’prediabetes’’ (O'Brien et al., 2014), a condition that has been linked to peripheral
neuropathy in nondiabetic obese patients and remains largely unstudied in
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neuropathy settings (Stino & Smith, 2017). The gradual development of metabolic and
neuropathic insults represents the human condition, making DIO models instrumental to
understand neuropathy onset and progression (O'Brien et al., 2014). Many HFD are
commercially available, and they differ on fat content and sources. The most popular
HFD contain either 54% fat from vegetable oil (Harlan Teklad) or 58% fat from coconut
oil (Research Diets). Rodents fed the former, develop mechanical allodynia and
decreased motor nerve conductance velocity after 8 weeks of diet onset; while mice fed
the latter, develop mechanical and thermal hypoalgesia following 16 weeks on HFD.
Remarkably, mice fed a HFD do not present fiber loss, hallmark of peripheral
neuropathy (O'Brien et al., 2014). Discrepancies are seen in neuropathy phenotyping
and they can be attributed to differences in diet composition, onset, duration, animals’
age and sex, among others (O'Brien et al., 2014) (Table 4).

25
Table 4. Diet-induced Obesity (DIO) Models to Study Obesity-induced Neuropathy
and Neuropathic Pain. DIO rodents present distinct neuropathy phenotyping with
regards to different diet composition, duration, and mice age. HFD, high-fat diet; IENFD,
intraepidermal nerve fiber density; MNCV, motor nerve conduction velocity; NCV, nerve
conduction velocity; Ns Δ, no significant change; SNCV, sensory nerve conduction
velocity. a Phenotyping was performed at final age unless indicated otherwise (O'Brien
et al., 2014).

The WD (Western-Diet, 42 % fat, 0.2% cholesterol, 34% sucrose)-fed
mouse model develop obesity, alongside with insulin resistance, glucose
intolerance, dyslipidemia, and exhibit indices of neuropathy and neuropathic pain
(Gavini et al., 2018; Jayaraj et al., 2018; Megat et al., 2019) (Gavini, Bonomo, &
Mansuy-Aubert, 2020; Gavini et al., 2018; Gavini, Cook, Rademacher, &
Mansuy-Aubert, 2020; Jayaraj et al., 2018) (Table 4 and Figure 6). Early thermal
hyperalgesia that progresses to hypoalgesia, tactile allodynia and reduced nerve
conduction velocities are all early neuropathy hallmarks of WD-fed mice. Further,
similar to human subjects with obesity, but in contrast to mice fed a simple high
fat diet (HFD: 50-60% fat), WD-fed mice display a reduction of IENF density
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(Obrosova et al., 2007) (Jayaraj et al., 2018) indicating loss of small sensory nerve fiber
terminals. Lastly, the WD better represents the diet consumed by obese humans, since
60% fat is extreme and not illustrative of human condition (O'Brien et al., 2014). The
WD-fed model is important to i) evaluate onset of disease and ii) discover novel early
targets that may delay disease progression (Hinder et al., 2017; O'Brien et al., 2014).
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Figure 6. Western Diet (WD)-fed Mouse Model: Metabolism and Behaviors.
WD-fed mice consume a diet composed of 42% fat, 34% sucrose and 0.2% cholesterol
(EnVigo TD88137). Compared to regular/normal chow-fed mice, these animals display
increased body weight, glucose intolerance, insulin resistance, hypertriglyceridemia and
hypercholesterolemia. After 6-10 weeks of feeding, they present reduced intraepidermal
nerve fiber density, mechanical allodynia, as well as hyperalgesia or hypoalgesia in
response to thermal stimulation (results vary between laboratories). From Bonomo et
al., Antioxidants and Redox Signaling, under review.
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Gut Microbiome.
Gut microbiome in metabolic health and disease. The gut microbiome
comprises trillions of microorganisms – mainly bacteria – that reside within the
digestive system (Patterson et al., 2016). Under healthy conditions, host and
microbiome are in a symbiotic relationship, exchanging factors and nutrients (Patterson
et al., 2016). This bidirectional signaling allows for a functional digestive tract and
overall host metabolism (Patterson et al., 2016). Recent technological advances,
including metagenomic sequencing and germ-free animal models, have permitted the
identification of microbiome species along the gastrointestinal (GI) tract and of their
roles in metabolic health conditions (Patterson et al., 2016).
Diet is one of the main environmental drivers of gut microbiome
abundance, composition and diversity (Patterson et al., 2016). While the gut
microbiome can be consistent and stable throughout the years, it is easily
susceptible to different dietary patterns that can promote the growth of specific
types of bacteria (Patterson et al., 2016). Although mainly a result of energy
imbalance, obesity has also been linked to gut microbiome alterations, commonly
referred to as dysbiosis (Gupta et al., 2020) (Figure 7).
Differences in gut microbiome composition have been observed in obese
humans and animal models, and while sometimes inconsistent, the results from
these studies linked obesity to decreased in bacteria richness, as well as to
changes in ratio of Firmicutes to Bacteroidetes – the two most prevalent phyla
(Gupta et al., 2020; Patterson et al., 2016; Thingholm et al., 2019). Thingholm et

28
al. identified lower alpha-diversity, taxonomic and functional profiles, and specifically
decreased levels of Akkermansia and Oscillibacter genera in obese patients in
comparison to healthy lean controls in a German cohort (Thingholm et al., 2019).
Moreover, certain anti-inflammatory species, including Faecalibacterium prausnitzii,
were also decreased in obese individuals (Thingholm et al., 2019).

Figure 7. Obesity-associated Alterations in Gut Microbiome. Obesity leads to
alterations in gut microbiome composition, abundance and taxonomic and functional
profiles. Modified from Thingholm et al.
Rodent models of obesity have also been associated with decreased microbiome
richness and abundance, that in part explain some of the obesity-associated phenotype
(Gupta et al., 2020). For instance, in a study by Caeser et al., mice fed a diet high in
saturated fat had increased levels of lipopolysaccharide (LPS) in comparison to mice
fed a diet rich in polyunsaturated fatty acids (Caesar, Tremaroli, Kovatcheva-Datchary,
Cani, & Bäckhed, 2015). Increased plasma LPS – a phenomenon called endotoxemia –
indicated disruption of intestinal epithelial barrier that allowed microbial factors to reach
the circulation and affect peripheral organs (Caesar et al., 2015). This effect was
concurrent with inflammation of white adipose tissue and alterations of gut microbiome
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composition. These results were further extended and confirmed in germ-free
mice, demonstrating that diet and gut microbiome interact to regulate obesityassociated adipose tissue inflammation and gut barrier function (Caesar et al.,
2015).
In addition, germ-free animals are protected from developing diet-induced
obesity (Bäckhed, Manchester, Semenkovich, & Gordon, 2007). In a seminal
work, Backhed et al. demonstrated that mice lacking gut microbiome colonization
are resistant against Western diet-induced obesity via mechanisms aiming at
increasing peripheral fatty acids oxidation (Bäckhed et al., 2007). The authors
observed that germ-free mice had increased levels of phosphorylated AMPactivated protein kinase (AMPK) in skeletal muscle and liver, suggesting an
increase in fatty acid metabolism in these tissues (Bäckhed et al., 2007). This
mechanism could explain, in part, the protective role the gut microbiome can
confer against diet-induced obesity (Bäckhed et al., 2007).
The gut microbiome synthesizes metabolites from dietary products and
regulates host compounds, including short-chain fatty acids (SCFA),
neurotransmitters (serotonin and dopamine, among others), bile acids and
histamine (Jameson, Olson, Kazmi, & Hsiao, 2020). SCFA are one of the main
byproducts of fiber fermentation by the gut microbiome (Gupta et al., 2020). The
most predominant SCFA are acetate, propionate and butyrate and they are used
as fuel source by colonocytes and hepatocytes, for example.
In cells, SCFA can act as signaling molecules through two main
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mechanisms: (i) by directly activating G-coupled protein receptors (GPCRs) and/or (ii)
by inhibiting histone deacetylases (HDACs). Free Fatty Acid Receptors 2 and 3 (FFAR2
and FFAR3, respectively) are the two most well-studied SCFA receptors and they are
largely expressed throughout the body. FFAR2 is mainly found in enteroendocrine and
immune cells, while FFAR3 is found in the colon and sympathetic neurons, among other
cells (Dalile et al., 2019). FFAR2 can be coupled to Gaq or Gai/o and thus it can activate
distinct signaling cascades (Ichimura, Hasegawa, Kasubuchi, & Kimura, 2014; Kimura,
Ichimura, Ohue-Kitano, & Igarashi, 2020). When associated with Gaq, FFAR2 leads to
phospholipase C (PLC) activation and terminally calcium (Ca2+) release from
endoplasmic reticulum (ER) via inositol 1,4,5-triphosphate (IP3). On the other hand,
when FFAR2 is linked to Gai/o, the main endpoint is decreased generation of cyclic
adenosine monophosphate (cAMP) by inhibition of adenylyl cyclase (AC). FFAR3 is,
however, exclusively coupled to Gai/o and therefore leads to reduced cAMP production
when activated (Kimura et al., 2020). Lastly, FFAR2 and FFAR3 can heterodimerize
and produce a completely distinct signaling pathway (Kimura et al., 2020). The main
features of the heterodimer are increased intracellular Ca2+ ([Ca2+]i) and decreased
cAMP generation (Kimura et al., 2020).
SCFA are known to regulate gene transcription via their histone deacetylase
(HDAC) inhibition activity (Dalile et al., 2019) (Figure 8). HDACs are enzymes that
catalyze removal of acetyl groups bound to N-tails of histones. When HDACs are
inhibited, histones are left acetylated and the chromatin is less compact, which allows
for enhanced gene transcription (Kimura et al., 2020). HDAC inhibition has been shown
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to be a mechanism via which butyrate exerts anti-inflammatory properties
(Chang, Hao, Offermanns, & Medzhitov, 2014). In LPS-stimulated bone marrowderived macrophages (BMDM), butyrate normalized production of proinflammatory cytokines, such as interleukin 6 (IL-6), suggesting an antiinflammatory role for butyrate (Chang et al., 2014). Moreover, butyrate acted as a
HDAC inhibitor in BMDM by promoting histone 3 hyperacetylation (Chang et al.,
2014). These data suggest that butyrate exerts its anti-inflammatory effects by
inhibiting HDACs.

Figure 8. SCFA Modulate Gene Expression. Upon internalization via
monocarboxylate transporters (MCTs) and sodium-dependent monocarboxylate
transporters (SMCTs), SCFA can modulate gene transcription. By inhibiting the activity
of histone deacetylases (HDACs) or possibly activating histone acetylases (HATs),
SCFA increase chromatin acetylation and allow for a more transcriptionally active
chromatin and enhancement of gene transcription. Modified from Dalile et al.
SCFA can reach the systemic circulation and are molecular mediators in
the gut-brain axis (Gupta et al., 2020; Patterson et al., 2016). A study by
Arnoldussen et al. demonstrated that obese mice fed a high-fat diet
supplemented with butyrate had improved metabolic parameters, including
weight loss and attenuation of hypertriglyceridemia, in addition to restored
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obesity-induced memory impairment demonstrated by shorter latency in the Morris
water maze (Dalile et al., 2019). Remarkably, obese mice supplemented with butyrate
also had decreased number of activated microglia in the thalamus and hippocampus,
indicating reduced neuroinflammation in comparison to obese controls (Dalile et al.,
2019). Together, these data reveal that host and gut microbiome interact to maintain
intact metabolic, brain and inflammatory functions and indicate the crucial role of gut
microbiome in obesity context.
Gut microbiome and the central nervous system (CNS). The gut-brain axis
refers to the bidirectional communication between the gut microbiome and the CNS and
it has been a topic of great interest in the past decade (Cryan, O'Riordan, Sandhu,
Peterson, & Dinan, 2020). The gut microbiome has been shown to play a critical role in
neurodevelopment in infants as well as in animal models (Cryan et al., 2020). Cognitive
function correlated with bacteria diversity in children and processes such as myelination
and neurogenesis have been associated with gut microbiome composition in mice
(Cryan et al., 2020). In a recent publication from Cryan et al., the authors reviewed
clinical studies aiming at identifying roles of the gut microbiome in neurological
disorders (Cryan et al., 2020). Parkinson’s disease (PD), autism spectrum disorder and
multiple sclerosis, for instance, were shown to be greatly influenced by the gut
microbiome. Patients with PD have altered microbiome composition when compared to
healthy controls (Cryan et al., 2020). Moreover, mice transplanted with feces from PD
patients developed PD hallmarks, such as motor deficits (Cryan et al., 2020). Similarly,
patients with autism spectrum disorder have altered gut microbiome composition (Cryan
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et al., 2020) and germ-free animals transplanted with feces from autistic patients
developed deficits in social behaviors, hallmarks of the disorder (Cryan et al., 2020).
These studies provide evidence for gut microbiome roles in neurodevelopment
and in the pathophysiology of neurological diseases.
Gut microbiome and peripheral pain. More recently, some of the
research focus has shifted from the CNS to the peripheral nervous system (PNS)
and groups have begun to investigate the role of the gut microbiome in the
development of peripheral pain, including fibromyalgia (FM) and chemotherapyinduced pain (Minerbi et al., 2019; Shen et al., 2017). A seminal work by Shen et
al. was one of the first studies evaluating if and how the gut microbiome could
underly chemotherapy-induced peripheral pain (Shen et al., 2017). In this elegant
study, the authors demonstrated that gut microbiome depletion by long-term
antibiotics exposure prevented mice from developing oxaliplatin-induced
mechanical hyperalgesia (Shen et al., 2017). Moreover, germ-free mice were
also protected from chemotherapy-induced pain in contrast with specific
pathogen-free animals (Shen et al., 2017). Some of the mechanisms underlying
the effects of gut microbiome eradication in preventing peripheral pain involved
dampening of inflammatory response in the animals’ DRG, including decreasing
macrophage infiltration in this specific site within the PNS (Shen et al., 2017).
These results suggest that gut microbiome eradication protects against the
development of mechanical hyperalgesia by diminishing DRG inflammatory
responses to oxaliplatin.
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In a rodent model of chronic constriction injury (CCI), sodium butyrate attenuated
neuropathic pain, concurrently with reduction of inflammatory markers (Kukkar et al.,
2014). Fourteen-day administration of sodium butyrate restored cold and mechanical
allodynia, as well as mechanical and heat hyperalgesia in CCI rats, suggesting a
therapeutic effect for sodium butyrate (Kukkar et al., 2014). Tumor Necrosis Factor α
(TNF-α) is an early proinflammatory cytokine that is elevated in CCI (Kukkar et al.,
2014). Remarkably, sodium butyrate administration also reduced CCI-induced TNF-α in
rat sciatic nerve, suggesting an anti-inflammatory effect of butyrate (Kukkar et al.,
2014).
Amir et al. demonstrated that women patients with FM had altered gut
microbiome composition in comparison to healthy controls (Minerbi et al., 2019). The
authors showed that FM patients had shifted levels of specific butyrate-producing
bacteria, ultimately increasing serum levels of butyrate (Minerbi et al., 2019). These
data suggest that gut microbiome and its metabolites, especially butyrate, are linked to
peripheral pain states as underlying causes or as novel therapeutic approaches.
By directly activating FFARs, butyrate might modulate both, [Ca2+]i and cAMP
levels, which are important second messengers involved in peripheral neuropathy
(Fernyhough & Calcutt, 2010). Alternatively, histone acetylation has been associated
with nociceptor sensitization and chronic pain states (Descalzi et al., 2015;
Niederberger, Resch, Parnham, & Geisslinger, 2017). HDAC inhibition also ameliorated
neuropathic pain in animal models (Descalzi et al., 2015; Niederberger et al., 2017).
Furthermore, epigenetic mechanisms may regulate pain sensitization since they can be
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long-lasting modifications (Niederberger et al., 2017). Thus, the epigenetic
regulatory function of butyrate may be crucial in nociceptor sensitization in
obesity-indued neuropathy and neuropathic pain.
Obesity, Pain and Inflammation.
Nociceptor sensitization. Peripheral pain often reflects a sensitized
state that generates increased pain perception (Basbaum et al., 2009).
Nociceptors can be sensitized – activated at lower thresholds – peripherally or
centrally. Peripherally, the most common form of nociceptor sensitization is
inflammation. The recruitment of cells from the inflammatory system,
accompanied by an increase in release of inflammatory molecules (including
cytokines, neuropeptides, lipids, and others) as well as an increase in expression
of respective receptors at the surface of the afferent fibers, often leads to
neuronal hyperexcitability and spontaneous firing (Basbaum et al., 2009; PinhoRibeiro, Verri, & Chiu, 2017) (Figure 9). Apart from some well-known cytokines
and lipid mediators known to be involved in nociceptor sensitization, such as IL-1
and prostaglandins, neuropeptides also play an important role in enhancing pain
sensation (Pinho-Ribeiro et al., 2017). During peripheral sensitization of the
nociceptive pathway, the persisted nociceptor activation leads to increase in
neuropeptide release, including of CGRP. This process, known as neurogenic
inflammation, causes vasodilation and axon-axon reflexes, ultimately culminating
in increased Ca2+ signaling, synaptic strength and increased in pain transmission
(Pinho-Ribeiro et al., 2017).
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Pain is a critical defense mechanism against injury processes, inflammation and
overall damage (Basbaum et al., 2009; Raja et al., 2020; Scholz & Woolf, 2002; Woolf &
Salter, 2000). Pain-sensing afferent fibers are named nociceptors and they are the
primary sensory terminals where pain is initiated by stimulation of specialized
transducer molecules (Basbaum et al., 2009; Julius & Basbaum, 2001; Woolf & Salter,
2000). Nociceptors’ cell bodies are located within the dorsal root ganglia (DRG)
alongside the spinal cord, and their axons are bundled together forming the peripheral
nerves. Moreover, nociceptors are pseudounipolar (Basbaum et al., 2009; Julius &
Basbaum, 2001; Pinho-Ribeiro et al., 2017; Woolf & Salter, 2000). Thus, although the
initiating of pain signaling starts at the terminals innervating organs and the skin, the
release of neurotransmitters can occur from both terminals: at the dorsal horn of spinal
cord – site of the primary synapse – but also at the free nerve endings on target
organs/skin (Basbaum et al., 2009; Julius & Basbaum, 2001; Pinho-Ribeiro et al., 2017;
Woolf & Salter, 2000).
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Figure 9. Mechanisms of Immune Cell-mediated Peripheral Sensitization. Upon
injury, immune cells in the injury site release molecules that act on the peripheral
nociceptor leading to pain sensitization. Certain cytokines, lipids, and growth factors act
on receptors expressed at the surface of the nociceptor generating increased action
potential and pain sensation. Interleukin 5 (IL-5) and IL-5 receptor (IL-5R); serotonin (5HT), and 5-HT receptor (5-HT2); histamine and histamine receptors (H1/2); nerve
growth factor (NGF); Tropomyosin receptor kinase A (TrkA); tumor necrosis factor alpha
(TNFα) and TNFα receptor 1 (TNFR1); interleukin 1- β (IL-1β) and IL-1 receptor 1 (IL1R1); interleukin 6 (IL-6); glycoprotein 130 (gp130); Transient Receptor Potential Cation
Channel Subfamily Vanilloid 1 (TRPV1) and Subfamily A, member 1 (TRPA1);
Prostaglandin E2 (PGE2) and PGE2 receptors 1–4 (EP1-4). interleukin 17 A (IL-17A) and
IL-17A receptor (IL-17RA).
Calcitonin gene-related peptide and pain. When damage and
inflammation happen, the release of endogenous factors by local cells lead to the
formation of an “inflammatory soup”, containing cytokines and chemokines
produced by immune cells, as well as release of nerve growth factor (NGF), and
lipid metabolites (Basbaum et al.; Julius and Basbaum). Successively, this
inflammatory soup gives rise to neurogenic inflammation, in which receptors for
the diverse repertoire of factors present in the soup are activated in the
nociceptors, that in turn release neuropeptides, such as Calcitonin Gene-Related
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Peptide (CGRP) (Basbaum et al.; Julius and Basbaum).
CGRP is a 37-amino acid neuropeptide mainly expressed by Ad and C-fibers
(Iyengar, Ossipov, & Johnson, 2017; Kee, Kodji, & Brain, 2018) with a half-life of only 7
minutes (Iyengar et al., 2017). CGRP has been largely studied as a potent vasodilator,
however, more recent data indicates that CGRP plays a crucial role in pain
sensitization, in addition to neurogenic inflammation (Iyengar et al., 2017; Kee et al.,
2018). Plantar injections of CGRP led to increased mechanical pain in a rodent model,
while administration of CGRP antagonist attenuated capsaicin-induced mechanical
hypersensitivity in a rat model of nerve injury (Iyengar et al., 2017). There have been
described two isoforms of CGRP, CGRPa and CGRPb (Iyengar et al., 2017; Kee et al.,
2018). They are transcribed from two different genes, CALCA and CALCB, and are
highly structurally and functionally similar (Iyengar et al., 2017; Kee et al., 2018).
Release of CGRP often follows nociceptor stimulation and assist in pain transduction.
CGRP acts on the heterodimer between Receptor Activity-Modifying Protein (RAMP
(RAMP1, 2 or 3)) and Calcitonin Receptor-Like Receptor (CRLR) or Calcitonin Receptor
(CTR). CRLR and CTR are G-coupled protein receptors (GPCRs) linked to Gas
(Barwell et al., 2012; Iyengar et al., 2017). Thus, upon biding to its receptor, CGRP
promotes cyclic adenosine monophosphate (cAMP) production by activating adenylyl
cyclase (Figure 10). While exerting similar functions, CGRPb remains largely
understudied, with a vast majority of publications focusing on the role of CGRPa.
CGRP is expressed by approximately 45% of DRG neurons, most of them
peptidergic nociceptors (Iyengar et al., 2017). At the injury site, CGRP release from
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nociceptors causes neurogenic inflammation, exacerbating the inflammatory
response and tissue damage. Moreover, the release of NGF from epithelial cells
upregulates CGRP transcription in the DRG, which leads to increased CGRP
levels in the dorsal horn of the spinal cord (Iyengar et al., 2017). In a model of
nerve injury, blocking of CGRP signaling attenuated capsaicin-induced
mechanical allodynia and hyperalgesia (Sun, Lawand, & Willis, 2003). CGRP has
also been implicated in the pathogenesis of migraine. Patients undergoing a
migraine episode have elevated blood levels of CGRP (Goadsby, Edvinsson, &
Ekman, 1988). In addition, when patients were treated with a commonly used
drug to treat migraine, sumatriptan, their CGRP levels were normalized
(Goadsby & Edvinsson, 1993). Finally, antibodies targeting CGRP have great
efficacy in reducing episodic migraine events and are largely commercialized
(Iyengar et al., 2017).
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Figure 10. CGRP-mediated Peripheral Sensitization. Molecules present in the
inflammatory soup lead to neurogenic inflammation, release of CGRP by nociceptors,
and increase in pain sensation. AC, adenylyl cyclase; AMPA, amino-3-hydroxy-5methylisoxazole-4-propionic acid; AMPA-R, amino-3-hydroxy-5-methylisoxazole-4propionic acid receptor; ATP, adenosine triphosphate; cAMP, cyclic adenosine
monophosphate; CREB, cAMP response element binding; NMDA-R, N-methyl-Daspartate receptor; pERK, phosphorylated extracellular signal–regulated kinase. nerve
growth factor (NGF), adenosine triphosphate (ATP), prostaglandin E2 (PGE2) and
creates acidic conditions (eg, H+). From (Iyengar et al., 2017)
Neuro-immune interactions in obesity-induced neuropathy. In an in-depth
review, Pop-Busui et al. described pre-clinical, clinical, and animal studies that
investigated the role of inflammation in neuropathy in obesity, as well as T1DM and
T2DM settings (Pop-Busui, Ang, Holmes, Gallagher, & Feldman, 2016). In one
particular study, Duksal et al. found that plasma levels of pro-inflammatory cytokine
TNFa were elevated in patients with T2DM and that levels of anti-inflammatory cytokine
IL-10 were decreased in both prediabetic and T2DM patients when compared to healthy
controls (Duksal, Tiftikcioglu, Bilgin, Kose, & Zorlu, 2016). Importantly, both groups
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showed impaired nerve conductance in distal sensory nerves (Duksal et al.,
2016). These results, thus, establish a link between a proinflammatory state,
seen in obese patients, and peripheral neuropathy.
Previous reports have shown that immunoregulatory transcripts are
differentially regulated in humans and animal models of neuropathy (Hur et al.,
2016; Junguk et al., 2011; Pande et al., 2011). Elzinga et al. identified changes in
Toll-like receptor (TLR) signaling pathway in the mentioned data sets and,
subsequently, deleted TLR2/4 in mice (Elzinga et al., 2019). Whole-body
knockout of TLR2/4 (TLR2/4 KO) protected obese mice from the early thermal
hypoalgesia seen in HFD-fed controls, but it did not affect IENF density or nerve
conductance velocities (NCV) (Elzinga et al., 2019). This protection was only
temporary, however, since TLR2/4 KO mice developed indices of neuropathy at
later stages, such as worsening of thermal hypoalgesia and NCV, similar to HFD
wild-type animals (Elzinga et al., 2019). TLR2/4 signaling is a well-known
proinflammatory mediator and, thus, these observations suggest that TLR2/4
could underly some early neuropathy indices seen in obesity.
Remarkably, deletion of CXCR4 chemokine receptors reversed
neuropathic pain in obese mice. Jayaraj et. al. demonstrated that loss of CXCR4
signaling in a subset of nociceptors prevented mechanical allodynia and IENF
loss seen in obese mice (Jayaraj et al., 2018). Furthermore, the authors
identified that CXCR4 activation by stromal cell derived factor 1 (SDF- 1) (also
known as CXCL12 chemokine) was able to increase neuronal Ca2+ levels in
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DRGs and primary sensory neurons from WD-fed animals (Jayaraj et al., 2018;
Menichella et al., 2014). Combined, the data above suggest that neuro-immune
interactions could play a major role in the pathophysiology of neuropathy in the context
of obesity.
It has been hypothesized that metabolic insults seen in obesity increase the
secretion of neuropeptides and proinflammatory cytokines and decrease the release of
anti-inflammatory cytokines in sensory fibers of the PNS (Bastard et al., 2006; Hozumi
et al., 2016; Myers, Campana, & Shubayev, 2006). Inflammation could lead to
peripheral and central sensitization in the pain transmission system and result in
hyperalgesia or allodynia. However, to our knowledge, the literature to date lacks any
direct evidence that obesity may induce peripheral pain and nerve damage via local or
systemic inflammation.
Tissue-specific inflammation in obesity. Low-grade inflammation is thought to
play an important role in the onset and progression of peripheral neuropathy in T2DM
and obese individuals, as well as in experimental models of obesity. A seminal work
from Hotamisligil described numerous mechanisms linking obesity, T2DM and
inflammation (Hotamisligil, 2006). More than a decade later, many questions remain
and whether inflammation is a cause or consequence of obesity is still unclear.
However, we do know that there is a fine balance between metabolic and immune
homeostasis and there is now evidence that low-grade, chronic systemic inflammation
observed in obese individuals may be linked to neuropathy onset and progression (PopBusui et al., 2016).
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An extensive literature has revealed that the central nervous system
(CNS) plays a fundamental role in the development of obesity (Gautron,
Elmquist, & Williams, 2015; Gavini, Cook, et al., 2020; Virginie Mansuy-Aubert et
al., 2015; Timper & Brüning, 2017). Specifically, the hypothalamic melanocortin
pathway is one of the main regulators of energy balance, controlling feeding and
energy expenditure (Gautron et al., 2015; Gavini, Cook, et al., 2020; Virginie
Mansuy-Aubert et al., 2015; Timper & Brüning, 2017). Hypothalamic neurons are
regulated by peripheral humoral factors – such as leptin and insulin – and neural
inputs to particular hypothalamic nuclei – such as the arcuate nucleus (Timper &
Brüning, 2017). Alterations in the hypothalamic neurons’ functions are associated
with leptin and insulin resistance seen in obesity and have been linked to WDdependent neuroinflammation (Timper & Brüning, 2017). Furthermore, diets rich
in saturated fatty acids are known to induce hypothalamic inflammatory response
by activating microglia within the hypothalamus (Timper & Brüning, 2017).
The brown adipose tissue (BAT) is also involved in energy homeostasis
(Alcalá et al., 2017; Alcalá, Calderon-Dominguez, Serra, Herrero, & Viana, 2019;
McGregor et al., 2013). BAT controls thermogenesis and its activity has been
reported as being reduced in obese individuals (Alcalá et al., 2017; Alcalá et al.,
2019; McGregor et al., 2013). BAT is highly specialized in catabolizing fatty acids
(Alcalá et al., 2017; Alcalá et al., 2019; McGregor et al., 2013; Tontonoz &
Spiegelman, 2008) and the color brown is attributed to the high concentrations of
mitochondria, organelles responsible for energy generation (Alcalá et al., 2017;
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Alcalá et al., 2019; McGregor et al., 2013; Tontonoz & Spiegelman, 2008). BAT
thermogenesis is mainly due to the expression of uncoupling protein 1 (UCP-1),
a BAT-specific mitochondria protein that uncouples respiration from oxidative
phosphorylation and dissipates heat (Alcalá et al., 2017; Alcalá et al., 2019; McGregor
et al., 2013; Tontonoz & Spiegelman, 2008). Normally BAT produces heat when the
energy balance is positive allowing bodyweight maintenance; however, obesity alters
BAT function by triggering inflammation, endoplasmic reticulum (ER) stress and
production of reactive oxygen species (Alcalá et al., 2017; Alcalá et al., 2019; McGregor
et al., 2013).
Abdominal obesity is associated with development of cardiovascular
complications (Grundy, 2016). Obese patients are at higher risks for heart failure and
myocardial infarction (Mouton, Li, Hall, & Hall, 2020), which in turn increases mortality
risk by approximately two times in comparison to nonobese individuals (Krauss,
Winston, Fletcher, & Grundy, 1998). The low-grade inflammation seen in obesity usually
leads to cardiac inflammation and correlates with heart failure (Mouton et al., 2020).
Moreover, epicardial adipose tissue (EAT) is a main hub for cardiac macrophages
(Mouton et al., 2020). Upon cardiac injury, resident EAT macrophages undergo a
polarization switch and assume an M1 pro-inflammatory phenotype that infiltrate the
myocardium and aggravate heart injury in obese patients by increasing the production
of proinflammatory cytokines (Mouton et al., 2020).
Obesity and caspase-1. Production of proinflammatory mediators, increased
levels of cytokines, as well as their upstream regulators are often used to assess
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inflammation (Talley et al., 2019). One of the most common methods to measure
inflammatory response is the detection of caspase-1 activation (Talley et al., 2019).
Briefly, danger signals are recognized by cells of the innate immune system,
culminating in the activation of caspase-1 that, in turn, leads to increased
production of the pro-inflammatory cytokines IL-1β and IL-18 (Talley et al., 2019).
A myriad of insults observed in chronic obesity, including saturated fatty acids
and ceramides, are thought to activate caspase-1 and could potentially mediate
the long-lasting maladaptive inflammatory response seen in obesity
(Vandanmagsar et al., 2011).
Measurements of caspase-1 activation, usually by immunoblots or
secretion of IL-1β and IL-18, are limited to studies’ terminal endpoints and do not
provide a spatiotemporal assessment. A novel method for detection of caspase-1
activation has overcome these limitations by employing an engineered mouse
model allowing for visualization of caspase 1 activation (Talley et al., 2019). In
this study, the authors cloned a caspase-1 cleavage sequence into a luciferase
construct that is activated upon caspase-1 proteolytic cleavage, identifying a
biosensor for caspase-1 activation (Talley et al., 2019). Therefore, this biosensor
mouse model could be used to monitor inflammation in whole body and tissues in
obese mice in vivo.
Summary.
More than 100 million -- 38% -- of the US population are obese. Dramatic
increases in prescription opioid use have occurred in recent years in the obese
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population, in part, because their pain phenotype is understudied and not well defined.
Painful peripheral neuropathy affects sensory neurons and their associated cells located
in the PNS. Painful neuropathy develops early in obesity and is characterized by
hyperactivation of PNS neurons (Cortez et al., 2014; Juster-Switlyk & Smith, 2016;
Kissel & Smith, 2016; Smith & Singleton, 2013), leading to hypersensitivity (Callaghan,
Cheng, et al., 2012; Johnson, Ryals, & Wright, 2008; K. A. Muller, Ryals, Feldman, &
Wright, 2008; Orstavik & Jorum, 2010). Clinical manifestations of early painful
neuropathy are still understudied in obesity and pre-diabetic patients but seem to
involve hypersensitivity and sometimes spontaneous pain (assessed by questionnaire
and quantitative sensory tests) (Arezzo & Zotova, 2002; Hong, Morrow, Paulson, Isom,
& Wiley, 2004). In rodent models, hypersensitivity is seen as early as 6 to 16 weeks
after the onset of WD feeding, accompanied or later followed by loss of nerve fibers
(Biessels et al., 2014; Guilford, Ryals, & Wright, 2011) (Menichella et al., 2014; Suzuki,
Sato, Kawanishi, & Mizumura, 2002). As published by Aubert (Gavini et al., 2018) and
others (Jayaraj et al., 2018; Menichella et al., 2014), the WD-fed rodent model used in
this dissertation is a physiological model that develops early hypersensitivity and
neuropathy phenotype.
Despite being one of the most common obesity complications, leading to a
massive use of opioids or other addictive drugs, there remains no disease-modifying
therapy for obesity-induced neuropathy and neuropathic pain. This lack of treatment is
due to a poor understanding of the early neurobiology underlying the complex pain
etiology in obesity. Glucose management has little or no effect on painful neuropathy in
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obese individuals. Thus, it is critical to identify innovative approaches to treat
neuropathy and neuropathic pain associated with obesity.
The relationship between the gut microbiota and neurological diseases, including
pain, has received increasing attention in recent years. The gut microbiome and its lipid
metabolites have been linked to peripheral immune regulation (Arpaia et al., 2013;
Chen, Xu, Su, & Zhu, 2018; Furusawa et al., 2013; Hu et al., 2018; Liu et al., 2014;
Schwarz, Bruhs, & Schwarz, 2017; Sikandar et al., 2017; Tian et al., 2017), visceral
pain (Long et al., 2018; SM et al., 2017; Vanhoutvin et al., 2009; J. Zhang et al., 2019),
chemotherapy-induced pain (Shen et al., 2017), and fibromyalgia (Minerbi et al., 2019).
A recent case report described amelioration of painful neuropathy following fecal
transplantation in an obese type 2 diabetic patient (Cai et al., 2018). We have therefore
begun to investigate the role of the gut microbiome in obesity-related neuropathic pain.
Neuropeptide secretion and inflammatory pathways have also been implicated in
the onset and progression of peripheral neuropathies. Calcium homeostasis has been
shown to be associated with sensory neurons hyperexcitability and peripheral
hypersensitivity (18, 20), while neuropeptide secretion and inflammatory pathways are
known to sensitize nociceptors and increase pain sensation (42, 43). Therefore, we
aimed at understanding the role of neuropeptide secretion and inflammation in WDinduced neuropathy mouse model and if butyrate can alter these specific pathways.
Hypothesis and Aims.
Aim 1 was to determine if gut microbiome modulation improved neuropathic pain
in obese mice. Literature has recently demonstrated that gut microbiome is involved in
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somatic pain, including chemotherapy-induced pain and fibromyalgia. Thus, we
hypothesized that modulation of gut microbiome of obese mice would alter obesityinduced neuropathy and neuropathic pain. We performed transplantation of feces from
lean animals to Western diet (WD)-fed mice and assessed pain behavior. Then, we
evaluated alterations of: (i) gene transcription in the peripheral nerve system (PNS), (ii)
calcium signaling, (iii) immune cell profile, (iv) nerve density in the skin, and (iv)
circulating levels of short-chain fatty acids (SCFA). (Bonomo et al., PNAS, 2020).
Aim 2 was to elucidate immune cell profile and activation of inflammatory
pathways in obese mice and obese mice subjected to butyrate treatment. Given the
extensive literature on obesity and inflammation and our own data indicating immune
cell profile changes following fecal transplantation (aim 1), we investigated activation of
inflammatory pathways in WD-fed mice treated or not with butyrate (detailed in Chapter
IV). We used a caspase-1 biosensor mouse model to monitor inflammation in a
spatiotemporal manner in male and female mice in vivo. We also evaluated WD- and
butyrate-induced changes in immune cell profile in the animals’ CNS and PNS using
flow cytometry.
Aim 3 was to determine the effects of butyrate on neuropeptide release in obese
mice. Calcitonin-gene related peptide (CGRP) is a neuropeptide involved in pain
sensitization and it is known to be elevated in pain states. Moreover, obese subjects
have elevated plasma levels of CGRP when compared to healthy controls. Thus, we
hypothesized that an increase in CGRP secretion by sensory neurons in spinal cord of
WD-fed mice may underlie pain. We also hypothesized that butyrate may decrease this
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secretion. We tested our hypothesis in vitro by measuring CGRPa released in media
from DRG organotypic cultures stimulated with butyrate and in the presence of high
saturated fat environment (palmitate). In vivo, we compared CGRP levels in the spinal
cord among normal chow (NC), WD-fed and WD-fed mice treated with butyrate.

CHAPTER III
FECAL TRANSPLANTATION IMPROVES NEUROPATHIC PAIN AND NEUROPAHTY
INDICES IN OBESE MICE.
Modified from Bonomo et. al. Proceedings of the National Academy of Science, 2020.
Introduction.
Almost half of the US population is overweight or obese (Stokes et al., 2019). A
report from the Institute of Medicine identified obesity as one of five major contributors
to chronic pain. Obesity raises risks of numerous conditions associated with neuropathic
pain, including the use of addictive drugs. Early clinical manifestations of peripheral
painful neuropathy are understudied in obese and pre-diabetic patients, but there is
evidence of distal hypersensitivity and spontaneous pain in the hands and feet (Arezzo
& Zotova, 2002; Hong et al., 2004; O'Brien et al., 2017; Sumner, Sheth, Griffin,
Cornblath, & Polydefkis, 2003). Despite being one of the most common complications of
obesity, treatment of painful neuropathy is frequently limited to use of addictive
analgesics, mostly because the neurobiology underlying the complex pain etiology in
obesity and prediabetes is poorly understood. In rodent models, hypersensitivity,
presenting as mechanical allodynia, is seen as early as 6-16 weeks after the onset of
feeding a Western-diet (WD: 45% fat, 34% sucrose, and 0.2% cholesterol) and is
followed by loss of epidermal sensory fibers (Aubert, Mansuy, Voirol, Pellerin, &
Pralong, 2011; Biessels et al., 2014; Gavini et al., 2018; Guilford et al., 2011; Menichella
et al., 2014; Suzuki et al., 2002). It has been shown that neuropathic pain that develops
50
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early in rodent model of prediabetes involves hyperexcitability of nociceptors
(Jayaraj et al., 2018). Many previous studies have focused on hyperglycemia as
the initiating insult in the development of pre-diabetic and diabetic neuropathy
while a growing body of evidence has also implicated dyslipidemia as a distinct
pathogenic event (Hur et al., 2016; Pande et al., 2011; Tashani, Astita, Sharp, &
Johnson, 2017; Wiggin et al., 2009).
The relationship between the gut microbiota and neurological diseases,
including pain, has received increasing attention in recent years. The gut
microbiome and its lipid metabolites have been linked to peripheral immune
regulation (Arpaia et al., 2013; Chen et al., 2018; Furusawa et al., 2013; Hu et
al., 2018; Liu et al., 2014; Schwarz et al., 2017; Sikandar et al., 2017; Tian et al.,
2017), visceral pain (Long et al., 2018; SM et al., 2017; Vanhoutvin et al., 2009;
J. Zhang et al., 2019), chemotherapy-induced pain (Shen et al., 2017), and
fibromyalgia (Minerbi et al., 2019). A recent case report described amelioration of
painful neuropathy following fecal transplantation to an obese type 2 diabetic
patient (Cai et al., 2018). We have therefore investigated the role of the gut
microbiome in obesity-related neuropathic pain. Our data demonstrate that
reshaping the gut microbiome of obese neuropathic mice by transplanting feces
from lean mice improved the pathophysiology of the disease by decreasing
evoked pain-associated behaviors and loss of nerve fibers in the skin.
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Results.
Fecal microbiome transplantation improves obesity-induced
hypersensitivity. We hypothesized that reshaping the gut microbiome of mice fed a
WD would alleviate indices of neuropathic pain. We therefore subjected mice to a 12week WD feeding paradigm known to cause metabolic syndrome features, mechanical
allodynia and thermal hyperalgesia (Gavini et al., 2018) (Figures 11, C and D, left side
of dashed line, and Appendix A, Fig. 29, A-C). To better characterize the WD-fed model,
we performed 16S analysis of fresh feces and cecal content. WD-fed mice exhibited a
poor bacterial diversity compared to lean, normal chow-fed (NC) mice, as represented
by lower alpha-diversity index (unpaired t test, p=2.7224e-05, Appendix A, Fig. 29, D).
In addition, WD reduced the abundance of butyrate-producing bacteria of the genera
Lactobacillus and Lachnospiraceae (unpaired t test, p=0.0107 and p=0.0174,
respectively, Appendix A, Fig. 29, E-F) in comparison to normal chow (NC)-fed animals.
We performed fecal microbiome transplantation (FMT) on WD-fed obese mice
and generated many other groups to test multiple variables individually. Following 12
weeks on WD, all obese mice were subjected to a regimen of 3 days of broad-spectrum
antibiotic treatment ((ABX) Figure 11, A). We chose the minimum time and dose of
antibiotic treatment necessary to deplete bacteria present in the feces (one-way ANOVA
with repeated measures p=0.0072, Tukey’s post hoc Pre-ABX vs. Post-ABX p=0.0315,
Pre-ABX vs. Post-FMT p=0.9196, and Post-ABX vs. post-FMT p=0.0189, Figure 11, B),
as extended periods of antibiotic exposure can modify nerve function and myelination
(McMurran et al., 2019). After antibiotic treatment, we initiated the 2-week FMT
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paradigm, which also included a diet switch (DS). For the diet switch, some WDfed, obese mice were switched to NC diet during the first 5 days of saline (sham
FMT) or fecal slurry from lean mice (FMT) gavage. The rationale, motivated by
previous literature (Bakker, Zhao, Herrema, & Nieuwdorp, 2015; Cabral et al.,
2019; de Clercq et al., 2017; de Clercq et al., 2016) was to allow for colonization
of the gut with bacteria thriving in NC rather than WD conditions. Importantly,
both sham FMT and FMT treated mice had similar amounts of cecal bacterial
DNA at endpoint (unpaired t test p=0.845, Appendix A, Fig. 30, A).
Of mice that did not receive antibiotics and subsequent gavage, WD-fed
mice developed significant allodynia compared to mice fed standard diet (p<0.05
by unpaired t test, Figure 11, C left side of dashed line). Of the groups that
received antibiotics (Figure 11, C, right side of dashed line), animals gavaged
with saline (S) showed the highest mechanical allodynia (lowest threshold),
irrespective of whether they underwent diet switch (DS) or not. Both groups
subjected to the fecal transplantation from lean mice (with or without diet switch)
showed significantly higher paw withdrawal thresholds compared to their
counterparts (two-way ANOVA main effect of fecal transplantation treatment,
p=0.0282 (#), Sidak post-hoc *p=0.05 between sham FMT and FMT).
Of mice that did not receive antibiotics and subsequent gavage, WD-fed
mice developed significant heat hyperalgesia compared to mice fed standard diet
(p<0.05 by unpaired t test, Figure 11, D left side of dashed line). Of the groups
that received antibiotics (Figure 11, D, right side of dashed line), animals

54
gavaged with S that did not undergo DS showed the highest thermal sensitivity (lowest
latency). Lean feces transplantation (F) without DS significantly increased heat
response latency compared to that of obese mice, subjected to ABX treatment, without
DS, and S gavage (Sidak post-hoc, p=0.01). Animals that received DS and saline
gavage (sham FMT) had an increase in thermal latency as well. DS also potentiated the
positive effect of gavaging feces from lean to obese mice on thermal hypersensitivity
(two-way ANOVA, all groups showed a main effect of fecal transplantation treatment
p=0.003 (#) and also a main effect of diet switch p=0.012 (&)). Our results suggest that
fecal transplantation of fecal slurry from lean to WD-fed, obese mice (previously
exposed to 3 days of antibiotic) prevented mechanical allodynia and thermal
hyperalgesia.
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Figure 11. Fecal Microbiome Transplantation (FMT) Improves Obesity-induced
Hypersensitivity. (a) Paradigm schematic; normal chow (NC), Western diet (WD),
antibiotics (ABX), diet switch (DS), saline gavage (S), lean feces gavage (F), short chain
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Thermal hyperalgesia in Normal chow (NC), and Western-Diet (WD) -fed mice (controls,
no treatment, left side of dashed lines; p=0.0044, and p=0.0214, for mechanical (c) and
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effect of fecal transplantation treatment, p=0.0282 (#), Sidak post-hoc *p=0.05 between
sham FMT and FMT for (c) mechanical allodynia. Two-way ANOVA main effect of fecal
transplantation treatment p=0.003 (#) and main effect of diet switch p=0.012 (&), Sidak
post-hoc *p=0.01 for (d) thermal hyperalgesia. All values represent mean±S.E.M, (n= 67 per group).
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Additionally, a diet switch at the beginning of the gavage procedure tended to potentiate
the positive effects of lean feces transplantation on pain behaviors. None of these
treatments decreased the animals’ bodyweight (Appendix A, Fig. 30, B). However, in
our model and as published by many authors (K. E. Bouter et al., 2017; H. Wang et al.,
2019; P. P. Zhang et al., 2020), fasting glucose was slightly lower after FMT in
comparison to sham FMT, but significant lower when compared to WD-fed, antibiotics
treated, saline gavaged mice that did not receive DS (two-way ANOVA showed a main
effect of fecal transplantation gavage p=0.0042 (#); Sidak post-hoc, *p=0.04, Appendix
A, Fig. 30, C)). Interestingly, this decrease in fasting glucose did not correlate with
improved pain, suggesting that other mechanisms were involved (Pearson r=-0.24;
Appendix A, Fig. 30, D).
Behavioral measurements were also made in cohort of mice treated with
antibiotics only (no gavage and no DS, Appendix A, Fig. 31, A-F). NC-fed mice
presented altered both mechanical threshold (unpaired t test p=0.0244, Appendix A,
Fig. 31, A) and thermal latency (unpaired t test p=0.0068, Appendix A, Fig. 31, C)
following antibiotics exposure. A three-day antibiotic treatment, performed two weeks
before any measurements, increased mechanical threshold in WD-fed mice (unpaired t
test p=0.0256, Appendix A, Fig. 31, B). In contrast, thermal latency was unchanged in
ABX-treated animals fed WD (unpaired t test p= 0.3316, Appendix A, Fig. 31, D). These
data suggest that even a short antibiotics treatment may modify mechanical sensitivity
differently in obese mice and will need to be followed-up. However, the paradigm:
antibiotics, gavage of fecal slurry from lean mice, accompanied by a short diet switch
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during the first days (called FMT in the current study), exhibited the greatest pain
improvement in WD-fed mice.
FMT increases nerve density in the skin of obese mice. In neuropathy
models, inflammation is often linked to papillary dermal and intra-epidermal nerve
fibers (IENF) densities (Beiswenger, Calcutt, & Mizisin, 2008). We observed that
WD-fed model had less skin fibers compared to NC-fed mice (unpaired t test
p=0.0149 and p<0.0001; Figures 12, A-B, left side of dashed line). We also
counted fibers in the hind paws of FMT- and auto FMT-treated mice. FMT mice
had a higher nerve density in the papillary dermis when compared to auto FMT
mice (unpaired t test p=0.0451, Figure 12, A, right side of dashed line). However,
both groups showed a similar IENF density (unpaired t test p=0.7618, Figure 12,
B, right side of dashed line). These data indicate that the FMT paradigm
impacted dermal nerve density, suggestive of either nerve regeneration or
attenuation of the rate of distal degeneration.
Nerve densities were also measured in mice treated with antibiotics only
(Appendix A, Fig. 32, A-F). Interestingly, antibiotic treatment alone did not have
an effect on either dermal or IENF densities in NC-fed animals (unpaired t test
p=0.1544, and p=0.1331, respectively. Appendix A, Fig. 32, A, C, and E-F).
However, WD-fed mice subjected to antibiotic exposure had a decrease in
number of both dermal and epidermal fibers when compared to WD control
animals (unpaired t test p=0.0043, and p=0.0029, respectively. Appendix A, Fig.
32, B, D, and E-F). Thus, brief antibiotic exposure affected nerve densities of

58
obese mice and will need to be followed-up in future experiments.
Fig.5 FMT increases nerve density in the skin of obese mice.
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Figure 12. FMT Increases Nerve Density in the Skin of Obese Mice. (a) Dermal
nerves density from normal chow (NC) versus Western diet (WD)-fed mice (unpaired t
test, (left side of dashed line) p=0.0149), and autologous (auto) FMT versus FMT
treated mice (unpaired t test, (right side of dashed line) p=0.0451 (n=6-10 per group).
(b) Intraepidermal nerve fiber densities (IENF) of NC versus WD-fed mice (unpaired t
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(unpaired t test, (right side of dashed line) p=0.07618). (n=6-10 per group). All values
represent mean±S.E.M, *p<0.05. In collaboration with Dr. Nigel Calcutt.
Discussion.
This study demonstrated that FMT can reverse early indices of sensory nerve
dysfunction induced by a Western-diet. It is well established that diet-induced obesity
murine models and human obesity are associated with gut dysbiosis (K. Bouter et al.,
2018; Dugas, Bernabe, et al., 2018; Dugas, Lie, et al., 2018; Fluitman, Wijdeveld,
Nieuwdorp, & RG, 2018; Lin, An, Hao, Wang, & Tang, 2016; Navarro et al., 2018).
Notably, the gut microbiome has recently been linked to pain (Fuyuan et al., 2018;
Kukkar et al., 2014; Shen et al., 2017; SM et al., 2017; Vanhoutvin et al., 2009) but to
date has not been associated with pain in obesity models. In the current study, we
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showed that FMT from lean to WD-fed mice improved both mechanical allodynia
and thermal hyperalgesia without changing body weight. FMT treated obese
animals also had higher nerve density in the skin. Loss of distal sensory nerves
is a measure of sensory neuropathology noted in both WD-fed mice (12) and
humans with metabolic syndrome (Pittenger et al., 2004; Smith et al., 2006). It
was particularly notable that while WD reduced density of both epidermal (IENF)
and dermal nerves, FMT impacted only dermal nerve density. This is suggestive
either of attenuation of the rate of distal degeneration that is associated with loss
of sensory nerves in the skin by FMT or initiation of regeneration from proximal
regions of nerve, but not of collateral sprouting from residual epidermal fibers.
The coexistence of sensory fiber loss with neuropathic pain and the
capacity of interventions that promote neuroprotection and/or regeneration of
fibers to alleviate indices of pain has also been reported in animals and humans
with diabetic peripheral neuropathy (41) and chemotherapy-induced peripheral
neuropathy (Anand et al., 2019; Boyette-Davis & Dougherty, 2011). A recent
study has shown that gut bacteria eradication by a longer antibiotics treatment
paradigm prevented development of mechanical hyperalgesia in a model of
chemotherapy-induced pain (Shen et al., 2017). Additionally, antibiotics exposure
did not have an effect in thermal latency in WD-fed mice, but it increased thermal
threshold in NC-fed animals. Antibiotics treatment had been linked to increased
risk of peripheral neuropathy and to nerve damage (Morales et al., 2019)
especially associated with comorbidities such as obesity. Thus, it is interesting
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that in our model, modulation of gut microbiome by a brief period of large spectrum
antibiotics led to mechanical hyperalgesia in NC-fed animals but improved mechanical
allodynia in obese mice.
Overall, our results indicate that gut microbiome modulation by transplantation of
feces from lean mice alleviates neuropathic pain and neuropathy indices in obese mice;
thus providing new avenues for novel therapeutic targets to treat or delay obesityinduced neuropathy

CHAPTER IV
FECAL TRANSPLANTATION AND BUTYRATE MODIFY IMMUNE CELL PROFILE
AND GENE EXPRESSION IN THE PNS OF OBESE MICE.
Modified from Bonomo et. al. Proceedings of the National Academy of Science, 2020.
Introduction.
Gut dysbiosis, i.e. alterations of overall bacteria diversity and abundance,
is known to occur in obesogenic settings (K. E. Bouter et al., 2017; de Clercq et
al., 2016; Patterson et al., 2016). Furthermore, reduction of specific bacteria
species, especially of butyrate-producers, have been linked to obesity (Patterson
et al., 2016), as well as some peripheral pain states, such as fibromyalgia
(Minerbi et al., 2019). Recent literature has started to investigate the role of gut
microbiome in pain conditions, suggesting that the gut microbiome and its
derived metabolites are critical for the development of chemotherapy-induced
pain and neuropathic pain (Kukkar et al., 2014; Shen et al., 2017). Our own data
(aim 1) indicated that transplantation of feces from lean mice to obese animals
alleviated WD-induced neuropathic pain and neuropathy. We observed an
improvement of mechanical allodynia and thermal hyperalgesia, concurrent with
rescued dermal nerve fiber density in obese mice subjected to the fecal
microbiome transplantation (FMT) paradigm. Thus, the goal of the present
chapter was to identify molecular mechanisms and FMT components associated
with neuropathy improvement.
61

62
RNA sequencing and flow cytometry identified modulation of PNS calcium
signaling and immune cells concurrent to FMT-induced pain improvement. Further, our
results point to modulation of circulating butyrate as one of the underlying causes of this
improvement in rodents. In parallel studies, we identified an association between lower
circulating butyrate and distal pain in obese humans. The gut microbiome, circulating
butyrate and its downstream pathways in the PNS may represent novel targets for
disease-modifying therapy.
Results.
FMT alters transcripts in dorsal root ganglia and sciatic nerve. To
understand the cause of pain relief by FMT, we performed RNA sequencing analysis on
dorsal root ganglia (DRG) and sciatic nerve (SN) of sham FMT and FMT obese animals.
We found 82 transcripts differentially regulated in the DRG of FMT mice compared to
sham FMT (Figure 13, A). Among them, were transcripts involved in (i) epigenetic
modifications, such as Lysine-specific methyltransferase 2A (KMT2A); (ii) calcium
release from endoplasmic reticulum (ER) and the Ryanodine receptor 2 (RYR2), (iii)
lipid metabolism, including ATP-binding cassette A1 (ABCA1) and Apolipoprotein E
(ApoE); (iv) and mechanosensory pathways, such as PIEZO2, all of which were
downregulated in DRG of FMT-treated mice compared to sham FMT. Interestingly it has
been shown that epigenetic regulators could play a role in neuropathic pain
(Niederberger et al., 2017). Calcium handling and lipid metabolism transcripts had also
previously been shown to be altered in peripheral neuropathy (Fernyhough & Calcutt,
2010; O'Brien et al., 2017). Moreover, the mechanosensory gene PIEZO2 had been
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linked to inflammation-mediated mechanical allodynia (Murthy et al., 2018).
Metascape pathway analysis (q-value <0.05) revealed changes in neuronal
morphogenesis, sensory perception of pain, behavioral response to pain, and
calcium handling among the topmost regulated pathways in DRG following FMT
intervention (Figure 13, C). This data suggests that FMT alters DRG neuronal
growth and hyperexcitability and pain response.
Thirty-nine transcripts were significantly differentially regulated when
comparing SN of FMT- and sham FMT-treated mice (Figure 13, B). Obese mice
subjected to FMT showed decrease in immunoregulatory transcripts, including
Cytokine-like 1 (CYTL1) previously described in monocyte/macrophage
recruitment (X. Wang et al., 2016), Interleukin 33 (IL33) known to be involved in
tissue repair. Interestingly, FMT also decreased expression levels of gammaaminobutyric A receptor subunit alpha 3 (GABRA3) transcripts. Activation of
GABAA ionotropic channels had been demonstrated to reverse neuropathic
hypersensitivity (Moon & Park, 2017). Metascape analysis (Figure 13, D)
indicated dysregulation of non-canonical Wnt and Bone Morphogenetic Protein
(BMP) pathways known to sensitize nociceptors (Follansbee et al., 2017;
Simonetti et al., 2014) and of Insulin-like Growth Factor (IGF) pathways that have
been shown to increase neuronal excitability via enhancing calcium currents and,
thus, increasing pain sensitivity (Y. Zhang et al., 2014), as well as to stimulate
mononuclear cell migration in a model of rheumatoid arthritis (Alunno et al.,
2017). Our data indicate that FMT modifies specific transcripts in the nerve, such
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as immune regulatory response, potentially underlying pain alleviation.
To better understand the neurobiology of our model, we performed RNA
sequencing in DRG and SN of NC and WD-fed mice. A total of 4,280 transcripts were
differentially expressed in DRG between NC and WD-fed mice. Choline
acetyltransferase (ChAT) and Solute Carrier Family 18 Member A3 (Slc18a3) – also
known as Vesicular Acetylcholine Transporter (VAChT) – were the two topmost
upregulated genes in DRG of WD compared to NC-fed mice (Appendix A, Fig. 33, A).
This suggested WD-induced activation of muscarinic receptor signaling, a pathway
known to confer neuroprotective effects in peripheral neuropathy when therapeutically
blocked (Calcutt et al., 2017). The upregulated pathways in DRG of WD- compared to
NC-fed animals involved pathways comprising many genes that regulate neuronal
excitability (Appendix A, Fig. 33, B), while a majority of the downregulated pathways in
DRG of WD-fed mice represented inflammatory responses, cytokine production,
neutrophil degranulation, and leukocyte migration (Appendix A, Fig. 33, C).

Fig. 2 FMT alters transcripts in dorsal root ganglia and sciatic nerve.
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Figure 13. FMT Alters Transcripts in Dorsal Root Ganglia and Sciatic Nerve. (a)
Topmost regulated transcripts after FMT in DRG (Sham FMT = ABX, DS, saline
gavage; FMT = ABX, DS, gavage of fecal slurry from lean mice. (b) Topmost regulated
transcripts after FMT in SN. (c) Metascape pathway analysis of dysregulated genes in
DRG. (d) Metascape pathway analysis of dysregulated genes in SN. FDR-adjusted pvalue<0.05 (n=2 biological replicates, each replicate = 6 lumbar DRG and 2 SN).
FMT decreases RYR2-dependent calcium release from the
endoplasmic reticulum of DRG neurons. To understand whether FMT
improved neuropathic pain by potentially rescuing some of the WD-induced
changes in the PNS and/or by increasing FMT-specific pathways, we sought to
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identify the genes that were inversely changed in WD versus NC-fed mice compared to
FMT versus sham FMT animals. Ryanodine Receptor 2 (RYR2) – a protein that
regulates calcium release from the endoplasmic reticulum (ER) to the cytoplasm – was
significantly increased in the DRG of WD-fed mice compared to that of NC-fed animals
(FDR-adjusted p-value p=8.30E-08, Figure 14, A) and decreased after FMT intervention
when compared to sham FMT (FDR-adjusted p-value p=0.00433), Figure 14, B). This
led us to investigate the caffeine-induced calcium transient response (RYR2-dependent
release of calcium from ER) in neurons from DRG of NC-fed, obese control and FMTtreated mice. We purified and cultured DRG neurons from mice from the
aforementioned groups and measured the ER calcium release post-caffeine-stimulation
as represented in Figure 14, C. Neurons cultured from WD-fed animals showed a higher
calcium release from the ER following caffeine stimulation (Figure 14, D) when
compared to neurons isolated from NC-fed mice. These data suggest a greater calcium
release by the ER that could potentially underlie neuronal hyperexcitability and high
intracellular calcium observed in WD-fed neurons as published in the past (Jayaraj et
al., 2018). Noticeably, neurons from FMT-treated animals showed a decrease in the
amplitude of caffeine-induced calcium transient in comparison to WD-fed only animals
(Figure 14, D). These data demonstrate that neurons from obese mice had higher
calcium release from ER, associated with a higher expression of RYR2 in DRG
neurons; whereas the DRG from mice subjected to FMT had a lower caffeine response
when compared to WD-fed animals, potentially due to decreased RYR2 expression in
the ER.

Fig. 3 FMT decreases RYR2-dependent calcium release from endoplasmic reticulum of DRG neurons.
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Figure 14. FMT Decreases RYR2-dependent Calcium Release from Endoplasmic
Reticulum of DRG Neurons. (a) Ryanodine receptor 2 (RYR2) mRNA levels in WD
versus NC-fed mice (FDR-adjusted p-value p=8.30E-08) and (b) in FMT versus Sham
FMT-treated animals (FDR-adjusted p-value p=0.00433) (n=2 biological replicates as
shown Figure 2). (c) Representative image of caffeine-induced calcium release from
endoplasmic reticulum (ER). (d) Quantitation of ER-calcium load in neurons from NC-,
WD- and FMT treated mice (n=20-25 cells from 3 animals for each conditions). All
values represent mean±S.E.M, *p<0.05. In collaboration with Dr. Aleksey Zima and Dr.
Elisa Bovo.
FMT alters macrophage polarization within the DRG and SN
compared to autologous FMT. It is well established that immune cells and
activated nociceptors orchestrate a neural reflex circuitry (Andersson & Tracey,
2012; Brain & Williams, 1985; Pinho-Ribeiro et al., 2017). Moreover, peripheral
monocytes and macrophages have a crucial role in enhancing or dampening
hypersensitivities in pain models (Ji, Chamessian, & Zhang, 2016). In a separate
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cohort, we performed flow cytometry to study immune cells within the DRG and SN of
FMT versus autologous FMT (auto FMT) treated mice. Autologous fecal gavage,
consisted of fecal transplantation from obese to obese mice, was done to rule out an
effect of fecal gavage on inflammation.
We used a specific set of cell surface markers to identify myeloid cell population
and M1/M2 macrophage polarization. The gating strategy utilized is shown in Appendix
A, Fig. 34, A. We observed an increase in percentage of M2 macrophages
(CD45+hiCD11B+CD206+) within the DRG of FMT mice when compared to auto FMT
animals (unpaired t test, p=0.0396, Figure 15, A). Interestingly, we observed a decrease
in percent of M2 macrophages within the SN of FMT-treated mice in comparison to auto
FMT (unpaired t test, p=0.0507, Figure 15, B). These results indicate a shift towards
alternative activation of macrophages – with an anti-inflammatory/tissue repair
phenotype – within the DRG of obese mice transplanted with feces from lean animals.
Of note, FMT mice showed improvement in mechanical allodynia when compared to
auto FMT treated animals (unpaired t test p=0.0436, Appendix A, Fig. 34, B).

Fig.4 FMT alters macrophage polarization within the DRG and SN compared to autologous FMT.
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Figure 15. FMT Alters Macrophage Polarization Within the DRG and SN
Compared to Autologous FMT. (a) Percent of M2 macrophages within dorsal root
ganglia (DRG) of autologous FMT (auto FMT (obese mice gavaged with feces from
obese animals)) – versus FMT treated mice (unpaired t test, p=0.0396). (b) Percent of
M2 macrophages within sciatic nerve (SN) of auto FMT versus FMT treated mice
(unpaired t test, p=0.0507). (n=8-10). All values represent mean±S.E.M, *p<0.05.
Butyrate correlates with mechanical allodynia improvement, modifies
DRG immune cell activation and DRG gene expression. Our data
demonstrated that FMT improved WD-induced neuropathic pain and potentially
modified neuronal excitability and PNS immune cells. Therefore, we sought to
identify components of the microbiome that could directly lead to some of the
gene reprogramming and immune cell changes in the PNS. Metascape analysis
(q value <0.05) identified lipid metabolism pathways to be upregulated in SN of
WD-fed mice compared to NC-fed animals (Appendix A, Fig. 35, A). Moreover,
one of the topmost dysregulated transcripts in SN between NC- and WD-fed
animals was Free Fatty Acid Receptor 2 (FFAR2). FFAR2 transcript was
identified as being increased by 25-fold in SN of WD-fed compared to NC-fed
mice (Appendix A, Fig. 35, B). FFAR2 is a G-coupled protein receptor that binds
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to short-chain fatty acids (SCFA) and is expressed by immune cells (Schulthess et al.,
2019). SCFA include acetate, butyrate, propionate and valerate and are produced by
the gut microbiome and pass into the blood stream (Bakker et al., 2015; K. E. Bouter et
al., 2017; de Clercq et al., 2017; de Clercq et al., 2016; Herrema, RG, & Nieuwdorp,
2017; Nieuwdorp et al., 2014; Samocha-Bonet et al., 2014; Wichmann et al., 2013). We
previously identified a negative correlation between plasma butyrate and body mass
index (BMI) in humans (M. Muller et al., 2019). Reports suggest that butyrate may
improve health (Hodin, 2000; Rivera-Chavez et al., 2016; Q. Zhang et al., 2016; Zou et
al., 2019) and lead to improvement of pain behaviors in models of nerve injury-induced
pain (Kukkar et al., 2014) but the molecular mechanisms are not known. Thus, we
evaluated the levels of butyrate in the plasma of sham FMT and FMT-treated mice and
observed that FMT intervention led to a significant increase in the serum levels of
butyrate (Mann-Whitney test, p=0.0411, Figure 16, A).
Given the potential link between butyrate and pain, we hypothesized that
increasing butyrate in the blood of WD-fed mice may improve WD-induced
hypersensitivity. We needle-fed obese, hypersensitive mice with tributyrin (3 butyrate
molecules with a glycerol backbone) or glycerol (used as vehicle) for 2 weeks and
observed an increase in circulating butyrate in blood of tributyrin-treated mice (unpaired
t test, p=0.0264, Appendix A, Fig. 36, A). Mechanical and thermal hypersensitivities of
WD-fed mice supplemented with tributyrin were also analyzed. Using a median-based
threshold, we selected mice with best pain phenotype and performed linear regression
analysis. We observed a positive correlation between plasma levels of butyrate and
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50% paw withdrawal threshold (Pearson’s r=0.8145, Figure 16, B), but not
between thermal latency (Pearson’s r=-0.3276, Appendix A, Fig. 36, B). Our
results suggest that the increase in circulating butyrate after FMT intervention
and tributyrin treatment may be involved in pain alleviation.
SCFA, and especially butyrate, have been described to modulate innate
and adaptive immune response via immune cells recruitment, proliferation, and
activation, as well as to regulate cytokine and chemokine production (CorrêaOliveira, Fachi, Vieira, Sato, & Vinolo, 2016; Dalile et al., 2019; Kim, 2018).
Butyrate has also been shown to increase extrathymic regulatory T (Treg) cells
population in vitro and in vivo (Arpaia et al., 2013; Furusawa et al., 2013). Tregs
are immune suppressive and have an important role in maintaining immune
tolerance. Thus, we analyzed immune cells activation levels within the DRG and
SN of tributyrin-treated obese animals using CD45 as a pan-leukocyte marker.
Tributyrin treatment decreased leukocyte activation levels in the DRG of obese
mice (unpaired t test, p=0.001, Figure 16, C) as represented by the lower CD45
mean intensity fluorescence (MIF), but not in SN (unpaired t test, p=0.532,
Appendix A, Fig. 36, C).
Butyrate is known to have an epigenetic role by altering histone
deacetylase (HDAC) function in many cell types (Davie, 2003). Given our data,
we hypothesized that butyrate treatment may directly change HDAC gene
expression in DRG explants (containing neurons, satellite, glial and immune
cells). Sodium butyrate-treated (5 µM) DRG explants showed an increase in
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HDAC2 mRNA expression levels when compared to vehicle-treated DRG explants
(unpaired t test, p=0.01, Figure 16, D). This result indicates that butyrate can directly
modify HDAC2 mRNA
levels in mouse DRG cells and alter gene expression.
Fig. 6 Butyrate correlates with mechanical allodynia improvement , modifies DRG immune cell
activation and DRG gene expression.
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Figure 16. Butyrate Correlates with Mechanical Allodynia Improvement,
Modifies DRG Immune Cell Activation and DRG Gene Expression. (a) Serum
butyrate concentration of sham FMT and FMT treated mice (Mann-Whitney test,
p=0.0411). (b) Linear regression and Pearson correlation between 50% paw withdrawal
threshold and serum butyrate concentration (numeral 2 represents the number of
undistinguishable, overlapping samples; Person’s r=0.8145). (c) CD45 mean intensity
fluorescence (MIF) in DRG from control and tributyrin treated mice (unpaired t test,
p=0.001) (n=8-10 per group). (d) HDAC2 mRNA fold-change normalized to actin from
vehicle and butyrate treated organotypic DRG cultures (unpaired t test, p=0.01). (n=3
per condition) All values represent mean±S.E.M, *p<0.05.
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Butyrate modulates TRPV1 activity as a partial agonist in vitro.
TRPV1 is a non-selective cation channel involved in pain sensation (Caterina et
al., 1997). In collaboration with Dr. Eleonara Zakharian, we uncovered that preactivation of TRPV1 channels with capsaicin primed strong TRPV1-activation
when butyrate was subsequently applied, (data shown elsewhere; (Bonomo et
al., 2020)). We also verified a dose dependent TRPV1 desensitization induced by
butyrate (data shown elsewhere; (Bonomo et al., 2020)). These findings implicate
butyrate as a partial agonist of TRPV1 that dose-dependently modulates active
state of channel function.
Low circulating butyrate correlates with distal pain in humans. Next,
we examined the association between circulating butyrate, distal pain, and
sensory loss in obese individuals. Briefly, in collaboration with Dr. Lara Dugas
and Dr. Gregory Aubert, we found that participants with distal pain tended to
have lower circulating SCFAs, including butyrate (p=0.1401, n=29) (data shown
elsewhere; (Bonomo et al., 2020)). These findings suggest that obese individuals
starting to develop distal pain might benefit from personalized treatments (e.g
butyrate, SCFA) or dietary plan (e.g containing fibers) aiming at increasing serum
levels of SCFA.
Discussion.
Our data suggest that FMT and potentially a metabolite secreted by the
gut microbiome in the bloodstream, butyrate, alter gene expression in PNS cells
(neurons, macrophages and Schwann cells) to modify neuronal calcium signaling
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and immune cells within the PNS. Identifying a mechanism linking the gut microbiome
with modulation of the peripheral neuroimmune system offers the possibility of
developing targeted therapeutic interventions to prevent onset of peripheral neuropathy
in pre-diabetes and reverse established neuropathy in patients with pre-diabetes and
type 2 diabetes.
Studies have shown that WD-induced hypersensitivity can be explained by
neuron hyperexcitability arising from an increase in intracellular calcium flux in response
to low concentrations of nociceptor activators (Jayaraj et al., 2018). Ryanodine
receptors (RYR), including RYR2 have been linked with pain (Cheng, Lü, Zhang, &
Zhao, 2010; Sanna, Peroni, Quattrone, Ghelardini, & Galeotti, 2015). These ERassociated receptors, widely studied in the heart, have been shown to regulate release
of peptide-containing vesicles following intracellular calcium release (McNally et al.,
2014; Shakiryanova et al., 2007). Our current study suggests a key role of RYR2
expressed by nociceptors in WD-induced painful neuropathy and also in the FMTinduced improvement. We, together with others, have previously shown that ER stress
in nociceptor is one of the first event occurring in WD-induced hypersensitivity (Bora et
al., 2015; Gavini et al., 2018). This ER stress may result in changes in RYR2 expression
or to abnormal calcium handling in neurons and subsequent hypersensitivity (Bora et
al., 2015; Entaz, Hyongsuk, & Hyonok, 2016). Our data identified neural RYR2 as
potentially involved in obesity-associated pain and in the efficacy of FMT. Manipulation
of RYR2 expression in PNS cell types using cre-lines and evaluation of live calcium
handling in PNS cell types may allow the regulation of RYR2 by butyrate and its
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potential as drug target to be studied.
The efficacy of FMT may result from actions on PNS immune cells. The
downregulation of immune regulatory transcripts in the sciatic nerve from FMT
treated mice, suggest that modulation of the gut microbiome and its metabolites
impacts immune mechanisms that mediate nociceptor sensitization. Cytokines
such as IL-1b, can mediate pain sensitization by altering neuron excitability and
increasing neuronal firing, leading to increased mechanical and thermal
sensitivities (Pinho-Ribeiro et al., 2017). Peripheral macrophages have been
implicated in the development of mechanical allodynia (Cobos et al., 2018) and
M2-polarized macrophages have been associated with wound healing and antiinflammatory function (Italiani & Boraschi, 2014). A recent study also pointed to
the role that DRG macrophages, but not macrophages located at the injury site,
have in peripheral pain initiation and maintenance in a model of nerve injury (Yu
et al., 2020). The lower percentage of M2 macrophages within the SN in our
model suggests that the termination of inflammatory response associated with
these immune cells is initiated locally in the DRG, where the neuronal cell bodies
are located and where we observed an increase in percent of M2 macrophages
following FMT intervention.
A recent report showed that transcriptional changes in DRG caused by
nerve injury correlated with temporal changes in nocifensive behavior – changes
observed in nociceptor-related transcripts correlated with the early development
of cold allodynia, while changes observed in immune-related genes correlated
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with the later development of tactile allodynia (Cobos et al., 2018). These findings may
be pertinent to the differences we observed in normalization of mechanical and thermal
sensitivities after diet switch and FMT.
The relationship between the gut microbiota, its derived metabolites, especially
butyrate, and neurological diseases, including pain, has received increasing attention in
recent years. Circulating butyrate, acetate and propionate are mainly derived from gut
microbiota, although small quantities are also produced by humans as products of
protein metabolism (Feng, Ao, & Peng, 2018). These SCFA are transported by the
blood and act on peripheral tissues (Bakker et al., 2015; K. E. Bouter et al., 2017; de
Clercq et al., 2017; de Clercq et al., 2016; Herrema et al., 2017; Nieuwdorp et al., 2014;
Samocha-Bonet et al., 2014). Notably, differences in butyrate-metabolizing species and
in serum levels of butyrate have been observed in fibromyalgia patients (Minerbi et al.,
2019). Butyrate also improved nerve injury-associated neuropathic pain in rodents
(Kukkar et al., 2014). Overall, these recent findings suggest that the gut microbiome is
involved in non-visceral pain. Moreover, human obesity is often accompanied by a lowgrade chronic inflammation (Monteiro & Azevedo, 2010) and butyrate has been shown
to be anti-inflammatory. However, systemic inflammation is not increased after 12-14
weeks of WD-diet regimen (Virginie et al., 2015) when compared to 60% high fat diet
(HFD) (V. Mansuy-Aubert et al., 2013) suggesting that, in our model, FMT may not act
by preventing systemic WD-induced inflammation.
A recent report demonstrated that butyrate can facilitate M2 macrophage
polarization and thus exert a therapeutic effect in a model of colitis (J. Ji et al., 2016).
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Interestingly, the authors suggested that butyrate-enhanced M2 polarization
could be mediated by histone deacetylase (HDAC) inhibitory activity. Previous
studies described butyrate as a HDAC inhibitor (Arpaia et al., 2013; Davie, 2003).
Another study indicated that HDAC2 normalization levels lead to pain alleviation
following peripheral nerve injury (Ouyang et al., 2019). We observed an increase
in HDAC2 mRNA levels in butyrate-treated DRG organotypic culture, indicating
that butyrate may alter gene transcription in DRG cells via HDAC2. Therefore,
epigenetic changes may offer a possible mechanism through which FMT and
butyrate improve indices of neuropathic pain in our model.
Our transcriptomic analyses revealed a 25-fold increase of FFAR2 mRNA
levels in the sciatic nerve of WD-fed mice, suggesting that nerve cells of obese
mice can respond to butyrate. The literature is currently unclear regarding the
cell-specific role of FFAR2. However, recent reports have highlighted the role of
FFAR2 in immune cell polarization (Nøhr et al., 2015; Nøhr et al., 2013). Further
cell-specific studies will be necessary to better delineate the role and function of
FFARs in FMT-induced pain relief and in the onset of pain in obesity.
Enteric projecting neurons (e.g vagal) may directly sense local changes in
gut composition and metabolomics (Dance, 2019; Lai et al., 2020). Thus, in
addition to DRG, enteric projecting neurons may be also involved in improving
pain behavior and in PNS immune cell recruitment/activation.
Our data offers new insights into the pathogenesis of obesity and early
diabetes-induced neuropathic pain and suggests that the gut microbiome/SCFA
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and their downstream pathways may represent new targets to ameliorate early obesityassociated pain.

CHAPTER V
LIVE MONITORING OF INFLAMMATION IN MICE REVEALS TISSUE-SPECIFIC
RESPONSE TO WESTERN DIET AND BUTYRATE TREATMENT
Bonomo, R.*, Talley, S.*, et al. Manuscript in preparation.
Introduction.
Obesity (body-mass index ³30kg/m2) is the result of long-term energy
homeostasis imbalance (e.g increased food intake, decreased energy
expenditure) involving neuronal systems and peripheral organs (Spiegelman &
Flier, 2001). Obesity is implicated in the pathogenesis of many diseases,
including painful peripheral neuropathy (Callaghan, Reynolds, et al., 2020;
O'Brien et al., 2017). Although still unclear, the pathophysiological mechanisms
of obesity-associated neuropathy and neuropathic pain involve the peripheral
and central nervous systems (PNS and CNS, respectively).
We and others have previously shown that mice fed a Western diet (WD)
develop metabolic syndrome features, in addition to mechanical allodynia,
thermal hyperalgesia, and alterations of DRG and SN function (Bonomo et al.,
2020; Gavini, Bonomo, et al., 2020; Gavini et al., 2018; Jayaraj et al., 2018).
Furthermore, we showed in aim 1 that obese mice had altered expression of
transcripts linked to inflammatory response and immune cell pathways.
Sensitization mechanisms involving neuro-immune interactions take place
centrally and/or peripherally and lead to increased pain sensation (Basbaum et
79
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al., 2009; Neumann, Doubell, Leslie, & Woolf, 1996; Raja et al., 2020; Scholz & Woolf,
2002; Woolf & Salter, 2000).
Recently, the gut microbiome and its derivative metabolites have received a lot of
focus as a potential causes and/or consequences of obesity (Bakker et al., 2015; K. E.
Bouter et al., 2017; Coppola, Avagliano, Calignano, & Berni Canani, 2021; de Clercq et
al., 2016; Dugas, Lie, et al., 2018; Fluitman et al., 2018; Herrema et al., 2017; Kimura et
al., 2020; Koh, De Vadder, Kovatcheva-Datchary, & Bäckhed, 2016; Nieuwdorp et al.,
2014; P. P. Zhang et al., 2020). Alterations of gut microbiome and specifically the
decrease in butyrate-producing species are observed in obesity (Coppola et al., 2021).
In the past, we and others have shown that butyrate may improve obesity
complications, such as diabetes (K. Bouter et al., 2018; Coppola et al., 2021; Kimura et
al., 2020) and neuropathic pain (Bonomo et al., 2020; Kukkar et al., 2014; Minerbi et al.,
2019; Vanhoutvin et al., 2009). Moreover, reports have to date demonstrated that
butyrate has anti-inflammatory effects since it can regulate T cell function, facilitate
macrophage polarization and act as antimicrobial (Arpaia et al., 2013; Chang et al.,
2014; J. Ji et al., 2016; Kimura et al., 2020; Kukkar et al., 2014; Schulthess et al., 2019;
Zou et al., 2019). However, no molecular mechanisms underlying butyrate’s effects
have clearly been identified. Butyrate was shown to have effects on complications of
obesity: such as glucose intolerance (Coppola et al., 2021; Dalile et al., 2019; Kimura
et al., 2020; Koh et al., 2016), heart disease (Trøseid, Andersen, Broch, & Hov, 2020),
and peripheral pain (Bonomo et al., 2020; Kukkar et al., 2014).
Caspase-1 activity is often used to assess inflammatory responses, as many
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insults lead up to cleavage of pro-caspase-1 into its active proteolytic form,
culminating in the production of pro-inflammatory cytokines, such as IL-1 and IL18 (Talley et al., 2019). Although many have reported increased expression of
inflammatory markers in obese individuals and animal models, the main caveat
of those studies is the lack of in vivo longitudinal analysis. In the present work,
we took advantage of an engineered mouse model combined with flow cytometry
studies to longitudinally monitor caspase-1 mediated inflammation in vivo in male
and female mice. To this end, we quantified caspase-1 biosensor activation upon
WD feeding and treatment with the gut-derived metabolite, butyrate. Lastly, while
focusing on nociceptive pathways structures, including DRG and brain, we also
assessed caspase-1 activation in metabolic tissues, such as the brown adipose
tissue and the heart.
Results.
Western diet alters genes involved in inflammatory response in
neural tissue. To better understand the link between inflammation, obesity and
neurological dysfunction, we performed a secondary transcriptional and pathway
analyses using a previously published dataset (Page 143 of this dissertation;
(Bonomo et al., 2020)). This dataset compared dorsal root ganglia (DRG) gene
expression of mice fed a normal chow (NC) and Western diet (WD) (Bonomo et
al., 2020). Pathway analysis revealed downregulation of a high number of terms
in the Inflammatory Response Pathway (Figure 17, A (Source GO:BP; Term
ID:GO:0006954)), including genes involved in inflammasome pathways, such as
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(i) Toll-like receptors (TLRs (TLRs 4, 7, 8, 9, and 13)), (ii) inflammasome interacting
proteins Nod-Like Receptor (NLR) Family Apoptosis Inhibitory Protein (Naip) 2 and 6
and Guanylate Biding Protein 5 (GBP5), (iii) inflammasome forming proteins Nlrp3,
Nlrc4, and Nlrp12, (iv) gene variants in the NF-κb pathway (Nfkb1, Nfkbia, and Nfkbiz),
as well as (v) Gasdermin D (Gsdmd), High Mobility Group Protein B1 (Hmgb1) and a
number of inflammatory cytokines, chemokines and Damage-Associated Molecular
Patterns (DAMPs). Transcripts in the caspase family were significantly downregulated,
including caspases-7, 8 and 12.
Metascape analysis (Zhou et al., 2019) showed dysregulation of several
pathways such as (i) inflammatory response, (ii) cytokine-cytokine receptor interaction,
(iii) defense response to other organism, and (iv) Nod-like receptor signaling pathway
among the topmost altered pathways in DRG between NC- and WD-fed mice (Figure
17, B). Nod-like receptor signaling pathway comprises numerous receptor subfamilies
including the inflammasome-forming NLR family pyrin domain containing 3 (Nlrp3)
protein (Sharma & Kanneganti, 2021).

Figure 1. Dorsal root ganglia RNAseq WD vs NC …
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Inflammatory Response Pathway
(Source: GO:BP; Term ID:GO:0006954)
NC
WD

A

B

Figure 17. Western Diet (WD) Alters Inflammatory Response Transcripts and
Pathways. (A) Heatmap of genes involved in inflammatory response in DRGs of WDversus normal chow (NC)-fed mice. (B) Dysregulated inflammatory response pathways
in DRGs of WD- versus NC-fed mice by Metascape pathway analysis. (n=2 biological
replicates).
Caspase-1 biosensor mice display expected WD-induced phenotype.
Next, we sought to monitor inflammation in vivo longitudinally upon WD regimen.
To this end we used the caspase-1 biosensor (C7) model that has been recently
generated to monitor inflammation in vivo in a spatiotemporal manner (Talley et
al., 2019). Briefly, a caspase-1 target sequence was cloned into a caspase7/luciferase construct that allows visualization of caspase-1-mediated
inflammatory response in live animals and in tissues ex vivo (Talley et al., 2019).
To validate the use of this model, we first confirmed that the genetic manipulation
did not affect whole body metabolism and response to WD. C7 mice were placed
on NC or WD feeding paradigms for a total of 20 weeks. We measured metabolic
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parameters longitudinally. As expected, we noted WD-induced metabolic syndrome
features such as increased body weight in comparison to NC-fed mice (Figure 18, A),
accompanied by WD induced glucose intolerance (Figure 18, B-C). WD-fed C7 animals
also presented elevated fasting glucose levels (Figure 18, D) and thermal hyperalgesia
(Figure 18, E) after 17 weeks on the feeding paradigm. We also observed increased
energy expenditure (Appendix A, Fig. 37, A), decreased respiratory exchange ratio
(RER (Appendix A, Fig. 37, B)), with no changes in cumulative food consumption
(Appendix A, Fig. 37, C) when the mice were switched from a NC to WD. Our data
demonstrate that the caspase-1 biosensor mouse model show expected behavioral
features upon prolonged WD feeding in males and females.
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Figure 18. Caspase-1 Biosensor Mice Display Expected WD-induced Phenotype.
(A) Body weight of normal chow (NC) and Western diet (WD)-fed mice. (B) Glucose
tolerance test (GTT) between NC- and WD-fed mice. (C) Representative GTT area
under the curve (AUC). (D) Overnight fasting glucose blood levels. (E) Thermal
latencies between NC and WD-fed mice. Student’s t test between NC and WD. All
values represent mean±S.E.M, *p<0.05, n=4-8 mice/group; males and females.
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Obese mice exhibit gradual increase in whole body caspase-1 activation in
vivo. Concurrent with phenotypic analyses, we performed longitudinal imaging of NCand WD-fed C7 mice. Males and females were imaged using in vivo imaging
system (IVIS). Obese animals from both sexes showed increased
bioluminescence signal when compared to lean mice as seen in the
representative images in Figure 19, A. WD-fed males displayed a higher
luciferase signal in comparison to NC-fed counterparts following 10 and 17, but
not 6 weeks of WD (Figure 19, B). Remarkably, female WD-fed C7 animals had
significant higher signal than lean controls starting at week 6 of WD, which
persisted at weeks 10 and 17 (Figure 19, C). Both, male and female obese mice,
showed a rise in signal from week 6 to week 10 that was sustained at week 17 of
WD feeding paradigm. Together, our results indicate that WD lead to activation of
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Figure 19. Obese Mice Exhibit Gradual Increase in Whole Body Caspase-1
Activation In Vivo. Representative IVIS images of normal chow (NC) and Western diet
(WD)- fed males and females over time. (B) and (C) Bioluminescence signal
quantification for males and females. Student’s t test between NC and WD. All values
represent mean±S.E.M, *p<0.05; n=4-8 mice/group; males and females.
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Tributyrin and WD alter caspase-1 activation differentially in nervous and
metabolic tissues. Butyrate is known to have effects on complications of obesity, such
as glucose intolerance (Coppola et al., 2021; Dalile et al., 2019; Kimura et al., 2020;
Koh et al., 2016), heart disease (Trøseid et al., 2020), and peripheral pain (Bonomo et
al., 2020; Kukkar et al., 2014). Furthermore, butyrate was shown to exert antiinflammatory properties by modulating T cell and macrophage function (Arpaia et al.,
2013; Chang et al., 2014; J. Ji et al., 2016; Kimura et al., 2020; Kukkar et al., 2014;
Schulthess et al., 2019; Zou et al., 2019). Particularly, butyrate was demonstrated to
decrease production of inflammatory cytokines, including IL-1β, in adipose tissue of
obese mice (db/db) (X. Wang et al., 2015). Thus, we tested whether an increase in
circulating butyrate would modify caspase-1 activation and immune cells in vivo in both
neurological and metabolic tissues. First, we defined the dose and time-course of
tributyrin administration (Figure 20, A). In a pilot study (n=1 animal/dose; NC-fed only),
serum lipidomics indicated that 5g/kg of tributyrin led to approximately 25 times increase
in circulating butyrate than basal levels, whereas the 8g/kg dose led to around 130
times rise (Figure 20, A). Circulating butyrate persisted higher than basal levels after
48h (Figure 20, A). Based on these results, we established a tributyrin treatment
paradigm by administrating the lower dose (5g/kg) every 48h using the C7 mouse
model (Figure 20, B). NC and WD control animals received phosphate buffered saline
(PBS) as gavage stressor control. After 2 weeks, tributyrin trended towards attenuating
fasting glucose levels in WD-fed mice when compared to WD control counterparts
(One-way anova; p=0.0989 between WD and WD+tributyrin) (Figure 20, C), and this
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result was independent of changes in body weight (Appendix A, Fig. 38). Two weeks of
tributyrin treatment did not exert a significant effect on algesia (Figure 20, D). This short
treatment duration allowed us to capture early changes that are not consequence of
metabolic improvements.
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Figure 20. Short Duration of Tributyrin Treatment Trends Towards Improvement
of Fasting Glucose Levels. (A) Serum lipidomics indicating circulating butyrate levels
2 or 48h after last tributyrin treatment in normal chow (NC) fed mice. (B) Experimental
paradigm. (C) Baseline overnight fasting glucose in NC, Western diet (WD), and WDfed tributyrin treated male and female mice. (D) Baseline thermal latencies among
experimental groups. One way-anova among NC, WD, and WD+Tributyrin and Tukey’s
post-hoc. All values represent mean±S.E.M, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, n=4-8 mice/group; males and females.
Nervous tissues. First, we investigated the effects of NC, WD and
tributyrin on activation of caspase-1 biosensor in brains following 2 weeks of
tributyrin treatment (Figure 21, A). The bioluminescence signal – measured as
total flux of ions per second – was significantly elevated in the brain of WD-fed
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mice when compared to NC and decreased following tributyrin treatment (Figure 21, B).
We did not detect alterations in bioluminescence signal in hypothalamus or brain stem
among the three groups (Appendix A, Fig. 39, B-C). We performed flow cytometry
studies (gating strategy in Appendix A, Fig. 40) to identify potential changes in immune
cell populations in the cortex and hypothalamus of the three experimental groups. We
found that the mean intensity fluorescence (MIF) of the pan-leukocyte marker, CD45,
was significantly higher in the hypothalamus of obese mice subjected to tributyrin in
comparison to WD controls (Figure 21, C), while there were no differences in CD45 MIF
between NC and WD-fed animals.
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Figure 21. Tributyrin Lowers Whole Brain Caspase-1 Activation and Increases
Pan-leukocyte Marker Expression. (A) Representative IVIS images of whole brain
from normal chow (NC), Western diet (WD) and WD-fed tributyrin treated male mice. (B)
Bioluminescence quantification of IVIS images. (C) Mean intensity fluorescence (MIF) of
the pan-leukocyte marker CD45 in hypothalamus of NC, WD and WD-fed tributyrin
treated mice. One way-anova among NC, WD, and WD+Tributyrin and Tukey’s posthoc. All values represent mean±S.E.M, *p<0.05, n=4-8 mice/group; males.
We also performed DRG analysis of the caspase-1 biosensor activation in NC-,
WD-, and WD-fed tributyrin treated C7 mice (Figure 22, A). Corroborating our RNA
sequencing data, we detected a trend, but not significant reduction in bioluminescence
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signal in DRG from obese mice when compared to NC-fed controls (Figure 22,
B). Tributyrin, however, did not have an effect in caspase-1-mediated
inflammation (Figure 22, B). Although, we did not observe differences in
caspase-1 activation signal between the DRG of WD- and WD-fed tributyrintreated rodents, we identified that DRG from the latter presented a reduction in
total macrophages percent when compared to DRG from WD controls (Figure 22,
C).
Next, we sought to evaluate the activation of the caspase-1 biosensor in
the sciatic nerve (SN) of the aforementioned groups (Figure 22, D). There were
no significant differences in the total flux of bioluminescent signal between NCand WD-fed mice, nor between WD- and WD-fed tributyrin-treated mice (Figure
22, E). We detected a strong trend, but not significant increase in caspase-1
biosensor activation when comparing SN from NC and WD-fed tributyrin treated
mice (Figure 22, E). Our flow cytometry studies (Appendix A, Fig. 41) revealed a
similar pattern in which we identified an increase in percentage of M1
macrophages in the SN of obese mice subjected to tributyrin treatment compared
to lean animals, without significant differences between NC- and WD-, or WDand tributyrin-treated WD-fed mice (Figure 22, F).
Both, caspase-1 biosensor activation and flow cytometry studies, were
performed in male and female mice. The results described above were solely
observed in male mice. We did not detect changes in bioluminescence signal
among the three groups in females’ whole brain, hypothalamus, brainstem
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(Appendix A, Fig. 39, A-C), DRG, nor SN (Appendix A, Fig. 42, A-B) Our data reveals
that tributyrin has tissue- and likely sex-specific effects in the PNS and CNS of obese
mice.
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Figure 22. Tributyrin Does Not Alter Caspase-1 Activation in the Peripheral
Nervous System (PNS). (A) and (D) Representative IVIS images of dorsal root ganglia
(DRG) and sciatic nerves (SN) from normal chow (NC), Western diet (WD) and WD-fed
tributyrin treated male mice. (B) and (E) Bioluminescence quantification of IVIS images.
(C) Percent of total macrophages in DRG from NC, WD and WD-fed tributyrin treated
mice. (D) Percent of M1 macrophages in SN from NC, WD and WD-fed tributyrin treated
mice. One way-anova among NC, WD, and WD+Tributyrin and Tukey’s post-hoc. All
values represent mean±S.E.M, *p<0.05, **p<0.01, ***p<0.001, n=4-8 mice/group;
males.
Metabolic tissues. The literature describes that butyrate may have effect on
cardiovascular diseases (Trøseid et al., 2020), glucose regulation and thermogenesis
(K. Bouter et al., 2018; Coppola et al., 2021; Li et al., 2018). Thus, we aimed at
evaluating caspase-1 biosensor activation in metabolic tissues including pancreas,
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white adipose tissue (WAT), intestines (Appendix A, Fig. 43, A-C) heart and
brown adipose tissue (BAT) (Figures 23 and 24).
We observed a significant increase in BAT bioluminescence in WD-fed
tributyrin treated mice compared with WD controls (Figure 23, A and B). We did
not detect significant changes in BAT bioluminescence between lean and obese
controls (Figure 23, B). However, because BAT size varied among animals
belonging to the different experimental groups, we also analyzed the maximum
biosensor radiance emitted by the tissue, which is irrespective of tissue amount
(Figure 23, C). BAT from WD-fed tributyrin treated mice had significant higher
maximum radiance than either NC- or WD-fed animals (Figure 23, C). There
were no significant differences in BAT maximum radiance between NC- and WDfed controls (Figure 23, C). Similar to the results obtained in the PNS and CNS,
our results in BAT were sex-specific, and not recapitulated in the females
(Appendix A, Fig. 44).

92
B

C
✱✱

✱✱
ns

✱✱

6×106
4×106
2×106

600000
400000
200000
0

rin
+T
rib
ut
y

W
D

W
D

N

C

N

C

0

✱✱

800000

W
D

ns

Max radiance (p/s/cm2/sr)

Total flux (p/s)

Males

8×106

rin

WD+Tributyrin

+T
rib
ut
y

WD

W
D

A BAT NC

Figure 23. Tributyrin Increases Caspase-1 Activation in the Brown Adipose Tissue
(BAT). (A) Representative IVIS images of BAT from normal chow (NC), Western diet
(WD) and WD-fed tributyrin treated male mice. (B) and (C) Total flux and maximum
radiance bioluminescence quantification of IVIS images. One way-anova among NC,
WD, and WD+Tributyrin and Tukey’s post-hoc. All values represent mean±S.E.M,
*p<0.05, **p<0.01, ***p<0.001, n=4-8 mice/group; males.
Lastly, we measured biosensor activation in the heart of animals from the
aforementioned groups (Figure 24, A-C). We detected changes in caspase-1 activation
in both males and females (Figure 24, A-C). In both sexes, there was a significant
increase in total flux between NC- and WD-fed mice (Figure 24, B). The increase in
bioluminescence signal was significantly attenuated by tributyrin treatment (Figure 24,
B).
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Figure 24. Tributyrin Decreases Caspase-1 Activation in the Heart. (A)
Representative IVIS images of heart from normal chow (NC), Western diet (WD) and
WD-fed tributyrin treated male and female mice. (B) Bioluminescence quantification of
IVIS images. One way-anova among NC, WD, and WD+Tributyrin and Tukey’s posthoc. All values represent mean±S.E.M, *p<0.05, n=4-8 mice/group; males and females.
Whole body. Because butyrate can exert systemic effects, we sought to
investigate caspase-1 activation in vivo in mice subjected to the tributyrin
paradigm (Figure 25, B). Tributyrin treatment was initiated following 17 weeks of
WD feeding, thus, we analyzed caspase-1 biosensor activation after 1 and 2
weeks of tributyrin treatment and at endpoint – weeks 18, 19, and 20 of WD
paradigm, respectively. Although the differences in caspase-1 activation
between NC- and WD- fed were maintained through endpoint (Figure 25, A-D),
we did not detect significant changes in caspase-1 biosensor activation between
WD- and WD-fed tributyrin-treated mice in either, males or females, at any of the
timepoints analyzed (Figure 25, A-D).
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Figure 25. Tributyrin Does not Affect Overall Caspase-1 Activation In Vivo. (A)
Representative whole body IVIS images from normal chow (NC), Western diet (WD)
and WD-fed tributyrin treated male and female mice over time. (B) Bioluminescence
quantification of IVIS images. Student’s t test between NC and WD. All values represent
mean±S.E.M; One way-anova among NC, WD, and WD+Tributyrin and Tukey’s posthoc for every timepoint. All values represent mean±S.E.M, *p<0.05, **p<0.01,
***p<0.001, n=4-8 mice/group; males and females.
Butyrate modifies caspase-1 and cytokine expression in bone marrowderived macrophages. Activation of caspase-1 is a critical step of innate immune
response that is mainly mediated by phagocytic cells, such as monocytes and
macrophages, upon recognition of harmful stimuli (Kelley, Jeltema, Duan, & He, 2019).
Thus, we stimulated bone marrow-derived macrophages (BMDM) from WD- and WDfed tributyrin treated mice with lipopolysaccharide (LPS) – a common innate immune
cell activator – in the presence or absence of sodium butyrate (NaBut). Exposure to
NaBut significantly decreased caspase-1 mRNA expression in BMDM from both animal
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groups (Figure 26, A). We verified that IL-1b mRNA expression was significantly
higher in LPS/NaBut-stimulated BMDM compared to LPS alone in WD-fed mice
only (Figure 26, B). Lastly, we analyzed expression of IL-6, a pro-inflammatory
cytokine known to be produced by macrophages via an alternate mechanism
other than caspase-1 activation. We detected a significant decrease in IL-6
expression in LPS/NaBut-stimulated BMDMs compared to LPS alone in both
animal groups (Figure 26, C). Collectively, these results suggest that butyrate
may have a protective role in preventing LPS-induced production of inflammatory
cytokines by BMDM in obese mice, partially by decreasing expression of some
inflammatory cytokines.
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Figure 26. Butyrate Modifies Caspase-1 and Cytokine Expression in Bone
Marrow-Derived Macrophages (BMDM). (A) Caspase-1, (B) IL-1b, and (C) IL-6 mRNA
levels in BMDM from Western diet (WD) and WD-fed tributyrin treated mice following
lipopolysaccharide (LPS) stimulation or LPS/sodium butyrate (NaBut) co-exposure.;
Two way-anova and Tukey’s post-hoc. All values represent mean±S.E.M, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, n=3 independent experiments; 2 mice/group;
males. In collaboration with Emily Gornick.
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Discussion
Obesity is a chronic state of systemic low-grade inflammation
(Hotamisligil, 2006, 2017a, 2017b; V. Mansuy-Aubert et al., 2013; Monteiro & Azevedo,
2010). Using a caspase-1 biosensor mouse model, we detected caspase-1 activation
longitudinally in vivo in obese mice over the course of 20 weeks of WD feeding. The
bioluminescent mouse model also allowed us to quantitatively analyze caspase-1
mediated inflammation in animals and tissues of interest ex vivo.
As mentioned, MetS and obesity are often accompanied by complications, such
as neuropathy, impaired glucose and insulin signaling, and cardiovascular disease
(Hozumi et al., 2016; Krauss et al., 1998; Larabee, Neely, & Domingos, 2020; Mouton et
al., 2020). Moreover, alteration of the gut microbiome composition has been implicated
as another major complication of obesity. A seminal work by Backhed et al. showed that
germ-free mice are protected from developing diet-induced obesity, demonstrating the
crucial role played by gut microbiome in energy balance and substrate utilization
(Bäckhed et al., 2004). The microbiome also produces many byproducts from fiber
fermentation, including some short-chain fatty acids: butyrate, propionate, acetate. We
and others have showed that WD led to drastic alterations of gut microbiome
composition, decreasing the relative abundance of butyrate-producers, as a well as
reducing the circulating plasma levels of butyrate when compared to lean counterparts
(Bonomo et al., 2020). Thus, in addition to assessing systemic and tissue-specific
inflammation in obese mice, we also aimed at evaluating caspase-1 activation in obese
mice subjected to a short butyrate treatment paradigm.
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While previous studies showed increased in inflammatory markers in
obese mice terminally, we demonstrated a gradual increase in systemic
inflammatory response in WD-fed mice that persisted over the course of the
study. Activation of caspase-1 in vivo seemed to localize mainly in the adipose
tissue surrounding the peritoneal cavity, including subcutaneous, gonadal and
mesenteric fat depots of both, male and female mice. Our data from a 2-week
tributyrin treatment duration demonstrated early functional changes rather than
indirect alterations due to improvements in body weight or fasting glucose, for
instance.
Butyrate effects observed in the brain can be explained by the gut-brain
axis – the bidirectional communication between the CNS and the gastrointestinal
system (Bourassa, Alim, Bultman, & Ratan, 2016; Dalile et al., 2019; Stilling et
al., 2016). Through vagal afferents and by crossing the blood brain barrier via
monocarboxylate transporters (MCT) expressed on endothelial cells, butyrate
can exert specific functions in certain brain nuclei, such as the frontal cortex and
the hippocampus (Bourassa et al., 2016; Dalile et al., 2019; Stilling et al., 2016).
For instance, butyrate can act as endogenous ligand for free fatty-acids receptors
(FFARs – G-coupled protein receptors) or it can also act as a histone
deacetylase inhibitor (HDACi) and enhance cell-specific gene transcription by
opening chromatin conformation (Bourassa et al., 2016; Dalile et al., 2019;
Stilling et al., 2016). The whole-brain biosensor data revealed a significant
increase in caspase-1 mediated inflammation upon WD feeding that was
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significantly attenuated by tributyrin treatment. Although it is known that WD can
severely impact brain function, including memory and cognition, we were able to
visually demonstrate caspase-1 activation following 20 weeks of WD feeding paradigm.
At that time point, the systemic low-grade inflammation seen in obesity likely induced
tissue-specific inflammatory response, including within the CNS. Flow cytometry
analysis of the hypothalamic region also revealed a distinct immune cell profile
influenced by diet and tributyrin. The fluorescence levels of the pan-leukocyte marker,
CD45, can be indicative of specific immune cells within brain regions i.e., lowly
expressing CD45 cells (CD45low) represent resident microglia, while highly expressing
CD45 cells (CD45hi) characterize infiltrating blood-derived monocytes, such as
perivascular and meningeal macrophages. NC- and WD-fed animals had low CD45
fluorescence, suggesting the presence of resident microglia population (Faraco, Park,
Anrather, & Iadecola, 2017; Guillemin & Brew, 2004). However, obese mice subjected
to tributyrin treatment presented significantly higher CD45 fluorescence levels in
comparison to WD controls, which is characteristic of perivascular and meningeal
macrophages (Faraco et al., 2017; Guillemin & Brew, 2004) . These differences in
immune cell profile could in turn suggest the overall level of inflammatory response
within the hypothalamus. The hypothalamus is a region of particular interest because of
its fundamental role in host metabolism and energy balance, controlling metabolic
functions – such as sleep, thermoregulation, and hunger – through the secretion of
neuroendocrine molecules (Waterson & Horvath, 2015). Within the hypothalamus,
nuclei in close proximity to the third ventricle, for instance the arcuate nucleus, are most
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likely to suffer the effects of circulating compounds, including butyrate, due to a
less restricted blood-brain barrier (Waterson & Horvath, 2015). Perivascular and
meningeal macrophages are blood-derived monocytes that infiltrate neural
tissues, while microglia are the CNS resident glial cells. Perivascular
macrophages recruitment to the hypothalamus can be part of an adaptive
immune response to systemic inflammation, since they have been implicated in
activation or suppression of the HPA axis in response to inflammatory stimuli
(Faraco et al., 2017; Guillemin & Brew, 2004). Thus, our results suggest that the
differential effect of tributyrin could be driven by particular immune cell
populations residing/infiltrating these organs. Centrally, tributyrin seems to exert
anti-inflammatory actions by decreasing caspase-1 activation in brain of obese
mice and by potentially increasing perivascular and meningeal macrophages
(CD45hi) in the hypothalamus. Differently, tributyrin does not alter caspase-1
activation in the PNS but it does act on macrophage infiltration and polarization.
Gut microbiome and metabolites have also been implicated in obesityinduced neuropathy and neuropathic pain onset and progression (Bonomo et al.,
2020). We previously showed that obese mice had decreased relative
abundance of butyrate-producing bacteria in the gut, in parallel we observed a
positive correlation between mechanical allodynia improvement and circulating
levels of butyrate (Bonomo et al., 2020). Unexpectedly, in the current study, we
did not observe thermal algesia improvement following the tributyrin paradigm,
suggesting that the distinct afferent fibers transducing mechanical and thermal
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pain are differently affected by diet/tributyrin. Besides a trend towards a decrease in
biosensor signal in DRG of obese mice when compared to lean counterparts, we were
unable to detect differential caspase-1 activation signal in DRG and SN of NC-, WD-fed,
and WD-fed mice treated with tributyrin. However, the immune cell characterization
studies revealed that DRG of WD-fed mice had lower percent of total macrophages than
DRG from NC-fed animals. Since immune cells are the main responsible for caspase-1
activity, these results potentially imply that upon 20 weeks of WD feeding, there is an
impaired recruitment of immune cells towards the DRG or an increase in immune cell
death in this tissue, which could explain the trend obtained with the caspase-1
biosensor signal. The DRG is of importance in peripheral neuropathy disease
progression because it is the site where nociceptors’ neuronal cell bodies are located
(O'Brien et al., 2017), thus our data implicates a dysregulated neuronal-immune cell
communication. Differently, the SN comprise the axonal projections of the peripheral
sensory afferents, in conjunction with Schwann cells, fibroblasts and a range of immune
cells (O'Brien et al., 2017). However, we were unable to detect significant changes in
caspase-1 biosensor activation nor in immune cells profile within the SN between NCand WD-fed mice or between WD- and WD-fed tributyrin-treated animals. Nonetheless,
we observed a strong trend towards increase in caspase-1 biosensor signal within the
SN of obese mice treated with tributyrin in comparison to lean controls, concurrent with
a significant increase in percentage of pro-inflammatory M1 macrophages. These data
indicate a tributyrin-induced increase in inflammation within the SN of obese mice and
suggest an adaptive inflammatory response that is possibly dysfunctional in WD-fed
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controls. Caspase-1 activation and recruitment of M1 macrophages in SN
following tributyrin treatment could be interpreted as an enhancement of the
inflammatory signaling in order for local or systemic inflammation resolution.
The main function of BAT is thermogenesis – to produce heat by
dissipating energy. Uncoupling proteins (UCPs) are the drivers of BAT
thermogenesis, as they dissipate mitochondrial proton gradient and allow the
uncoupling between the respiratory chain and ATP generation (Fedorenko,
Lishko, & Kirichok, 2012). However, thermogenesis was impaired in mice fed
high-fat diet (58% fat) due to BAT inflammation and damage involving ER stress
and mitochondrial dysregulation (Alcalá et al., 2019). In our WD model (42% fat),
we did not observe changes in biosensor signal in BAT of WD- compared to NCfed mice. We did, however, see a significant increase in caspase-1 activation in
BAT of obese mice following tributyrin treatment. Similar to SN results, tributyrin
seems to enhance inflammatory response by activating caspase-1 signaling. Li et
al. demonstrated that oral butyrate treatment led to increased BAT thermogenic
capacity (Li et al., 2018). In this work, the authors showed that chronic butyrate
administration activated BAT by increasing UCP-1 mRNA expression and via
increased sympathetic outflow, leading to improvements of some high-fat diet
phenotype, such as glucose metabolism and insulin signaling (Li et al., 2018).
Therefore, the changes in inflammatory response observed with our model likely
precede the behavioral changes that would occur with a longer tributyrin
paradigm.
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Lastly, the biosensor data obtained from hearts were the only results
recapitulated in female mice. In both genders, we observed a significant increase
in caspase-1 activation upon 20 weeks of WD that was significantly attenuated following
tributyrin administration. Obese individuals are at higher risks for developing
cardiovascular disease and the systemic low-grade inflammation is known to impair
cardiac remodeling (Mouton et al., 2020). Immune cell infiltration and M1 macrophage
polarization, both associated with obesity and MetS components, lead to cardiac injury.
(Mouton et al., 2020) In addition, gut microbiome alteration in obesity has recently been
linked to cardiovascular disease and myocardial infarct (Battson et al., 2019). Obese
mice transplanted with cecal contents from lean animals presented reduced myocardial
infarct size, concomitant with alterations in gut permeability and cecal butyrate content
(Battson et al., 2019). Thus, our findings, in agreement with the literature, indicate that
not only WD leads to increased caspase-1 mediated inflammation of the cardiac tissue,
but also that tributyrin is able to rescue WD-induced cardiac injury by reducing
inflammation within the heart.
In an attempt to decipher the cellular mechanisms underlying tributyrin action on
caspase-1 activation, we stimulated BMDM from obese mice treated with tributyrin and
obese controls with LPS or LPS/NaBut. We verified differential mRNA expression of
pro-inflammatory markers between animal and in vitro stimulation groups. Remarkably,
caspase-1 mRNA was decreased following NaBut exposure in BMDM from both
experimental animal groups. Il-1b expression did not observe the same trend, as it was
elevated in BMDM from WD-fed mice treated with NaBut. We also detect lower IL-6

103
mRNA, basal and post-NaBut stimulation, in BMDM from obese mice subjected
to tributyrin treatment and obese controls, respectively. These results indicate
that macrophages possibly mediate some of the tributyrin effects on caspase-1
activation, potentially due to high expression of FFARs by this cell type. We can
infer that tributyrin seems to confer protection against LPS-induced inflammatory
response – and possibly against other insults – since IL-6 expression is lower in
BMDM from WD-fed tributyrin treated mice compared to WD-fed controls prior to
NaBut exposure.
Although a powerful technique to assess inflammation dynamics in vivo
and tissue-specific capsase-1 mediated inflammation, a drawback of our method
is the lack of cell specificity. Thus, in future studies we aim to assess what cell
type (s) are indeed involved in caspase-1 mediated inflammation within the
tissues studied, providing a further knowledge on WD-induced inflammation and
butyrate action. Another limitation of the current study is that we solely assessed
activation of caspase-1, and despite being often used to evaluate inflammation,
caspase-1 is not the only mediator of inflammatory response. For instance,
activation of NF-kB – upstream of caspase-1 activation – or production of IL-6 –
independent of caspase-1 activation – are two examples of inflammatory markers
not assessed in our model. Thus, we can only conclude with regards of caspase1 activation. Lastly, activation of caspase-1 does not necessarily translate into
production of inflammatory cytokines, since those need to be upregulated and go
through posttranslational modifications. Therefore, assessment of IL-1 and IL-18
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– downstream targets of active caspase-1 – could provide further insight regarding the
inflammatory status in our model.

CHAPTER VI
IMPLICATIONS OF CALCITONIN GENE-RELATED PEPTIDE IN OBESITY-INDUCED
NEUROPATHIC PAIN.
Introduction.
Pain is a conserved defense function essential for organism’s well-being
(Basbaum et al., 2009; Raja et al., 2020; Scholz & Woolf, 2002; Woolf & Salter,
2000). Nociceptors are the initially stimulated pain-sensing fibers that carry pain
signal from the periphery to higher orders of the CNS (Basbaum et al., 2009;
Julius & Basbaum, 2001; Pinho-Ribeiro et al., 2017; Woolf & Salter, 2000).
Nociceptors are pseudounipolars and can release neuromodulators from both
terminals: the free nerve endings at the skin/organs and the dorsal horn of spinal
cord (Basbaum et al., 2009; Julius & Basbaum, 2001; Pinho-Ribeiro et al., 2017;
Woolf & Salter, 2000).
During inflammation, molecular mediators, such as cytokines and
prostaglandins, are released from immune cells within the inflammatory milieu
and can originate a process called neurogenic inflammation (Basbaum et al.;
Julius and Basbaum). This is a bidirectional process by which sensory neurons
release pro-inflammatory mediators, such as CGRP, in response to
environmental stimuli present in the inflammatory soup, which in turn, leads to
increased pain sensation (Basbaum et al.; Julius and Basbaum).
CGRP is a well-known mediator of episodic migraine (Bigal, Lipton,
105
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Holland, & Goadsby, 2007; Iyengar et al., 2017) and it is thought to play a role in pain
sensitization (Iyengar et al., 2017). Interestingly, obese individuals have been found with
increased plasma levels of CGRP plasma (Recober & Goadsby, 2010; Zelissen,
Koppeschaar, Lips, & Hackeng, 1991). Thus, given the role of CGRP on neurogenic
inflammation and as a possible link between pain states and obesity, we hypothesized
that obese mice would have higher levels of CGRP in the DRG and spinal cord, that
could be attenuated by butyrate treatment.
Results.
CGRPa secretion is unaltered by butyrate treatment in DRG organotypic
culture media. To test our hypothesis, we collected lumbar DRG from 7-8-week-old
mice (n=9 mice; 3 independent experiments). We performed organotypic cultures to
preserve the tissue structure and cell-cell interactions. DRG were cultured in the
presence of high glucose and saturated fat (palmitate (PA)), to mimic WD-induced
cellular insults (O'Brien et al., 2020), and treated or not with sodium butyrate (PA+BUT).
We measured CGRPa levels in the culture media to assess CGRP release using an
enzyme-linked immunosorbent assay (ELISA) (Figure 27). We focused on CGRPa
because of its primary role in neurogenic inflammation and pain sensitization (Iyengar,
Ossipov and Johnson; Kee, Kodji and Brain). We did not observe changes in CGRPa in
the media of PA treated DRG in comparison to control wells (bovine serum albumin
(BSA)) (Figure 27). And although a strong trend, we were unable to detect a significant
increase in CGRPa in the media from PA+BUT co-treated DRG (p=0.066) (Figure 27).
In vitro studies are simpler and less expensive than in vivo experiments and can
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offer insights on particular mechanisms. However, in vitro results are sometimes
not recapitulated in vivo and cannot be extrapolated to whole organisms. Thus, to
assess, confirm or disprove the results obtained with the organotypic cultures, we
next sough to investigate CGRP levels in vivo.
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Figure 27. CGRPa Secretion in DRG Organotypic Culture Media is Unaltered by
Butyrate Treatment. CGRPa levels in media of DRG organotypic cultures: nonstimulated (bovine serum albumin (BSA), stimulated with palmitate (PA), or co-treated
with PA and sodium butyrate (PA+BUT). One-way anova with Tukey’s post hoc. All
values represent mean±S.E.M, *p<0.05, n=9 mice; 3 independent experiments; males.
CGRPa and CGRPb levels are unaltered in spinal cord of obese mice
and obese mice subjected to tributyrin treatment. Because of their unique
pseudounipolar morphology, nociceptors can release CGRP at the free nerve
endings, but also at the dorsal horn of the spinal cord, site of the primary synaptic
transmission. Thus, we next sought to investigate in vivo levels of CGRP in the
spinal cord of NC-, WD-fed and WD-fed tributyrin treated animals (as detailed in
Chapter IV) At endpoint, entire spinal cord was collected from animals from the
aforementioned group (n=4-6 mice/group) and processed for CGRPa
quantification (Figure 28, A-B). We also assessed CGRPb levels (Figure 28, CD) to better characterize if and how WD and butyrate may influence secretion of
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both isoforms. We did not observe significant differences in the spinal cord levels of
either, CGRPa and CGRPb, among the 3 experimental animal groups (Figure 28, A-D).
The raw levels of CGRPa appear to be slightly higher than CGRPb (Figure 28, A, C).
We then normalized the raw levels of both CGRP isoforms to spinal cord amount in
weight (Figure 28, B, D), but once again, did not observe significant differences among
the experimental groups. These results suggest that CGRP release in whole spinal cord
may not be a driving factor in WD-induced neuropathic pain and seem not to be affected
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Figure 28. CGRPa and CGRPb Levels are Unaltered in Spinal Cord of Obese
Mice and Obese Mice Subjected to Tributyrin Treatment. (A) raw and (B) normalized
CGRPa levels in spinal cord of normal chow (NC), Western diet (WD) and WD-fed
tributyrin treated mice. (C) raw and (D) normalized CGRPb levels in spinal cord of NC,
WD and WD-fed tributyrin treated mice. All values represent mean±S.E.M, *p<0.05;
n=4-6 mice /group; males.
Discussion.
Although recent data has suggested CGRP as a possible link between pain
states and obesity, we did not see changes in CGRP levels after saturated fat, WD
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feeding or butyrate treatment. It is possible that CGRP is being quickly degraded
following secretion due to its short half-life of 7 minutes. Thus, our conclusions are
limited, as it would be important to assess CGRP basal levels (pre-stimulated)
and perform CGRP analysis over a time course.
We did not detect alterations of CGRPa and CGRPb in mice spinal cord
among our treatment groups. In the future, to confirm these data, we could
separate the spinal cord into cervical/thoracic and lumbar/sacral regions before
processing for CGRP analyses. By splitting the tissue in regions of interest, we
could evaluate CGRP release in the precise site expected to hold synaptic
transmission from peripheral nociceptors. Nociceptors are pseudounipolar,
meaning that CGRP can be released in the free nerve endings at the skin and
lead to neurogenic inflammation. Thus, it would also have been important to
assess CGRP in the paws of the animals.

CHAPTER VII
FINAL DISCUSSION
Summary.
Despite recent advances, the molecular mechanisms underlying obesity-induced
neuropathy and neuropathic pain remain obscure. In many cases, neuropathy is
unrelated to chronic hyperglycemia, and impaired insulin signaling and dyslipidemia
have both been linked to onset and progression of neuropathy in normoglycemic obese
patients. Recent evidence in humans and rodent models suggests that the gut
microbiome plays a critical role in pain development, including chemotherapy-induced
peripheral pain, fibromyalgia and neuropathic pain (Kukkar et al., 2014; Minerbi et al.,
2019; Shen et al., 2017). Murine and human obesity are known to modify gut microbes
(K. Bouter et al., 2018; Dugas, Bernabe, et al., 2018; Dugas, Lie, et al., 2018; Fluitman
et al., 2018; Lin et al., 2016; Navarro et al., 2018), including those responsible for
production of short-chain fatty acids (SCFA) butyrate, acetate, and propionate. One
recent clinical case also found that fecal microbiome transplantation (FMT) from a
healthy lean donor to an obese patient relieved early type 2 diabetic neuropathy
independent of glucose management (Cai et al., 2018). While many questions remain,
this observation suggests that gut microbiome may be linked to obesity-associated pain
in humans. The work presented in this dissertation is the first to identify that modulation
of gut microbiome ameliorates neuropathic pain and neuropathy indices in a mouse
model of obesity (Bonomo et al., 2020). The results show that FMT leads to a tissue110

111
specific gene reprograming, including alterations of calcium handling and
immune pathways. Moreover, we identified a microbiome component – butyrate
– as being associated with mechanical pain improvement. Because of the
involvement of immune cells in the onset and progression of obesity-induced
neuropathy, we also aimed at evaluating butyrate-mediated changes in
inflammatory response using a biosensor mouse model to monitor inflammation.
Butyrate altered caspase-1 activation in brain and some metabolic tissues of
obese mice, including heart and BAT. The novel work revealed herein provides
new avenues for the development of disease-modifying therapies involving
modulation of gut microbiome and derived metabolites that may improve
neuropathy and neuropathic pain in obesity.
Key Findings.
Chapter III. FMT improves neuropathic pain and neuropathy indices in
obese mice.
•

Transplantation of feces from lean to obese mice improves obesity-induced
mechanical allodynia and thermal hyperalgesia

•

Transplantation of feces from lean to obese mice combined with a diet switch (DS
(FMT)) improves obesity-induced mechanical allodynia and thermal hyperalgesia

•

DS (Sham FMT) improves obesity-induced thermal hyperalgesia

•

FMT rescues obesity-induced dermal nerve loss
Chapter IV. FMT and butyrate alter PNS gene expression and immune

cell profile in obese mice
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FMT alters gene expression in DRG and SN of obese mice, including transcripts

•

involved in calcium handling (Ryr2) and immune response
•

FMT rescues neuronal Ryr2-mediated calcium release from endoplasmic

reticulum expression in mice DRG
•

FMT increases total percent of anti-inflammatory M2 macrophages in mice DRG
and decreases it in mice SN

•

FMT is associated with increased levels of circulating butyrate

•

Circulating butyrate correlates with mechanical allodynia improvement

•

Butyrate decreases inflammatory marker in mice DRG

•

Butyrate alters expression HDAC2 in DRG organotypic cultures
Chapter V. Butyrate changes caspase-1 activation in the CNS and metabolic

tissues of obese mice.
•

WD leads to gradual increase in whole body caspase-1 activation in vivo

•

Butyrate rescues caspase-1 activation in brains of obese mice

•

Butyrate increases expression of a pan-leukocyte marker in hypothalamus of
obese mice

•

•

Butyrate does not affect caspase-1 activation in the PNS of obese mice

•

Butyrate increases caspase-1 activation in BAT

•

Butyrate rescues caspase-1 activation in hearts of obese mice

•

Butyrate does not affect whole body caspase-1 activation in vivo

Butyrate modifies expression of caspase-1 and cytokines in BMDM in vitro
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Chapter VI. CGRP likely is not implicated in obesity-induced neuropathy
and neuropathic pain pathophysiology.
•

Secretion of CGRP is unaltered by butyrate in DRG organotypic exposed to
saturated fat environment.

•

CGRP levels are indifferent in spinal cord of lean, obese or obese mice subjected to
tributyrin treatment.
Final Thoughts and Future Directions.
The results in Chapters III and IV propose gut microbiome modulation as a

new intervention to alleviate obesity-induced neuropathy and neuropathic pain.
Recent studies reported on microbiome’s crucial role for the development of
certain peripheral pain conditions (Aguilera et al., 2015; Minerbi et al., 2019; Shen
et al., 2017; SM et al., 2017). A particular study showed that gut microbiome is
critical for mechanical allodynia in a mouse model of chemotherapy-induced pain
(Shen et al., 2017). The authors demonstrated that depletion of gut microbiome
by long-term antibiotics treatment prevented mice from developing paclitaxelinduced neuropathic pain (Shen et al., 2017). They further demonstrated that
germ-free mice are also protected from chemotherapy-induced hypersensitivity,
concluding that gut microbiome is critical for pain development (Shen et al.,
2017). Differently, we did not establish causation in our model. In order to test
whether gut microbiome is responsible for causing obesity-induced pain, pain
testing would have to have been performed during microbiome depletion, either
during antibiotics treatment or in germ-free WD-fed mice. Instead, we evaluated a
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possible novel therapeutic approach to treat obesity-induced neuropathy by promoting
obese mice gut recolonization with NC-thriving bacteria. In our model, the antibiotics
exposure was short enough to lead to an overall depletion of the gut microbiome without
causing neuronal damage. The short antibiotics treatment was mainly used to allow for
gut recolonization by bacteria present within the transplanted fecal matter. Interestingly,
however, NC-fed mice subjected to antibiotics treatment had increased mechanical and
thermal sensitivities. In the case of healthy lean mice, a short exposure to antibiotics may
have impacted peripheral nociceptor’s’ function. Antibiotics treatment in healthy – nondysbiotic conditions – may be harmful, either by altering gut microbiome composition –
changing diversity and potentially selecting certain species – or by directly acting on
normal functioning peripheral afferents. Differently, 3 days of antibiotics exposure
improved mechanical allodynia in WD-fed animals, suggesting that the modulatory
effects of antibiotics alone on gut microbiome can be beneficial to alleviate mechanical
hypersensitivity, although, to a less extent than FMT.
Studies by Feldman, Wright and others have demonstrated that a dietary switch
from WD/HFD to NC/KD are beneficial interventions to treat neuropathic pain in obese
humans and rodent models (Cooper et al., 2018; Hinder et al., 2017; Kluding et al.,
2012). Furthermore, dietary switch is used in the clinic as one the main therapy to
alleviate neuropathy in obese individuals because weight loss had been associated with
neuropathy improvement (Callaghan, Gallagher, et al., 2020; Cooper et al., 2018; Dodet
et al., 2013).Thus, we tested the effects of a 5-day diet switch (DS) from WD to NC
following antibiotics exposure, concomitant with lean feces transplantation. In agreement
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with the literature, we observed that obese animals subjected to the combination
of DS and lean feces transplantation had the best mechanical and thermal pain
improvements among all experimental groups. DS alone also improved thermal
hyperalgesia, but it did not affect mechanical allodynia by itself. These results are
intriguing because they imply that dietary components affect nociceptors in
distinct ways. Early mechanical allodynia, thermal hyperalgesia, and small-fiber
loss are hallmarks of WD-associated neuropathy. Mechanical and thermal
nociceptors are often polymodal, of small caliber unmyelinated C-fibers or lightly
myelinated Ad fibers, thus, very susceptible to obesogenic insults. Therefore,
although we did not identify the specific nociceptor types injured in our model, we
can argue that afferents sensing mechanical stimuli are likely more affected by
WD components/WD-induced gut microbiome dysregulation than thermal
afferents, since a DS alone was able to rescue thermal hyperalgesia, but not
mechanical allodynia. Moreover, the histological data from nerve density in the
skin assessment demonstrated loss of dermal and intraepidermal nerve fibers
following WD feeding. However, only dermal nerve density was restored by FMT.
Combined, these data suggest a retraction of small fibers in a distal to proximal
manner, and potentially imply a neuronal regrowth (neurogenesis) or delayed
disease progression in the animals subjected to FMT. Therefore, it would be
important to assess nerve densities following DS alone to determine which fibers
are being primarily affected and restored in the paradigm used. Unraveling how
and what fibers are more susceptible to obesogenic insults and then rescued or
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protected by FMT may shed a light in the disease pathophysiology, onset and
progression.
Imbalances of gut microbiome composition are associated with obesity and type 2
diabetes (Thingholm et al., 2019). Dietary intake of fiber and SCFA supplementation are
associated with reduced risk of obesity and improved insulin sensitivity. Therefore, one
could argue that FMT-mediated pain improvement could have been due to FMT indirect
effects on glucose metabolism. However, although we indeed observed lower fasting
glucose levels in animals subjected to FMT paradigm, there was no association between
fasting glucose and hypersensitivity improvements in our model. The FMT-associated
changes in behavior and glucose homeostasis seem to occur independently, but in
parallel.
One main remaining outstanding question is whether or not gut microbiome
dysregulation is causative of obesity-induced neuropathy. It is important to notice that we
employed a therapeutic approach by modulating gut microbiome to alleviate obesityinduced pain. However, to understand causation, pain behavior and molecular
mechanistic assessments should be performed during a state of gut microbiome
depletion (i.e. during antibiotics treatment or by perhaps the use of germ-free mice).
Although our studies lacked cell-specificity, we were able to elucidate a few
mechanisms that likely underlie obesity-induced neuropathic pain: (i) neuronal
intracellular calcium signaling due to dysregulated RYR2 levels; (ii) PNS inflammatory
response due to changes in immune cell profile in DRGs and SN. RYR2 is one of the
main players that regulates intracellular calcium homeostasis. Upregulation of Ryr2
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transcript in DRG of obese mice and increased RYR2-mediated calcium release
from ER in primary neurons from WD-fed mice suggest dysfunctional neuronal
calcium signaling that could potentially be linked to increased pain sensation.
Remarkably, both Ryr2 transcriptional levels and RYR2 function, were restored by
FMT, indicating that modulation of gut microbiome, and likely of some of its
derived metabolites, have direct effects on peripheral neurons calcium signaling.
Butyrate was identified as one of the microbiome components linked to improved
neuropathic pain in our model. Two of butyrate’s mechanisms of actions, (i) direct
biding to FFARs and (ii) indirect regulation of gene transcription via HDAC
inhibition (Dalile et al., 2019), could underlie these observations. By inhibiting
HDAC, butyrate induces chromatin opening and consequent enhancement of
gene transcription (Dalile et al., 2019). Thus, it is remarkable that we observed a
downregulation of Ryr2 mRNA, concurrent with downregulation of many other
transcripts in the FMT group compared to sham FMT in both DRG and SN. These
data suggest that butyrate is probably not the solely responsible for neuropathy
alleviation in obese mice subjected to fecal transplantation and its action seemed
to be overruled at gene transcriptional levels. Consequently, it would be essential
to characterize the interplay between FMT – and potentially butyrate –, RYR2,
and obesity-induced hypersensitivity and to define whether RYR2 function is
linked to activation of FFARs expressed by peripheral afferents.
Despite not overt inflammation, the low-grade chronic systemic
inflammation seen in obesity is thought to contribute to neuropathy
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pathophysiology (Pop-Busui et al., 2016). Immune cells are known to be critical in
enhancing pain sensation by mechanisms involving nociceptor sensitization
(Pinho-Ribeiro et al., 2017). Furthermore, disruption of the gut barrier is implicated in
some obesity-associated metabolic complications as it can lead to endotoxemia and to
increased systemic inflammation (Patterson et al., 2016); while butyrate had been shown
to improve gut barrier function (Dalile et al., 2019). Similar to Ryr2 results, we identified
mostly a downregulation of transcripts involved in inflammatory response following FMT
intervention. Therefore, these data imply that FMT could also be restoring gut barrier
function, leading to a decrease in inflammation in obese mice, culminating in improved
pain behavior.
Although butyrate was identified as one of the FMT components associated with
improved neuropathic pain, the presented work lacks an in-depth metabolomics analysis.
Fecal transplantation involves the transfer of many species of bacteria, some of which
produce metabolites other than butyrate, for instance serotonin and dopamine (Jameson
et al., 2020). Thus, it is possible that some of the results observed are mainly not – or not
at all – mediated by butyrate. It is important to fully characterize what components are
present/absent/modified upon FMT to define better therapeutic targets to alleviate
obesity-induced pain.
In Chapter V, we begun to investigate the effects of WD feeding and butyrate
treatment on whole body and tissue-specific inflammation. The method employed
allowed for monitoring of caspase-1-mediated inflammation longitudinally in vivo. Thus,
the presented work is the first to demonstrate that WD feeding lead to a gradual increase
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in capsase-1 activation in vivo over time. The bioluminescence signal originated
from activated luciferase/caspase-1 construct allowed for visualization and
quantification of inflammation in the animals and it was mainly coming from in the
abdominal cavity. This result implies that increases in inflammation in obese mice
could be occurring in: (i) the white adipose tissues – subcutaneous and visceral
fat –, (ii) internal organs, including pancreas and intestines, or (iii) the peritoneal
cavity – loaded with immune cells, such as macrophages. Thus, to confirm the
sites of increased caspase-1 activation, we analyzed tissues ex vivo at the study
endpoint. Remarkably, we did not detect differences in bioluminescent signal in
the fat tissue, suggesting that internal organs were responsible for the increase in
inflammation observed. Ventrally, there were significant changes among the
experimental groups in the heart only; there were no differences in the remaining
anteriorly located organs analyzed (the brown adipose tissue was collected from
the posterior cervical region). Therefore, these data indicate that the
bioluminescence signal is likely originating in cells within the peritoneal cavity – a
major hub of circulating immune cells – overlooked in our studies.
Previous studies have reported on the sexual dimorphism of obesity
(Palmer & Clegg, 2015). Differential adipose tissue distribution and function
between men and women that lead to distinct metabolic and neural features are
mainly driven by the hormonal patterns in both sexes (Palmer & Clegg, 2015).
The results from Chapter V highlight WD-associated sex differences regarding
caspase-1 activation. Although there was a similar gradual increase in caspase-1
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activation over time in both male and female obese mice in vivo, the majority of the
tissue-specific analyses revealed alterations in inflammation in male only, with
exceptions to the heart. These data agree with the literature and suggest a differential
regulation of caspase-1 inflammation between males and females upon WD feeding and
butyrate treatment, likely driven by sex hormones.
Despite a powerful method to monitor in vivo inflammation, the biosensor model
only detects caspase-1-mediated inflammation, while disregarding other inflammatory
responses independent of caspase-1 activation. Thus, it is possible that some of the
results obtained do not entirely reflect the true inflammatory status upon the feeding and
treatment paradigms utilized, besides the sex differences. Assessing other inflammatory
markers via alternative and complementary methods, such as immunoblotting and flow
cytometry, could greatly strength the presented work.
The tributyrin treatment paradigm utilized was based on a pilot study in which lean
mice received 5 consecutively doses of tributyrin and circulating butyrate was assessed
after 2 or 48 hours following the 5th dose. While informative with respect to dosage and
treatment time course, the data from the pilot study were obtained from lean, NC-fed
mice. NC-fed mice represent healthy subjects that have a normal – non-dysbiotic – gut
microbiome, and thus, present levels of butyrate-producing bacteria associated with
metabolic health (Patterson et al., 2016). Therefore, the increase in circulating butyrate
observed in NC-fed mice could very likely be to a different extent than WD-fed animals.
This could explain the reasons why there were no significant changes in host metabolism
functions tested, such as body weight, fasting glucose, and thermal algesia, following
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tributyrin treatment, as previously shown (Dalile et al., 2019). Perhaps, the
treatment duration was too short in comparison to the entire WD feeding
paradigm (2 weeks of tributyrin compared to 20 weeks on WD); perhaps the
dosage in WD-fed mice needed to be higher than the one utilized in the NC-fed
mice from the pilot study, mainly due to very distinct body weights. Thus,
determining circulating levels of butyrate using the same pilot strategy but in WDfed mice could offer better insights of dosage and treatment time course for obese
subjects – who would benefit from the therapeutic approach suggested.
Remarkably, there were alterations in caspase-1 activation in mice CNS,
not concurrent with changes in the PNS. PNS structures, including the DRG and
SN, lie outside the blood-brain barrier, and thus, are very susceptible to dietary
insults. In contrast, structures from the CNS are highly protected against
circulating factors due to a functional blood-brain barrier. Therefore, it is surprising
that WD and butyrate led to increase and decrease in caspase-1 activation levels,
respectively, in mice brains, while unaltering caspase-1 signal in the DRG or SN.
Some SCFA have been demonstrated to cross the blood brain barrier in rats
(Oldendorf, 1973) and in humans (Bachmann, Colombo, & Berüter, 1979),
possibly due to high expression of SCFA transporters, monocarboxylate
transporters (MCTs) in blood cells and astrocytes (Bachmann et al., 1979; Dalile
et al., 2019). MCTs are also expressed in the PNS, especially MCT1, in DRG,
Schwann cells (SC) and perineurial cells (Feldman et al., 2017; Morrison et al.,
2015) and their expression has been linked to peripheral neuropathy in models of
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crush injury (Morrison et al., 2015) and T1DM (Jha et al., 2020). Monocyte-derived
circuiting macrophages are recruited to neural tissues upon injury and inflammation and
cross the blood-brain barrier (Faraco et al., 2017; Guillemin & Brew, 2004). After
recruitment, these cells infiltrate the CNS or PNS and localize alongside blood vessels,
the meninges, or within brain regions (Faraco et al., 2017; Guillemin & Brew, 2004).
Perivascular and meningeal macrophages exert a patrolling function within the CNS, but
also play a role in vascular permeability, which allows for movement of metabolites from
the blood to the brain (Faraco et al., 2017; Guillemin & Brew, 2004). The flow cytometry
data presented herein revealed an increase in perivascular and meningeal
macrophages in mice hypothalamus following tributyrin treatment. Taken together,
these data suggest a butyrate-induced recruitment of immune cells to a brain region
known as one of the main regulators of host metabolism, in parallel with an increase in
caspase-1 activation in whole brains – likely occurring in newly recruited cells.
Therefore, a fundamental next step would be to assess cell-specific caspase-1
activation particularly in brain areas with active immune cell recruitment. However, even
though PNS cells are more vulnerable to peripheral factors, these results also suggest
that butyrate effects in PNS are potentially overruled by its effects in CNS regions in the
paradigm utilized.
Because of BAT’s essential role in energy balance metabolism, chapter V also
investigated caspase-1 activation in BAT of lean, obese and obese mice treated with
tributyrin. The results revealed an increase in caspase-1 signal in BAT following
tributyrin treatment, while remaining unaltered between lean and obese controls,
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suggesting a butyrate-induced in BAT inflammation. obesity is known to cause
BAT inflammation leading to impaired BAT function (Alcalá et al., 2017).
Moreover, chronic butyrate treatment had been shown to induce BAT-mediated
thermogenesis by increasing UCP-1 expression and function without changes in
food intake (Li et al., 2018). The discrepancies between our model and the
literature may be explained by the differences in diet and butyrate paradigms
employed, as well as the model of inflammation assessment. It is interesting,
however, that we did not detect baseline changes in caspase-1 between lean
and obese controls, although a previous report indicated increases in proinflammatory cytokines in mice fed a HFD (60% kcal from fat) for 20 weeks
(Alcalá et al., 2017). The increase in caspase-1 in BAT of tributyrin treated mice
perhaps indicate a detrimental effect of rising circulating butyrate levels on host
metabolism and should be further investigated.
Lastly, chapter VI investigated the role of neuropeptide secretion as an
underlying cause of obesity-induced neuropathic pain that could potentially be targeted
by butyrate treatment. Our results revealed no significant differences in CGRP levels in
either, DRG in vitro, or spinal cord in vivo. DRG primary afferents are pseudounipolar,
this implies that CGRP can be released from both nerve endings: at the skin or at the
spinal cord. Thus, it is possible that CGRP is leading to neurogenic inflammation in our
model following neuropathy progression, i.e., in a distal-to-proximal manner, being
released in the skin, instead of in the dorsal horn of the spinal cord, site of the first
synapse. CGRP secretion may also be localized in the lumbar region of the spinal cord,
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where primary nociceptors that comprise the sciatic nerve converge. Therefore,
assessing CGRP in the skin, as well as in individual sections within the spinal cord –
cervical/thoracic and lumbar/sacral – are essential to decipher its role in obesity-induced
neuropathy, before a complete ruling-out.
Recently, new interventions, possibly disease-modifying therapies, have been
demonstrated to alleviate neuropathy and neuropathic pain in obesity, helping further
understand the disease pathophysiology. However, it is still not clear whether diet and
gut microbiome are causes of peripheral neuropathy or primarily beneficial therapeutic
approaches. This dissertation shed light on novel cellular and molecular mechanisms
involving modulation of gut microbiome, butyrate treatment and neuro-immune
communication that are likely underlying interactions between metabolic tissues and the
somatosensory system.

CHAPTER VIII
GENERAL METHODS
Chapter III and IV.
Animal studies. Animal studies were conducted in accordance with
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and with the approval of the Loyola University
Chicago Institutional Animal Care and Use Committee. Wild type, male C57BL/6J
(#000664) mice were obtained from Jackson Laboratories (Maine, USA). The
animals were housed under a 12:12 hour light/dark cycle. The lean donor group
was fed Normal Chow (NC) (Teklad LM-485), while the experimental groups were
fed Western Diet (WD) (TD88137, Teklad Diets; 42%kcal from fat, 34% sucrose
by weight, and 0.2% cholesterol total - Envigo, Indiana, USA) for 14 weeks
starting at 7 weeks of age.
Fecal microbiome transplantation paradigm. FMT group: At the end of
12 weeks on WD, mice were given antibiotics (ABX), a combination of penicillin
(2,000U/Kg) and streptomycin (2mg/kg: Gibco, Life Technologies), for 3 days in
drinking water. Following antibiotic treatment, some obese mice were subjected to
a diet switch (DS) in which the animals were placed on NC for 5 days and then
back on WD and gavaged with feces from lean NC-fed mice (same bacterial load
in all mice: 0.04 mg/mL) in 0.9% saline solution by oral gavage daily for two
weeks, with a 2-day break between weeks (5 days on, 2 days off, 5 days on).
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Sham or Auto FMT: These groups were subjected to either saline gavage (sham FMT)
or autologous fecal transplantation (auto FMT; obese mice gavaged with feces from
obese mice) as indicated in corresponding figures. Other groups: To evaluate multiple
variables, some mice were treated only with ABX, some mice were treated with ABX and
gavaged with saline, some mice were treated with ABX and gavaged with feces but
without having been subjected to a short diet switch (see Figure 1). (n=6-10 mice per
group).
Tributyrin treatment. 7-week old mice were fed NC or WD for 12 weeks. At the
end of week 12, animals were needle fed with tributyrin (3 butyrate molecules attached
to a glycerol backbone. 5g/kg body weight. Sigma-Aldrich)) or glycerol (used as vehicle)
daily for 2 weeks (n=7-8 mice per group).
Bacterial DNA isolation and 16S quantification and diversity analysis. Fecal
pellets were collected and DNA extracted and purified using QIAmp PowerFecal DNA Kit
according to manufacturer’s instructions. Briefly, 2mg of feces were homogenized in
0.7mm garnet bead tubes using Next Advance Bullet Blender. After microbial cell lysis
and precipitation of non-DNA material, the DNA-containing supernatant was purified and
eluted in Tris-EDTA buffer. Quantification of bacterial load was estimated using Femto
DNA Quantification Kit (Zymo). Purified fecal DNA from each animal was diluted 1:100,
and qPCR was performed with universal 16S primers. Critical threshold (Ct) values from
samples were plotted against a curve of known bacterial DNA standards to estimate the
unknown concentration of 16S DNA (ng) per mg of feces. The Loyola Genomic Core
performed PCR of 16S rRNA V4-5 regions sequenced by Illumina HiSeq4500 platform to
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generate ~100,000 250 bp paired end reads per sample as done previously
(Pearce et al., 2014). Sequence data was quality filtered and de-multiplexed, and
annotated using SILVA database. Sequences were aligned using the Silva
Taxonomy Annotation and files were uploaded to Microbiome Analyst for Analysis
(Chong, Liu, Zhou, & Xia, 2020).
Mechanical sensitivity. Tactile allodynia was assessed using calibrated
Von Frey ﬁlaments (Stoelting Co, Wood Dale, IL, USA) as previously described
(Gavini et al., 2018). Animals were acclimated for 1 hour to a wire mesh platform
and then subjected to plantar stimulation with 7 calibrated filaments (0.07, 0.16;
0.4; 1; 2; 4; 6; and 8g). A 50% threshold was calculated using Hill equation (Origin
2018, OriginLab). The measurements were done by a blinded, single
experimenter.
Thermal sensitivity. Thermal sensation was assessed by the Hargreaves
Method (IITC Life Science, California USA) as previously described (Gavini et al.,
2018). The animals were acclimated to a glass bottomed platform for 1 hour.
Paws were heated at a rate of 1oC/sec, with the paw starting at 30oC and with an
upper cut-off at 20 sec. Five measurements, every other 10 min and in alternate
paws, were recorded. The median was calculated and the three values closest to
the median were averaged and used for statistical analysis.
Fasting glucose and glucose tolerance test (GTT). Mice were fasted for
5 hours and then given an intraperitoneal dose of glucose (1g/kg BW). Fast
glucose was measured at time 0 and glucose levels were monitored from blood

128
drops using AlphaTrak glucometer for rodents (Fisher Scientific, Pennsylvania, USA) at
time 15, 30, 60, and 120 minutes.
Nerve Fiber Densities. Animals were anesthetized with isoflurane before
decapitation. Foot pads were collected from hind paws and fixed in Zamboni solution for
4-6 hours on ice. Samples were then transferred to a 30% sucrose solution in phosphate
buffered saline and processed for immunohistochemistry as described in detail
elsewhere (Jolivalt et al., 2016). Nerve fibers were identified by immunostaining with antiPGP9.5 antibody (#7863-0504, AbD Serotec, UK) and viewed by light microscopy.
Nerve profiles present in the epidermis and papillary dermis were quantified relative to
length of dermal:epidermal border examined.
RNA isolation, cDNA library construction and Illumina sequencing. Total
RNA was extracted from dorsal root ganglia and sciatic nerve of mice with RNAeasy
micro isolation kit (Qiagen). Two biological replicates (2 sciatic nerve per replicate, or 6
lumbar DRG per replicate) were used for each group. Total RNA was quantified by Qubit
and assessed for quality on an Agilent Bioanalyzer using Total RNA Pico Chip. Total
RNA samples that passed QC were used as input for library construction. Full-length
cDNA synthesis and amplification were carried out with the Clontech SMART-Seq v4
Ultra Low Input RNA Kit. Subsequently, Illumina sequencing libraries were prepared from
the amplified full-length cDNA with the Nextera XT DNA Library Preparation Kit. Prior to
sequencing, the prepared libraries were quantified with Qubit and validated on a
bioanalyzer with a High Sensitivity DNA chip. The sequencing of the libraries was
conducted on an Illumina NextSeq 500 NGS System. Single 75 bp reads were
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generated with dual indexing. RNA-seq analysis was done with STAR and
DESeq2. The quality of reads, in FASTQ format, was evaluated using FastQC.
Reads were trimmed to remove Illumina adapters from the 3’ ends using cutadapt
(Martin, 2011). Trimmed reads were aligned to the Mus musculus genome
(mm10) using STAR (Dobin et al., 2013). Read counts for each gene were
calculated using htseq-count (Anders, Pyl, & Huber, 2015) in conjunction with a
gene annotation file for mm10 obtained from Ensembl
(http://useast.ensembl.org/index.html). Normalization and differential expression
were calculated using DESeq2 that employs the Wald test (Love, Huber, &
Anders, 2014). For determining significance, a q value or FDR (false discovery
rate 10%)- adjusted p value < 0.05 was used to obtain all genes regulated. No
cutoff was applied to keep all significantly regulated genes in the analysis. Log2
fold change (LFC) of the genes in experimental groups relative to control group.
“LFC Standard Error” expresses the confidence in the LFC calculation. “Wald
Statistic” is the test used to calculate the p-value. Metascape
(http://metascape.org) was used to identify enriched pathways among genes with
significant differential expression. Genes with significant changes in expression
were divided into upregulated and downregulated genes and analyzed separately.
Pathways with q-values less than 0.05 were considered significant. Timestamp for
pathway analysis: 6/29/2020.
Organotypic DRG cultures. As previously described (Gavini et al., 2018),
male mice were anesthetized with isoflurane before decapitation and lumbar DRG
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extracted and cultured on an air-interface membrane (Millipore). DRG cultures were
maintained for a week in Minimum Essential Medium (MEM) -. Culture medium was
replaced every other day and maintained in a 37oC and 5% CO2 incubator. After an
overnight incubation in low serum (2.5%) MEM supplemented with GlutaMAX (2mM),
DRG were stimulated with either vehicle or 5µM sodium butyrate (Sigma-Aldrich) for 24
hr in presence of 20 mM glucose and 100µM palmitate. RNA was extracted using
RNeasy Micro Kit (Qiagen) and converted to cDNA using the High Capacity Reverse
Transcription Kit (Life Technologies).
Quantitative PCR. For all genes of interest, qPCR was performed using Sybr
green-based assay (Roche, Indiana, USA) using IDT primers (IDT technologies, Iowa,
USA). Actin was used to normalize data and quantification was done using ΔΔCT
method with vehicle treated group’s mean value set at 100% as reported before (Gavini
et al., 2018).
Actin
Forward 5’-3’ ACCTTCTACAATGAGCTGCG
Reverse 5’-3’ CTGGATGGCTACGTACATGG
HDAC2
Forward 5’-3’ CTCCACGGGTGGTTCAGT
Reverse 5’-3’ CCCAATTGACAGCCATATCA
Neuron dissociation and calcium studies. Neuron dissociation was performed
as previously described (Gavini et al., 2018). Lumbar dorsal root ganglia ((DRG) L-4-6)
were collected from NC, WD, and FMT mice, axotomized, and then transferred to a
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collagenase A/trypsin mix (1.25mg/ml each – Sigma Aldrich) in advanced DMEM
(Corning) and incubated for 30 min at 37oC in a 5%CO2 incubator as previously
described (Gavini et al., 2018). Enzymatically digested DRG were carefully
resuspended by the use of glass pipettes and neurons were pelleted by a 3 min
centrifugation at 3000x g. Dissociated neurons were resuspended in advanced
DMEM medium supplemented with 10% fetal bovine serum (FBS: Gibco – Life
Technologies) and 4mM GlutaMAX (Gibco – Life Technologies). Cells were plated
onto cover slips coated with poly-l-lysine (Sigma Aldrich) and maintained at 37oC
in a 5% CO2 incubator for 3 days. Media was changed the day after dissociation
and then every other day (DMEM/F12 – Corning) and supplemented with Ara-C
(2uM). An overnight serum depletion was performed before each experiment
using 2% serum, 1%BSA. At day 4 DRG neurons plated on coverslips were used
for measurements of [Ca]i changes. Changes in cytosolic free Ca2+ concentration
([Ca2+]i) were measured with a laser scanning confocal microscope (Radiance
2000 MP, Bio-Rad, UK and LSM 410, Zeiss, Germany) equipped with a ×40
oil-immersion objective lens (N.A., 1.3). To record [Ca2+]i we used the high-affinity
Ca2+ indicator Fluo-4 (Molecular Probes/Invitrogen, Carlsbad, CA, USA). To load
the cytosol with Ca2+ indicator, cells were incubated at room temperature with 10
μm Fluo-4 AM for 15 min in Tyrode solution (in mm: NaCl 140; KCl 4; CaCl2 2;
MgCl2 1; glucose 3; Hepes 10; pH 7.4), followed by a 20 min wash. Fluo-4 was
excited with the 488 nm line of an argon laser and fluorescence was measured at
>515 nm. Action potentials were induced by electrical field stimulation using a pair
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of platinum electrodes, which were connected to a Grass stimulator (Astro-Med. Inc.,
USA) set at a voltage ∼50% above the threshold. Neurons were paced at a frequencies
of 0.5Hz and 1Hz, while being continuously perfused with tyrode solution. During
application of caffeine (dissolved in tyrode solution), field stimulation was temporarily
paused, and resumed after washing out of caffeine with tyrode alone. Fluo-4 images
were acquired in line-scan mode (3 ms per scan; pixel size 0.12 μm).
Flow cytometry. Following euthanasia, DRG and SN were dissected and placed
in trypsin/collagenase A (1.25mg/ml each – Sigma Aldrich) in 1X Phosphate-buffered
saline (PBS) and incubated for 30 min at 37oC in a 5%CO2 incubator. Enzymatically
digested tissues were carefully resuspended by the use of glass pipettes and dissociated
cells were pelleted by a 5 min centrifugation at 300x g. The supernatant was carefully
removed and cells were placed in blocking solution (5% horse serum in 1X PBS) for 30
min on ice. After pelleting the cells at 300x g for 5 min, fluorescently conjugated
antibodies were added at 1:1000 dilution (anti-CD45, anti-CD11b, anti-F4/80, anti
CD206, anti-IA-IE – Biolegend) and incubated for 30 min on ice. Cells were then washed
and resuspended in 5% horse serum 1X PBS. Flow cytometry data was acquired using
BD FACS Aria III and data was analyzed using FlowJo (Treestar).
Plasma SCFA. For mice, after decapitation under anesthesia, blood was
collected in K3EDTA tubes (Sarstedt), and centrifuged at 2,000xg for 10 minutes.
Plasma was separated and processed for extraction. For humans, blood was collected
after overnight fasting and plasma was separated. Acetic acid, propionic acid, n-butyric
acid and isovaleric acid were dissolved in MS grade H2O: Acetonitrile (1:1, v: v). A
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standard curve was created with 8 points: 0μM, 1μM, 3μM, 5μM, 10μM, 25μM and
50μM. The aqueous samples stored in the -80oC freezer were thawed in a water bath for
30 seconds. Acetonitrile was added and samples were kept at 4oC for 45min. The
samples were centrifuged at 4000xg and 4oC for 10min and the supernatant was
collected for derivatization. Stock solutions of four SCFAs were freshly and
individually prepared in 50% aqueous acetonitrile. Mixed standard solutions
containing equal amount of individual SCFA at desired concentrations were made
in 50% aqueous acetonitrile (ACN). For derivatization, 40uL of each standard
solution or of each supernatant were mixed with 20uL of 10mM 3-NPH in 50%
aqueous acetonitrile and 20uL of 120 mM EDC in the same solution. 1mL 10%
ACN was added to the reaction solution. The LC/MS analysis was performed on
AB Sciex Qtrap 5500 coupled to Agilent UPLC/HPLC system. All samples were
analyzed by Agilent poroshell 120 EC-C18 Column, 100Å, 2.7 μm, 2.1 mm X 100
mm coupled to an Agilent UPLC/HPLC system, which was operated at a flow rate
of 400 uL/min. A gradient of buffer A (H20, 0.1% Formic acid) and buffer B
(Acetonitrile, 0.1% Formic acid) was applied as: 0 min, 30% of buffer B; increase
buffer B to 100% in 4 min; Kept B at 100% for 5 min. Quantification was achieved
using area of monitored transitions. All the samples were analyzed in triplicate
and an internal control was used to evaluate inter-assay variability (3 independent
measurements were done).
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TRPV1 studies.
Cell culture. HEK-293 cells were maintained in minimal essential medium
(MEM) solution (Thermo Fisher Scientific, Waltham, MA), supplemented with 10% fetal
bovine serum (Invitrogen, San Diego, CA) and 1% penicillin/streptomycin, at 37°C as
previously described (Zakharian, Thyagarajan, French, Pavlov, & Rohacs, 2009). The
cells were transfected with rat TRPV1 cDNA using the effectene reagent (Qiagen,
Chatsworth, CA). The TRPV1 stable cell line was developed with TRPV1 tagged with
myc on the N-terminus as previously described (Zakharian et al., 2009).
Intracellular Ca2+ measurements. The extracellular solution used in ratiometric
[Ca2+]i measurements contained 137 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
10 mM glucose and 10 mM Hepes, pH 7.4. Cells were incubated with 2 µM Fura-2
acetoxymethyl ester (Invitrogen) for 60 min at room temperature. The fluorescence
signals of the cells grown on the coverslips were measured using alternating excitation at
340 and 380 nm and emission was detected at 510 nm. The ratio of fluorescence
(340/380) was plotted against time. The obtained values of ratios from each coverslip
were first analyzed and then the mean values of stimuli-induced signals were combined
and statistically averaged values with mean errors were plotted in summary graphs. The
total number of measurements/cover slips (n) are indicated in the figure legend. The
measurements were performed using a Photon Technology International (PTI)
(Birmingham, NJ) imaging system mounted on a Zeiss-AXIO Observed D1 microscope,
equipped with a DeltaRAM excitation light source, or with a Ratiomaster 5 Imaging
System (PTI) equipped with a Cool-snap HQ2 (Roper) camera.
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Human neuropathy assessment. Participants are enrolled in an ongoing
longitudinal, international prospective study titled METS-Microbiome. This study is
investigating the relationship between the gut microbiota, short chain fatty acids
and obesity in populations of African-origin and is funded by the National
Institutes of Health (R01-DK111848). The METS-Microbiome protocol was
approved by the Institutional Review Board of Loyola University Chicago,
Chicago, IL, USA (LU 209537). The recruitment of the participants is detailed here
(Dugas, Lie, et al., 2018).
Utah Early Neuropathy Scale (UENS) examination and questionnaires.
The UENS requires a number 2 (13/4 inch) safety pin and a 128 Hz tuning fork.
The dorsal surface of the foot and leg was pricked by the pin, working
centripetally from the great toe, in 1–2 cm increments, while asking the subject to
respond when he/she first feel sharpness of any kind. On each side, 2 points were
scored for each region in which the patient fails to feel any sharpness. One
additional point was scored for each additional region, in which the pin feels less
sharp than expected (as detailed in (Singleton et al., 2008)).
NeuroQOL questionnaire. The unweighted NeuroQol questionnaire was
used to assess physical symptoms (questions 1-13). Patient with results equal or
higher to 3 were qualified as harboring spontaneous distal pain (Vileikyte et al.,
2003).
Statistical analysis. All data are represented as mean ± S.E.M. Analyses
were performed using Origin 2018, OriginLab and Graphpad Prism. For single
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group comparisons a 2-tailed t-test or Mann-Whitney test were used as appropriate and
multiple comparisons were performed using ANOVA between groups with differences
identified by post-hoc tests as shown in corresponding figure legends. p< 0.05 was
considered significant. Correlation studies were performed by linear regression with
Pearson’s correlation. For the human statistical analysis, multiple linear regression was
used to explore the association between circulating butyrate and hypersensitivity. All
human analyses were completed using STATA v.14 (College Station, Texas, USA).
Chapter V.
Animal studies. Animal studies were conducted in accordance with
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and with the approval of the Loyola University Chicago
Institutional Animal Care and Use Committee. Wild type, male C57BL/6J (#000664) mice
were obtained from Jackson Laboratories (Maine, USA). Caspase-1 biosensor mice
were generated in-house as described elsewhere (Talley et al., 2019)The animals were
housed under a 12:12 hour light/dark cycle. The lean group was fed Normal Chow (NC)
(Teklad LM-485), while the experimental groups were fed Western Diet (WD) (TD88137,
Teklad Diets; 42%kcal from fat, 34% sucrose by weight, and 0.2% cholesterol total Envigo, Indiana, USA) for 20 weeks starting at 13 weeks of age.
Tributyrin treatment. 13-week old mice were fed NC or WD for 20 weeks. At the
end of week 17, animals were needle fed with tributyrin (3 butyrate molecules attached
to a glycerol backbone. 5g/kg body weight. Sigma-Aldrich)) or 1X PBS (used as vehicle)
every 48 hours (2 days on/2 days off) for 2 weeks (n=4-8 mice per group).
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Thermal sensitivity. Thermal sensation was assessed by the Hargreaves
Method (IITC Life Science, California USA) as previously described (Gavini et al., 2018).
The animals were acclimated to a glass bottomed platform for 1 hour. Paws were
heated at a rate of 1oC/sec, with the paw starting at 30oC and with an upper cutoff at 20 sec. Five measurements, every other 10 min and in alternate paws, were
recorded. The median was calculated and the three values closest to the median
were averaged and used for statistical analysis.
Fasting glucose. Mice were overnight fasted and glucose was measured
from tail blood drops using AlphaTrak glucometer for rodents (Fisher Scientific,
Pennsylvania, USA).
IVIS imaging. In vivo imaging was done as previously described (Talley et
al., 2019) Briefly, mice were anesthetized and injected i.p. with a single dose of
150 mg/kg VivoGlo Luciferin. Anesthetized mice were imaged with the IVIS 100
Imaging System (Xenogen) 10 min after administration of the luciferase substrate.
Ex vivo tissues were placed in a 6-well plate with 1mL of luciferase substrates
Bioluminescence was quantified and analyzed use Living Image software.
Flow cytometry. Following euthanasia, hypothalamus, DRG and SN were
dissected and placed in trypsin/collagenase A (1.25mg/ml each – Sigma Aldrich)
in 1X Phosphate-buffered saline (PBS) and incubated for 30 min at 37oC in a
5%CO2 incubator. Enzymatically digested tissues were carefully resuspended by
the use of glass pipettes and dissociated cells were pelleted by a 5 min
centrifugation at 300x g. The supernatant was carefully removed and cells were

138
placed in blocking solution (5% horse serum in 1X PBS) for 30 min on ice. After pelleting
the cells at 300x g for 5 min, fluorescently conjugated antibodies were added at 1:1000
dilution (anti-CD45, anti-CD11b, anti-F4/80, anti CD206, anti-IA-IE – Biolegend) and
incubated for 30 min on ice. Cells were then washed and resuspended in 5% horse
serum 1X PBS. Flow cytometry data was acquired using BD FACS Aria III and data was
analyzed using FlowJo (Treestar).
Culture and treatment of murine bone marrow-derived macrophages
(BMDM). Starting at 7 weeks of age, mice were fed a Western diet (WD). At week 12 of
WD, mice were needle-fed with either 1X PBS or tributyrin (5g/kg of body weight) daily
for 2 weeks. Following euthanasia, bone marrow was isolated from the femurs and tibias
of the mice and cultured in differentiation medium containing 30% L929 cell-conditioned
medium, 20% fetal bovine serum (Corning), 1X penicillin-streptomycin (Corning),
1X GlutaMax (Gibco), and β-mercaptoethano (Thermofisher)l. Differentiated bone
marrow-derived macrophages (BMDMs) were observed after 7 days in culture. At this
time, BMDMs from each treatment group were pooled and replated in 6-well tissue
culture plates (Nunc) at a density of about 1.5x106 cells per well. BMDMs were cultured
for 24 hours in differentiation medium and then treated in triplicate wells with
differentiation medium containing either vehicle, 100ng/mL LPS (from Escherichia
coli O26:B6; Sigma-Aldrich), 1mM sodium butyrate (), or 100ng/mL LPS with 1mM
sodium butyrate for 4 hours.
Quantitative PCR. Following treatment, BMDMs were washed once with 1X PBS
(Corning), and RNA was isolated using the RNEasy Mini Kit (Qiagen). To obtain cDNA, a
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reverse transcription reaction was performed using Taq polymerase reverse
transcription kit (Applied Biosciences). For all genes of interest (listed in Table 5),
qPCR was performed using Sybr green-based assay (Roche, Indiana, USA) using
IDT primers (IDT technologies, Iowa, USA). Actin was used to normalize data and
quantification was done using ΔΔCT method with vehicle treated group’s mean
value set at 100% as reported before (Gavini et al., 2018).
Table 5. Primer Sequences for Genes of Interest.
Gene

Forward Primer

Reverse Primer

18S

AGGACCGCGGTTCTATTTTGTTGG ATGCTTTCGCTCTGGTCCGTCTTG

Il6

AAGCCAGAGTCCTTCAGAGAGATA ATTTCAAGATGAATTGGATGGTCT

Caspase- TGGTCTTGTGACTTGGAGG

GGTCACCCTATCAGCAGTG

1
Il1B

TGGACCTTCCAGGATGAGGACA

GTTCATCTCGGAGCCTGTAGTG

Statistical analysis. All data are represented as mean ± S.E.M. Analyses
were performed using Graphpad Prism. For single group comparisons a 2-tailed
t-test or Mann-Whitney test were used as appropriate and multiple comparisons
were performed using ANOVA between groups with differences identified by posthoc tests as shown in corresponding figure legends. p< 0.05 was considered
significant.
Chapter VI.
Animal studies. Animal studies were conducted in accordance with
recommendations in the Guide for the Care and Use of Laboratory Animals of the
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National Institutes of Health and with the approval of the Loyola University Chicago
Institutional Animal Care and Use Committee. Wild type, male C57BL/6J (#000664) mice
were obtained from Jackson Laboratories (Maine, USA). The animals were housed
under a 12:12 hour light/dark cycle. The lean group was fed Normal Chow (NC) (Teklad
LM-485), while the experimental groups were fed Western Diet (WD) (TD88137, Teklad
Diets; 42%kcal from fat, 34% sucrose by weight, and 0.2% cholesterol total - Envigo,
Indiana, USA) for 14 weeks starting at 7 weeks of age.
Tributyrin treatment. 7-week old mice were fed NC or WD for 14 weeks. At the
end of week 12, animals were needle fed with tributyrin (3 butyrate molecules attached
to a glycerol backbone. 5g/kg body weight. Sigma-Aldrich)) or glycerol (used as vehicle)
daily for 2 weeks (n=4-6 mice per group).
Spinal cord collection and processing. At endpoint, animals were euthanized
by cervical dislocation under isoflurane anesthesia and entire spinal cords were carefully
excised. Tissues were homogenized in 0.7mm garnet bead tubes using Next Advance
Bullet Blender in 1X PBS (100μL of 1XpBS for every 10 mg of tissue) at speed 8 for 5
min. The homogenates were centrifuged at 1,000g for 20 min at 4oC. Supernatant was
used for CGRPa and CGRPb ELISA assays (MyBiosource: MBS026850 and
MBS028988, respectively).
Organotypic DRG cultures. As previously described (Gavini et al., 2018), mice
were anesthetized with isoflurane before decapitation and lumbar DRG extracted and
cultured on an air-interface membrane (Millipore). DRG cultures were maintained for 6
days in Minimum Essential Medium (MEM), 10% FBS and 4.5g/dL glucose. Culture
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medium was replaced every other day and maintained in a 37 C and 5% CO2
incubator. At day 4, cultures were incubated in low serum (2.5%) MEM
supplemented with GlutaMAX (2mM) overnight. The following day, DRG were: (i)
non-stimulated (exposed to bovine serum albumin (BSA) only), (ii) stimulated with
400µM palmitate (PA), or (iii) co-treated with 400µM palmitate and 5µM sodium
butyrate (Sigma-Aldrich) for 24 hours. Culture media was collected at endpoint
and used for CGRPa ELISA assay.
CGRPa and CGRPb ELISA assays. ELISA assays were performed according to
manufacturer’s protocol (MyBiosource: MBS026850 and MBS028988, respectively).
Statistical analysis. All data are represented as mean ± S.E.M. Analyses
were performed using Graphpad Prism. For single group comparisons a 2-tailed
t-test or Mann-Whitney test were used as appropriate and multiple comparisons
were performed using ANOVA between groups with differences identified by posthoc tests as shown in corresponding figure legends. p< 0.05 was considered
significant.
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SI Appendix, Fig. 1.
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Figure 29. Western Diet Alters Gut Microbiome Composition. (a) Body weight of
normal chow (NC) and Western diet (WD) fed mice. (b) Glucose tolerance test (GTT) for
NC and WD-fed animals. (c) Area under the curve (AUC) for GTT of NC and WD-fed
mice. (d) Alpha-Diversity Index, (e) Lactobacillus and (f) Lachnospireceae abundancies
in NC vs. WD-fed mice. (n=6-10 per group). All values represent mean±S.E.M, *p<0.05
by unpaired t-test.
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Figure 30. FMT Does Not Change Bacterial Load, Body Weight and Does Not
Correlate with Thermal Algesia in Obese Mice. (a) Bacterial DNA quantification from
cecal contents of Western-diet (WD) fed mice, treated with antibiotics (ABX), subjected
to diet switch (DS) and gavaged with saline (S) or fecal slurry from lean mice (F) (Sham
FMT=ABX, DS, S; FMT=ABX, DS, F) (unpaired t test p=0.845). (b) Body weight of
Western-diet (WD) fed mice, treated with antibiotics (ABX), subjected or not to diet
switch (DS) and gavaged with saline (S) or fecal slurry from lean mice (F) (Sham
FMT=ABX, DS, S; FMT=ABX, DS, F). (c) Fasting glucose levels of mice from
aforementioned groups (two-way ANOVA showed a main effect of fecal transplantation
gavage p=0.0042 (#); Sidak post-hoc, *p=0.04). (d) Linear regression and Pearson
correlation between fasting glucose and 50% paw withdrawal threshold (Pearson’s r=0242). (n=6-10 per group). All values represent mean±S.E.M.
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SI Appendix, Fig 3.
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Figure 31. Antibiotics Exposure Modifies Pain Behavior in Lean and Obese Mice..
(a), (b) Mechanical allodynia assessments from normal chow (NC) and Western diet
(WD)-fed mice vs. NC and WD-fed animals subjected to antibiotics exposure (NC+ABX,
WD+ABX) (unpaired t test, NC vs. NC+ABX p=0.0244), (unpaired t test, WD vs.
WD+ABX p=0.0256). (c) (d) Thermal hyperalgesia from NC and WD-fed mice vs. NC
and WD-fed animals subjected to antibiotics exposure (unpaired t test, NC vs. NC+ABX
p=0.0068), (unpaired t test, WD vs. WD+ABX p= 0.3316) (e) Mechanical allodynia and
(f) thermal hyperalgesia for all experimental groups: NC, WD, NC+ABX, WD+ABX, S
(WD, ABX, no diet switch, saline gavage), F (WD, ABX, no diet switch, fecal gavage
from lean mice), sham FMT(WD, ABX, diet switch, saline gavage), FMT (WD, ABX, diet
switch, fecal gavage from lean mice). Dashed lines separate groups subjected to same
stressors and used for statistical comparisons. (e) Mechanical allodynia and (f) thermal
hyperalgesia in NC (black bar), and WD- (red bar) fed mice (controls, no treatment, left
side of dashed lines; p=0.0044, and p=0.0214, for mechanical and thermal
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hypersensitivities, respectively, by unpaired t test). (e) Mechanical sensitivities for mice
subjected to antibiotic exposure (NC+ABX (white bar) vs. WD+ABX (green bar)
p=0.2177 by unpaired t test). (f) Thermal sensitivities for mice subjected to antibiotic
exposure (NC+ABX (white bar) vs. WD+ABX (green bar) p<0.0001 by unpaired t test).
(e) Mechanical and (f) thermal sensitivities for S, F, sham FMT and FMT (right side of
the dashed lines, two-way ANOVA, main effect of fecal transplantation (#, p=0.03059),
post-hoc Sidak *p=0.05 for (e) mechanical allodynia and main effects of both fecal
transplantation (#, p=0.00255) and diet switch (&, p=0.01063) for (f) thermal
hyperalgesia. All values represent mean±S.E.M, (n= 6-7 per group).
SI Appendix, Fig. 6.
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Figure 32. Antibiotics Alters Nerve Fiber Density in the Skin of Obese Mice. (a), (b)
Dermal nerves density (unpaired t test, NC vs. NC+ABX test p=0.1544), (unpaired t test,
WD vs. WD+ABX p=0.0043) and (c), (d) Intraepidermal nerve fiber densities ((IENF)
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unpaired t test, NC vs. NC+ABX p=0.1331), (unpaired t test, WD vs. WD+ABX
p=0.0029) in normal chow ((NC) black bar) and Western diet ((WD) red bar)-fed mice
vs. NC and WD-fed animals subjected to antibiotics exposure (NC+ABX (white bar),
WD+ABX (green bar)). (e) (f) Dermal nerves and IENF densities for all experimental
groups: NC, WD, NC+ABX, WD+ABX, Auto FMT (WD, ABX, diet switch, autologous
gavage (blue)), FMT (WD, ABX, diet switch, fecal gavage from lean mice (purple)).
Dashed lines separate groups subjected to same stressors and used for statistical
comparisons. (e) Dermal nerves for NC vs. WD-fed mice (unpaired t test, (left side of
dashed lines) p=0.0149), NC+ABX vs. WD+ABX (unpaired t test p=0.01) and Auto FMT
vs. FMT treated mice (unpaired t test, (right side of dashed lines) p=0.0451. (f)
Intraepidermal nerve fiber densities (IENF) of NC versus WD-fed mice (unpaired t test,
(left side of dashed lines) p<0.001), NC+ABX vs. WD+ABX (unpaired t test p=0.0013)
and of Auto FMT and FMT treated animals (unpaired t test, (right side of dashed lines)
p=0.07618). (n=6-10 per group). All values represent mean±S.E.M, *p<0.05.
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DRG - Top 50 regulated genes WD vs. NC

A.

Z Scores of Normalized Counts
Group
Chat
Slc18a3
Chodl
Slc10a4
Hoxc11
Hoxd11
Hoxd10
Sh3rf2
2310065F04Rik
Krtdap
Fgfbp1
Aldh1a2
Gjb2
Slc22a6
Dapl1
Chst13
Il18rap
Apol11b
Fat2
Epb42
Chil3
Cd177
Camp
Treml2
A430078G23Rik
Btnl10
Mpo
Ltf
S100a9
Kng2
Slfn14
Spib
Hist1h1b
Fam180a
Dsp
Itgb2l
Tnfrsf11b
Mmp8
Lmntd1
Dsg2
Fn1
C1ql1
Cd79b
Prss34
Pamr1
Chrm5
Kcnj15
Rspo3
Vsx1
Gucy2c

Group
NC
WD

0.5
0
−0.5
−1

VM16_2R_S49

VM15_2N_S48

VM14_1L_S47

VM13_1RR_S46

B.

1

DRG - Upregulated pathways WD vs. NC

0

10

C.

20

30
-ORg10(3)

40

5-008-112316: 1euURnaO 6ysteP
G2:0050808: synaSse RUganizatiRn
G2:0050804: PRGuOatiRn Rf chePicaO synaStic tUansPissiRn
G2:0048812: neuURn SURMectiRn PRUShRgenesis
G2:0007610: behaviRU
G2:0098655: catiRn tUansPePbUane tUansSRUt
G2:0099504: synaStic vesicOe cycOe
G2:0042391: UeguOatiRn Rf PePbUane SRtentiaO
G2:0035249: synaStic tUansPissiRn, gOutaPateUgic
G2:0035418: SURtein ORcaOizatiRn tR synaSse
G2:0016358: GenGUite GeveORSPent
5-008-6794362: 3URtein-SURtein inteUactiRns at synaSses
G2:0098742: ceOO-ceOO aGhesiRn via SOasPa-PePbUane aGhesiRn PROecuOes
G2:0007626: ORcRPRtRUy behaviRU
5-008-5576891: CaUGiac cRnGuctiRn
G2:0072657: SURtein ORcaOizatiRn tR PePbUane
G2:0001508: actiRn SRtentiaO
G2:0050805: negative UeguOatiRn Rf synaStic tUansPissiRn
G2:0050905: neuURPuscuOaU SURcess
PPu04080: 1euURactive OiganG-UeceStRU inteUactiRn

50

60

DRG - Downregulated pathways WD vs. NC
G2:0072358: caUGiRvascuOaU systeP GeveORpPent
G2:0001816: cytRNine pURGuctiRn
G2:0006954: infOaPPatRUy UespRnse
G2:0030155: UeguOatiRn Rf ceOO aGKesiRn
G2:0001503: RssificatiRn
G2:0030198: extUaceOOuOaU PatUix RUganizatiRn
G2:0007507: KeaUt GeveORpPent
5-008-1474244: (xtUaceOOuOaU PatUix RUganizatiRn
G2:0030099: PyeORiG ceOO GiffeUentiatiRn
PPu04512: (C0-UeceptRU inteUactiRn
G2:0001501: sNeOetaO systeP GeveORpPent
G2:0042060: wRunG KeaOing
G2:0031349: pRsitive UeguOatiRn Rf Gefense UespRnse
G2:0031589: ceOO-suEstUate aGKesiRn
G2:0000165: 0A3K cascaGe
G2:0002683: negative UeguOatiRn Rf iPPune systeP pURcess
G2:0008285: negative UeguOatiRn Rf ceOO pUROifeUatiRn
5-008-6798695: 1eutURpKiO GegUanuOatiRn
G2:0048729: tissue PRUpKRgenesis
G2:0050900: OeuNRcyte PigUatiRn

0

5

10

15

20
25
-ORg10(3)

30

35

40

Figure 33. Altered Transcripts and Pathways in Dorsal Root Ganglia (DRG) of
Western Diet (WD) versus Normal Chow (NC)-fed Mice. (a) Heatmap representing
the top 50 altered transcripts in dorsal root ganglia (DRG) of WD versus NC-fed mice.
(b) Metascape pathway analysis of upregulated genes in DRG of WD versus NC -fed
mice. (c) Metascape pathway analysis of downregulated genes in DRG of WD versus
NC-fed mice. FDR-adjusted p-value<0.05 (n=2 biological replicates).
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Figure 34. FMT Improves Mechanical Allodynia in Obese Mice when Compared
to Autologous FMT. (a) Gating strategy utilized in flow cytometry studies. (b)
Mechanical allodynia from Auto FMT and FMT treated mice (unpaired t test p=0.0436).
All values represent mean±S.E.M, (n= 6-7 per group).
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Figure 35. Altered Transcripts and Pathways in Sciatic Nerve (SN) of Western Diet
(WD) versus Normal Chow (NC)-fed Mice. (a) Metascape pathway analysis of
upregulated genes in sciatic nerve (SN) of WD versus NC-fed mice. (b) Heatmap
representing the top 50 altered transcripts in SN of WD versus NC-fed mice. FDRadjusted p-value<0.05 (n=2 biological replicates).
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Figure 36. Tributyrin Increases Circulating Levels of Butyrate, but Does Not
Correlate with Thermal algesia and Does Not Alter Inflammation in Sciatic Nerve
of Obese Mice. (a) Circulating serum butyrate levels from WD-fed mice treated with
tributyrin or vehicle (unpaired t test, p=0.0264). (b) Linear regression and Pearson
correlation between thermal latency and serum levels of butyrate (Pearson’s r=-0.3276).
(c) CD45 mean intensity fluorescence (MIF) in sciatic nerve (SN) from control and
tributyrin treated mice (unpaired t test, p=0.532) (n=8-10 per group). All values
represent mean±S.E.M, *p<0.05.
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Figure 37. Caspase-1 Biosensor Mouse Model Display Expected Western Diet
(WD) Features. (A) Energy expenditure, (B) Respiratory exchange ratio, and (C)
Cumulative food intake from normal chow (NC) and WD-fed C7 mice. All values
represent mean±S.E.M, *p<0.05.
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Figure 38. Short Duration of Tributyrin Treatment Does Not Alter Mice Body
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treated C7 male and female mice. All values represent mean±S.E.M, *p<0.05.
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Figure 39. Tributyrin Treatment Does Not Alter Caspase-1 Activation in Brain of
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quantification of (A) brain, (B) hypothalamus, and (C) brain stem of normal chow (NC),
Western diet (WD) and WD-fed tributyrin treated C7 female mice. All values represent
mean±S.E.M, *p<0.05.
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Figure 40. Microglia Gating Strategy. Flow cytometry gating strategy for tissues in the
central nervous system.

Q1
0

Comp-PE-Cy5-A :: CD80

Comp-PE-Cy5-A :: CD80

10

10

10

5

10

200821_Tube_403.fcs
Q1: CD169- , CX3CR1+
26871

200821_Tube_403.fcs
CD45+
65848

5

3

4

Comp-PerCP-Cy5-5-A :: CD169

Comp-PE-Texas Red-A :: IAIE

Comp-PerCP-Cy5-5-A :: CD169

10

4

Comp-PE-Texas Red-A :: IAIE

3

10

0

3

10

Q2
19.1

200821_Tube_403.fcs
CD45+
65848

Q2
19.1

3

3

10

Q1
1.34

M2a
10

0

200821_Tube_403.fcs
cells
4.35E5

Comp-PE-Cy5-A :: CD80

5

10

3

10

-10

Comp-APC-Cy 5-5-A :: CD206

10

4

10

Q3
0.16
3

10

Q1
1.34

5

INFILTRATING
4

10

200821_Tube_403.fcs
CD45+
150K 65848
200K
250K

100K

Q1
40.8

FSC-A

Comp-APC-Cy 5-5-A :: CD206

Q2
0.40

Comp-Pacific Blue-A :: CX3CR1

Comp-Pacific Blue-A :: CX3CR1

Q1
40.8

3

Q4
58.6

Comp-PerCP-Cy5-5-A :: CD169

0

5

3

-10

200821_Tube_403.fcs
Ungated
1.00E6

5

RESIDENT

3

250K

10

4

CD45+
15.1
0

FSC-A

10

Q2
0.40

10
10

-10

10

Q1
40.8

0

50K

200821_Tube_403.fcs
Ungated
1.00E6

10

10

200821_Tube_403
cells
4.35E5

Comp-APC-Cy 5-5-A :: CD206

250K

100K

10

5

Comp-APC-Cy 5-5-A :: CD206

cells
43.5

10

Comp-Pacific Blue-A :: CX3CR1

SSC-A

150K

5

Comp-PE-Cy5-A :: CD80

Comp-PE-A :: CD45

10

Comp-Pacific Blue-A :: CX3CR1

SI Appendix Fig. 12

200K

Comp-PE-A :: CD45

250K

50K

FSC-A

4

150K

SSC-A

250K

10

cells
79.0

5

100K

Comp-PE-A :: CD45

200K

SSC-A

150K

cells
79.0
100K

10

Comp-PE-A :: CD45

200K

CD45+
25.7

4

10

10

CD45+
25.7

4

3

0
50K

10

-10

3

3

0
0

50K

100K

150K

200K

0

250K

50K

100K

0

0
0

50K

100K

150K

200K

0

250K

50K

201209_Tube_430.fcs
Ungated
82616

Comp-PE-A :: CD45

150K

cells
79.0
100K

10

CD45+
25.7

4

50K

10

3

-10

3

50K

100K

150K

200K

0

250K

-10

3

0
150K

200K

0

250K

50K

150K

200K

250K

10

10

CD45hi+CD11B+
8.84

3

CD45hi+CD11B+F4_80+
96.2

-10

3

200K

-10
-10

10

4

10

3

3
Comp-PE-A
-10

5

3

201209_Tube_430.fcs
CD45+
16796

10
10

CD45hi+CD11B+F4_80+
96.2
0
3

10

10

0
10

-10

3

0

10

3

10

4

10

3

3

-10

3

0

10

3

10

4

10

Comp-PE-A-10

5

10

10

3

-10

3

0

3

10

4

10

3

0

10

3

10

4

201209_Tube_430.fcs
CD45hi+CD11B+
Comp-APC-Cy 5-5-A :: CD206
1484

5

10

3

5

-10

0

10

3

4

10

10

10

5

10

4

CD45hi+CD11B+CD206+
4.92

4

SI Appendix Fig. 14

3

10

10

CD45hi+CD11B+MHCII+
94.2

3

3

10

4

CD45hi+CD11B+CD206+
4.92

4

10

CD45hi+CD11B+MHCII+
94.2

3

10

A

3

CD45hi+CD11B+MHCII+
94.2

10

0

0

10

-10

5
-10

3

-10

-10
10

3

3

5

-10

3

0

3

0

10

3

3

10
4

4

10

5

-10

5

0

10

3

10

4

10

5

-10

400000

Comp-APC-Cy 5-5-A :: CD206

-10
3

3

0

10

3

3

-10

10
4

4

0
10
Comp-APC-Cy
5-5-A10:: CD206

0.9683

10
10

5

5

5

0.7705

3

0

10

3

10

4

B

10

0.6662

5

Comp-Qdot 655-A :: IAIE

300000
200000
100000

0.8666

1500000

201209_Tube_430.fcs
CD45hi+CD11B+
1484

CD45hi+CD11B+
201209_Tube_430.fcs
1484
CD45hi+CD11B+
1484

Total flux (p/s)

Total flux (p/s)

3

Comp-Qdot 655-A :: IAIE

201209_Tube_430.fcs
201209_Tube_430.fcs
CD45hi+CD11B+
1484

4

-10

0.4595

1000000

500000

+T
rib
ut
y

rin

0
W
D

rin
+T
rib
ut
y
W
D

W
D

C

0
N

0

10

3

201209_Tube_430.fcs
CD45hi+CD11B+
1484

CD45hi+CD11B+
201209_Tube_430.fcs
CD45hi+CD11B+
1484
1484

3

3

10

4

Comp-Qdot 655-A :: IAIE

10
10
10
Comp-APC-Cy
5-5-A
:: CD206

Comp-Qdot 655-A :: IAIE

W
D

3

0.5748

3

3

5

3

CD45hi+CD11B+MHCII+
94.2

10

10

3

C

-10

-10
-10

10

4

10

4

0

0

0

0

Comp-PE-A :: CD45

Comp-PE-A :: CD45

Comp-PE-A :: CD45

10

10

3

5

5

10

4

10

201209_Tube_430.fcs
CD45hi+CD11B+
1484

5

10

201209_Tube_430.fcs

10

0

Comp-PE-Cy7-A :: F_480

M1

201209_Tube_430.fcs
CD45hi+CD11B+
1484

5

3

Comp-APC-A :: CD11B
262856.655

0

-10

4

10

4

Figure 41. Macrophages Gating Strategy. Flow cytometry gating strategy for tissues
in the peripheral nervous system.
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Figure 42. Tributyrin Treatment Does Not Alter Caspase-1 Activation in Dorsal
Root Ganglia (DRG) and Sciatic Nerve (SN) of Female Mice. IVIS quantification of
(A) DRG and (B) SN of normal chow (NC), Western diet (WD) and WD-fed tributyrin
treated C7 female mice. All values represent mean±S.E.M, *p<0.05.
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Figure 43. Tributyrin Treatment Does Not Alter Caspase-1 Activation in Pancreas,
White Adipose Tissue (WAT) and Intestines of Male and Female Mice. IVIS
quantification of (A) pancreas, (B) WAT, and (C) intestines of normal chow (NC),
Western diet (WD) and WD-fed tributyrin treated C7 male and female mice. All values
represent mean±S.E.M, *p<0.05.
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Figure 44. Tributyrin Treatment Does Not Alter Caspase-1 Activation in Brown
Adipose Tissue (BAT) of Female Mice. (A) IVIS quantification of BAT of normal chow
(NC), Western diet (WD) and WD-fed tributyrin treated C7 female mice. All values
represent mean±S.E.M, *p<0.05.
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